

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 31/70, 37/02, 39/395 A61K 48/00, 49/00, 49/02 C07H 15/12, C07K 3/00, 7/00 C07K 15/28, C12N 15/00, 15/03 C12N 15/04, 15/05, 15/06 C12N 15/07, 15/17, C12Q 1/02 G01N 33/53, 33/543, 33/566 G01N 33/577, 33/536, 33/543 G01N 33/566, 33/577</p>	A1	<p>(11) International Publication Number: WO 90/13300</p> <p style="text-align: center; font-size: 1.2em;">BEST AVAILABLE COPY</p> <p>(43) International Publication Date: 15 November 1990 (15.11.90)</p>
<p>(21) International Application Number: PCT/US90/02357 (22) International Filing Date: 27 April 1990 (27.04.90) (30) Priority data: 345,151 28 April 1989 (28.04.89) US 359,516 1 June 1989 (01.06.89) US 452,675 18 December 1989 (18.12.89) US (60) Parent Application or Grant (63) Related by Continuation US 452,675 (CIP) Filed on 18 December 1989 (18.12.89) (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : HESSION, Catherine, R. [US/US]; 96 Fountain Lane, South Weymouth, MA 02190 (US). LOBB, Roy, R. [GB/US]; 62 Loring Street, Westwood, MA 02090 (US). GOELZ, Susan, E. [US/US]; 195 Pond Street, Winchester, MA 01890 (US). OSBORN, Laurelee [US/US]; 39 Englewood Avenue, #31, Brighton, MA 02146 (US). BENJAMIN, Christopher, D. [US/US]; 2 Oak Hill Lane, Beverly, MA 01915 (US). ROSA, Margaret, D. [US/US]; 32 Brove Street, Winchester, MA 01890 (US).</p>		<p>(74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 875 Third Avenue, New York, NY 10022-6250 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

(57) Abstract

BEST AVAILABLE COPY

DNA sequences encoding endothelial cell-leukocyte adhesion molecules ELAMs, methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VLAM1 and 1b) essentially free of normally associated animal proteins are disclosed. Antibodies to ELAMs are also disclosed. DNA sequences encoding molecules involved in leukocyte adhesion (MILAs), method for producing such molecules and MILAs (including the specific molecule, CDX) essentially free of normally associated animal proteins are also disclosed. Antibody preparations which are reactive for MILAs are also disclosed. Methods for identifying molecules which inhibit binding of leukocytes to endothelial cells, methods for inhibiting leukocyte binding to endothelial cells, and methods for detecting acute inflammation are disclosed.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

- 1 -

ENDOTHELIAL CELL-LEUKOCYTE ADHESION
MOLECULES (ELAMs) AND MOLECULES
INVOLVED IN LEUKOCYTE ADHESION (MILAs)

5

TECHNICAL FIELD OF INVENTION

This invention relates to molecules involved in the adhesion of leukocytes to endothelial cells during inflammation and to DNA sequences that code on expression for them. More particularly, it relates to
10 Endothelial Cell Adhesion Molecules (ELAMs), including ELAM1 and Vascular Cell Adhesion Molecule 1 and 1b (VCAM1 and VCAM1b). It also relates to molecules on the surface of leukocytes involved in leukocyte adhesion to endothelial cells (MILAs). These include
15 CDX, a molecule involved in the ELAM1 adhesion pathway, and VLA4, the ligand of VCAM1 and VCAM1b. This invention further relates to antibodies that recognize these adhesion molecules and anti-idiotypic antibodies that recognize both those antibodies and the ligands or
20 receptors for the adhesion molecules. The invention also relates to antisense DNA and RNA molecules complementary to mRNA for such adhesion molecules and also relates to ribozymes which recognize mRNA for such molecules. The invention also relates to methods for
25 using the aforementioned molecules, DNA sequences, antibodies, anti-idiotypic antibodies, antisense molecules and ribozymes, for example in developing

- 2 -

diagnostic and therapeutic agents to detect or inhibit leukocyte adhesion to endothelial cells.

BACKGROUND OF THE INVENTION

5 Inflammation is the response of vascularized tissues to infection or injury. Clinically it is accompanied by four classic signs: redness, heat, pain and swelling. Its course may be acute or chronic.

At the cellular level, inflammation involves the adhesion of leukocytes (white blood cells) to the
10 endothelial wall of blood vessels and their infiltration into the surrounding tissues. (Harlan, 1985.) Acute inflammation is characterized by the adhesion and infiltration of polymorphonuclear leukocytes (PMNs). (Harlan, 1987 and Malech and Gallin,
15 1987.) PMN accumulation in the tissues reaches its peak between two and one half to four hours after an inflammatory stimulus and ceases by about twenty-eight hours. (Bevilacqua and Gimbrone, 1987.) In contrast, chronic inflammation is characterized by the adhesion
20 and infiltration of other leukocytes, especially monocytes and lymphocytes.

In normal inflammation, the infiltrating leukocytes phagocytize invading organisms or dead cells, and play a role in tissue repair and the immune
25 response. However, in pathologic inflammation, infiltrating leukocytes can cause serious and sometimes deadly damage. Rheumatoid arthritis and atherosclerosis are examples of chronic inflammatory diseases in which mononuclear leukocytes infiltrate the
30 tissues and cause damage. (Hough and Sokoloff, 1985 and Ross, 1986.) Multiple organ failure syndrome, adult respiratory distress syndrome (ARDS), and ischemic reperfusion injury are acute inflammations in which infiltrating PMNs cause the damage (Harlan, 1987

- 3 -

and Malech and Gallin, 1987). In multiple organ failure syndrome, which can occur after shock such as that associated with severe burns, PMN-mediated damage exacerbates the injury. In ARDS, PMNs cause the lungs to fill with fluid, and the victim may drown. In ischemic reperfusion injury, which occurs when tissue cut off from the supply of blood is suddenly perfused with blood (for example after heart attack, stroke, or limb re-attachment), PMN adhesion causes serious tissue damage (Harlan, 1987).

Recognizing that leukocyte infiltration is the cause of much inflammation-related pathology and that leukocyte adhesion is the first step in infiltration, investigators have recently focused attention on the mechanism of leukocyte binding to the endothelial cell surface. Studies show that binding is mediated by cell-surface molecules on both endothelial cells and leukocytes which act as receptor and ligand (Harlan et al., 1987; Dana et al., 1986; and Bevilacqua et al., 1987a).

During the course of inflammation, certain inflammatory agents can act on the leukocytes, making them hyperadhesive for endothelium. Known inflammatory agents include leukotriene-B₄ (LTB₄), complement factor 5a (C5a), and formyl-methionyl-leucyl-phenylalanine (FMLP). These agents activate a group of proteins called LeuCAMs. The LeuCAMs are dimers of the CD11 and CD18 proteins. One of the LeuCAMs, CD11a/CD18 (also called LFA1) binds to a receptor on endothelial cells called ICAM1 (intercellular adhesion molecule 1). (Harlan, 1985 and Dana et al., 1986.) Investigators have shown that monoclonal antibodies (Moabs) to LeuCAMs inhibit PMN adhesion to endothelium both in vitro and in vivo. (Arfors, 1987; Vedder et al., 1988; and Todd, 1989.)

- 4 -

Other inflammatory agents act directly on endothelial cells to substantially augment leukocyte adhesion. These agents include the cytokines interleukin-1 (IL-1), lymphotoxin (LT) and tumor
5 necrosis factor (TNF), as well as the bacterial endotoxin, lipopolysaccharide (LPS). For example, IL-1 has been shown to stimulate adhesion of PMNs, monocytes, and the related cell lines HL-60 (PMN-like) and U937 (monocyte-like), to human endothelial cell
10 monolayers. The action is both time-dependent and protein-synthesis dependent. (Bevilacqua et al., 1987a; Bevilacqua et al., 1987b; and Bevilacqua et al., 1985.)

Current evidence indicates that these agents
15 induce a group of molecules on the endothelial cell surface called ELAMs (endothelial cell-leukocyte adhesion molecules). To date investigators have identified two of these molecules, intercellular adhesion molecule 1 (ICAM1) and endothelial cell-
20 leukocyte adhesion molecule 1 (ELAM1). (Simmons et al., 1988; Staunton et al., 1988; and Bevilacqua et al., 1987b.) ICAM1 is found on many cell types, and its expression on vascular endothelium is strongly upregulated both in vitro and in vivo by the
25 inflammatory cytokines interleukin-1 (IL-1), tumor necrosis factor- α (TNF), and gamma interferon (IFN- γ). (Pober et al., 1986; Dustin and Springer, 1988; and Cotran and Pober, 1988.)

ELAM1 was initially detected and
30 characterized by a monoclonal antibody (Moab) that partially blocked PMN adhesion to cytokine-treated human umbilical vein endothelial cells (HUVECs). ELAM1 is a 116 kD cell surface glycoprotein rapidly synthesized by HUVECs in response to the inflammatory
35 cytokines IL-1 or TNF, but not IFN- γ . (Bevilacqua

- 5 -

et al., 1987b.) Unlike ICAM1, ELAM1 appears to be expressed only in endothelium, and its expression is transient even in the continued presence of cytokine. Like ICAM1, ELAM1 is present at inflammatory sites in vivo. Immunohistologic studies show that it exists at sites of acute, but not chronic, inflammation and is absent from the non-inflamed vessel wall. (Cotran et al., 1986 and Cotran and Pober, 1988.) Therefore, ELAM1 appears to be a major mediator of PMN adhesion to the inflamed vascular wall in vivo. Importantly, the presence of ELAM1 on the cell surface follows the natural course of acute inflammation, appearing a few hours after stimulation and gradually dissipating within a day. (Bevilacqua et al., 1987b.)

Indirect evidence suggests that other ELAMs exist. Although inflammatory agents induce binding of PMNs, monocytes, and lymphocytes to endothelium in vitro, Moabs against ELAM1 inhibit only the binding of PMNs and related cells. (Bevilacqua and Gimbrone, 1987.) Furthermore, maximal accumulation of lymphocytes and monocytes at sites of inflammation in vivo occurs at about twenty-four hours, when ELAM1 expression has returned to basal levels. On the basis of such information investigators inferred the presence of other ELAMs that mediate binding of these lymphocytes and monocytes. (Bevilacqua et al., 1987b.) As set forth in detail below, we have characterized and cloned two more ELAMs, designated VCAM1 and VCAM1b, that mediate binding of lymphocytes to endothelial cells. ELAMs accordingly may be regarded as a family of molecules.

A growing body of evidence indicates that ELAMs may play important roles in a wide range of pathological states involving cell-cell recognition, including tumor invasion, metastasis and viral

- 6 -

infection. (Harlan, 1985; Wallis and Harlan, 1986; Bevilacqua et al., 1987a; and Cotran and Pober, 1988.)

The adhesion of leukocytes to cells expressing ELAMs suggests the existence on leukocytes of ELAM ligands. One such molecule is the ICAM1 ligand, lymphocyte function associated antigen 1 (LFA1). LFA1 is one of a trio of heterodimeric molecules known as the B2 integrins or the CD11/18 family. (Dustin et al., 1986; Rothlein et al., 1986; and Marlin and Springer, 1987.) Recent studies show that the ICAM1/LFA1 pathway plays a role in both lymphocyte and polymorphonuclear leukocyte (PMN) adhesion to endothelial cells in vitro. (Dustin and Springer, 1988; Smith et al., 1989.) We report here the isolation of a molecule involved in leukocyte adhesion to endothelial cells (MILA) which may prove to be an ELAM1 ligand. The molecule, designated CDX, is a protein of approximately 150 kD and was isolated from HL-60 cells. Monoclonal antibodies that recognize CDX inhibit the binding of PMNs and HL-60 cells to ELAM1-expressing cells. Furthermore, CDX is present on leukocyte cell types known to adhere to ELAM1 and is absent from leukocyte cell types and other cell types that do not adhere to ELAM1. Thus, CDX is a molecule expressed on certain leukocytes that plays an important role in ELAM1-mediated leukocyte-endothelial cell adhesion. We also report the isolation and sequencing of cDNA encoding CDX.

We also report the identification of a VCAM1 and VCAM1b ligand, VLA4. (Hemler and Takada, EP 330 506). Antibodies specific for the the α^4 and β_1 subunits of VLA4 completely eliminate binding of VLA4-expressing cells to VCAM1.

Because leukocyte adhesion to the vascular wall is the first step in inflammation, therapies

- 7 -

directed to preventing this step are attractive for the treatment of pathologic inflammation. Clinicians are already testing, with some success, therapies based on inhibiting leukocyte-mediated adhesion. One such
5 approach involves Moab binding to the leukocyte cell-surface complex, CD11/CD18, to inhibit PMN adhesion. (Arfors et al., 1987; Vedder et al., 1988; and Todd et al., 1989.)

We believe that alternative therapies for
10 preventing leukocyte adhesion, based on endothelial cell-mediated binding, and on ELAMs and MILAs (including ELAM ligands), in particular, are more promising. The ELAM system is particularly appealing for two reasons: First, because ELAM expression on
15 endothelial cells is induced rather than constitutive, ELAMs are concentrated at sites of inflammation and are limited in number. This means that adhesion inhibitors need act only locally and, consequently, would be effective at lower doses than inhibitors directed to
20 constitutively expressed molecules. Second, ELAM binding is selective for different leukocyte classes. For example, ELAM1 binds PMNs, and VCAM1 binds lymphocytes. Therefore, these therapies would be specific for certain classes of leukocytes and would
25 not affect the circulation or migration of other leukocyte classes. Furthermore, for the above reasons, such therapies may prove to be cheaper and less toxic.

ELAM-based approaches to therapy require, as starting materials, both ELAMs and MILAs in highly
30 purified form, free of normally associated animal proteins. There is also a need for methods to produce these molecules. These and other needs have now been met as described herein, by isolating DNA sequences that code on expression for particular adhesion

- 8 -

molecules and by constructing recombinant DNA molecules and expression vehicles for their production.

SUMMARY OF THE INVENTION

It is the principal object of this invention
5 to provide new means to study, diagnose, prevent and
treat inflammation. More particularly, it is an object
of this invention to provide molecules involved in
leukocyte binding to endothelial cells and to isolate
other molecules which are themselves useful in
10 inhibiting the endothelial cell binding of leukocytes.

This invention provides DNA sequences that
code on expression for endothelial cell-leukocyte
adhesion molecules (ELAMs), genomic DNA sequences for
ELAMs (including ELAM expression control sequences),
15 recombinant DNA molecules containing these DNA
sequences, unicellular hosts transformed with these DNA
molecules, processes for producing ELAMs, and ELAM
proteins essentially free of normally associated animal
proteins. The present invention also provides for
20 antibody preparations reactive for ELAMs.

This invention also provides DNA sequences
that code on expression for molecules involved in
leukocyte adhesion to endothelial cells (MILAs). MILAs
will include leukocyte surface molecules that bind
25 directly to ELAMs, i.e., ELAM ligands. Monoclonal
antibodies recognizing ELAM ligands can inhibit
ELAM/ELAM ligand binding directly. MILAs will also
include leukocyte surface molecules that are involved
indirectly in adhesion, for example molecules that
30 inhibit ELAM/ELAM ligand binding by interacting with a
third molecule, such as a monoclonal antibody. Such
molecules may act, for example, by changing the surface
conformation of an ELAM ligand so that its affinity for
the ELAM is reduced. This invention also provides

- 9 -

recombinant DNA molecules containing MILA DNA sequences and unicellular hosts transformed with them. It also provides for MILA proteins essentially free of normally associated animal proteins, methods for producing
5 MILAs, and monoclonal antibodies that recognize MILAs, particularly CDX. This invention also particularly provides recombinant DNA molecules containing DNA sequences encoding CDX and provides unicellular hosts transformed with them.

10 This invention further provides methods for inhibiting PMN binding to endothelial cells involving the use of ELAMs, MILAs including ELAM ligands, or portions of those molecules to block receptors or ligands. It also relates to the use of antisense
15 nucleic acids and ribozymes to inhibit ELAM expression. The invention also relates to methods for identifying binding inhibitors by screening molecules for their ability to inhibit binding of an ELAM to its ligand. It provides methods for identifying ELAMs and their
20 ligands. One such method involves using anti-idiotypic antibodies against antibodies that recognize ELAMs or ELAM ligands.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the composite ELAM1 cDNA
25 sequence and deduced amino acid sequence derived from the DNA sequences of ELAM pCDM8 clone 6, pSQ148 and pSQ149. The nucleotides are numbered from 1 to 3863. Throughout this application we refer to the coding DNA sequence of this figure as the DNA sequence for ELAM1.
30 We also refer to the molecule comprising the amino acid sequence depicted in this figure as ELAM1.

Figure 2 depicts the DNA sequence of the synthetic polylinker of pNN11.

- 10 -

Figure 3 depicts the sequence of cDNA coding for VCAM1 and the deduced amino acid sequence of VCAM1 derived from AM pCDM8 clone 41. The nucleotides are numbered 1 to 2811. In this application we refer to the coding DNA sequence of this figure as the DNA sequence for VCAM1. We also refer to the molecule comprising the amino acid sequence depicted in this figure as VCAM1.

Figure 4 depicts the sequence of cDNA coding for VCAM1b and the deduced amino acid sequence of VCAM1b derived from VCAM1b pCDM8 clone 1E11. The nucleotides are numbered 1 to 3080. In this application we refer to the coding DNA sequence of this figure as the DNA sequence for VCAM1b. We also refer to the molecule comprising the amino acid sequence depicted in this figure as VCAM1b.

Figure 5 depicts the domain structure of VCAM1. The amino acids are indicated according to the one letter code used by the University of Wisconsin Genetics Computer Group. (Devereux et al., 1984.)

Figure 6 depicts the domain structure of VCAM1b. The amino acids are indicated according to the one letter code used by the University of Wisconsin Genetics Computer Group. (Devereux et al., 1984.)

Figure 7 depicts the DNA sequence of portions of the 5' untranslated and untranscribed region of ELAM1 derived from clone EL1-07.

Figure 8 depicts the DNA sequence of portions of the 5' untranslated and untranscribed region of VCAM1 derived from clone VC1-16.

Figure 9 depicts the sequence of cDNA coding for CDX and the deduced amino acid sequence of CDX derived from pSQ219 and CDX pCDM8 clone 7.2. The nucleotides are numbered 1-2175. In this application we refer to the coding DNA sequence of this figure as

- 11 -

the DNA sequence for CDX. We also refer to the polypeptide comprising the amino acid sequence depicted in this figure as CDX.

DETAILED DESCRIPTION OF THE INVENTION

5 In accordance with this detailed description, the following definitions apply:

Expression control sequence -- A DNA sequence that controls and regulates the transcription and translation of another DNA sequence.

10 Operatively linked -- A DNA sequence is operatively linked to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes
15 having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded
20 by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

Antibody -- An immunoglobulin molecule or
25 functional fragment thereof, such as Fab, F(ab')₂ or dAb. An antibody preparation is reactive for a particular antigen when at least a portion of the individual immunoglobulin molecules in the preparation recognize (i.e., bind to) the antigen. An antibody
30 preparation is non-reactive for an antigen when binding of the individual immunoglobulin molecules in the preparation to the antigen is not detectable by commonly used methods.

- 12 -

Standard hybridization conditions -- salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash.

DNA sequences -- The DNA sequences of this invention refer to DNA sequences prepared or isolated using recombinant DNA techniques. These include cDNA sequences, DNA sequences isolated from their native genome, and synthetic DNA sequences. The term as used in the claims is not intended to include naturally occurring DNA sequences as they exist in Nature.

ELAM -- A molecule expressed on the surface of endothelial cells that mediates adhesion of leukocytes to endothelial cells.

MILA -- A molecule expressed on the surface of leukocytes that is involved in ELAM-mediated binding to endothelial cells. This includes ELAM ligands, i.e., molecules that bind directly to ELAMs.

As described below, we have isolated and sequenced cDNAs from ELAM mRNAs, expressed ELAM molecules in an appropriate host, isolated and sequenced cDNAs encoding MILAs, and isolated and expressed DNA sequences for MILAs.

Expression of recombinant DNA molecules according to this invention may involve post-translational modification of a resultant polypeptide by the host cell. For example, in mammalian cells expression might include, among other things, glycosylation, lipidation or phosphorylation of a polypeptide, or cleavage of a signal sequence to produce a "mature" protein. Accordingly, as used herein, the terms ELAM and MILA encompass full-length polypeptides and modifications or derivatives thereof, such as glycosylated versions of such polypeptides, mature proteins, polypeptides retaining a signal

- 13 -

peptide, truncated polypeptides having comparable biological activity, and the like.

ELAMs are expressed on the surface of endothelial cells only during inflammation. We
5 utilized this phenomenon to isolate ELAM cDNAs. We have designated the polypeptides encoded by our cDNA isolates ELAM1, VCAM1 and VCAM1b. The first step involved in the isolation was selection of cells that
10 differentially expressed the ELAM molecules. We chose human umbilical vein endothelial cells because they produce ELAMs when induced by the inflammatory cytokine, IL-1 β . However, the practitioner is not limited to this cytokine, to this cell type, or even to
15 human cells in particular. Other mammalian cells, e.g., baboon endothelial cells, are also known to produce ELAMs. (Cotran and Pober, 1988.)

The next step was to isolate mRNA from cells expressing ELAMs, in this case, IL-1 β -induced HUVECs, and to create a cDNA library from them. Many methods
20 are known for isolating mRNA and for producing cDNA from it. (See, e.g., Gubler and Hoffman, 1983 and Maniatis et al., 1982.)

We then inserted the cDNA into an appropriate vector. We chose the eukaryotic expression vector
25 pCDM8, described by Brian Seed. (Seed, 1987.) This plasmid has several advantages including a high copy number in E.coli, a eukaryotic promoter, and high level of expression in transient expression systems such as COS 7 cells. However, several other vector systems are
30 available. (See, e.g., Cate et al., 1986.)

After constructing a cDNA library, the next step was to isolate from it clones containing ELAM cDNA sequences. There are currently many ways to isolate cDNA for a differentially expressed mRNA. These
35 include, for example, (1) plus/minus screening with

- 14 -

labeled cDNA; (2) production of subtracted cDNA libraries; and (3) screening with subtractive cDNA probes. (Davis, 1986; Sargent, 1987; Davis et al., 1985, Hedrick et al., 1984; and Duguid et al., 1988.)

5 We chose the third technique, screening with subtractive cDNA probes, and produced a cDNA sublibrary enriched for ELAM sequences.

As we will describe in more detail below, we produced a subtractive cDNA probe enriched for mRNA
10 produced by cytokine-induced, but not uninduced cells. Then we probed the cytokine-induced cDNA library with the subtracted cDNA probe using techniques well known to the art. This enabled us to isolate clones forming a sublibrary enriched for ELAM sequences.

15 At this point we used two techniques to identify clones that contained cDNA for ELAM sequences. In a first method, we tested clones for expression of ELAM activity in an appropriate eukaryotic expression system. One can use a variety of direct expression
20 techniques, including antibody screening of fusion proteins encoded by cDNA cloned in λ GT11 (Young and Davis, 1983; Young and Davis, 1984); or activity assay of oocyte-conditioned media after injection of mRNA from cloned cDNA, or from plasmid or phage DNA carrying
25 SP6/T7 promoters. Alternatively, one can make libraries in plasmid, phage, and cosmid vectors containing a variety of promoter, selection and replication elements. Animal cells may be transfected with the library for transient or stable expression.
30 Transfection can be accomplished by a variety of methods. For transient expression, investigators have used spheroplast fusion, DEAE dextran, and electroporation. For stable expression they have used calcium phosphate, spheroplast fusion, and
35 electroporation. We used COS 7 cells, a transient

- 15 -

expression system, transfected by spheroplast fusion.
(Aruffo and Seed, 1987.)

Until recently, identification of cloned
molecules by direct expression has required sensitive
5 assays and has been restricted to lymphokines.
However, cDNA cloning of single-chain cell-surface
molecules in efficient transient expression vectors
(see, e.g., Seed and Aruffo, 1987 and Seed, 1987),
either by antibody "panning" technology (Wysocki and
10 Sato, 1978) or by identification of functional
molecules by FACS (Yamasaki et al., 1988), has expanded
the range of cloned molecules that one can identify by
direct expression. We have extended this technology by
using an adhesion assay in that an appropriate cell
15 type, expressing the ligand for the cloned molecule, is
used to identify that molecule.

We detected ELAM expression by testing the
ability of transfected cells to bind either the human
neutrophil-like cell line, HL-60 (Bevilacqua et al.,
20 1985), or the human B-lymphocyte-like cell line, RAMOS
(American Type Culture Collection, ATCC accession no.
CRL 1596, human Burkitt lymphoma). We describe this in
more detail below. Because the transfected cells were
non-human, those producing human ELAM polypeptides did
25 so in substantially purified form and essentially free
of normally associated animal proteins. We picked
cells that tested positive in this assay, collected the
plasmid DNA, and isolated the inserts from them. These
inserts contained DNA sequences encoding ELAM1
30 (selected by adhesion to HL-60 cells) and VCAM1
(selected by adhesion to RAMOS cells).

In a second method, we identified cDNA
inserts from the enriched sublibrary that hybridized on
a Northern blot to a 4 kb band of induced, but not
35 uninduced, mRNA. Two of these inserts contained DNA

- 16 -

sequences for ELAM1. Other inserts from the sublibrary encode different induced mRNAs.

We isolated a cDNA for another VCAM, VCAM1b, by probing the IL-1 β -induced HUVEC cDNA library with a
5 random-primed oligonucleotide ³²P-labeled probe derived from the VCAM1 cDNA sequence. VCAM1b is larger than VCAM1.

Using the clones identified by these three methods, we determined the sequences of cDNAs for ELAM1
10 and VCAM1 and 1b. It should be noted that due to the degeneracy of the genetic code, one may alter many of the nucleotides of these sequences and retain DNA sequences that code on expression for an amino acid sequence identical to those encoded by the DNA
15 sequences we have presented in Figures 1, 3 and 4. Additionally, DNA sequences for fragments of the ELAM cDNA sequences, or DNA sequences that are substantially homologous to the ELAM cDNA sequences and that themselves encode ELAM polypeptides, would hybridize to
20 the disclosed ELAM cDNA sequence under standard hybridization conditions.

From the DNA sequences described above, we deduced the amino acid sequences of ELAM1, VCAM1 and VCAM1b. It should be clear that given the current
25 state of the protein-engineering art, an artisan could make purposeful alterations, insertions or deletions in these amino acid sequences and obtain a variety of molecules having substantially the same biological or immunological activities as those of the molecules we
30 have disclosed herein.

We have also isolated genomic DNA sequences, including transcriptional promoters, for the ELAM1 and VCAM1 and 1b genes. We screened a human genomic library with ³²P-labeled probes derived from the coding
35 regions of the ELAM1 or VCAM1 DNA sequences. This

- 17 -

yielded clones that contained portions of the 5' untranscribed and untranslated regions of both the ELAM1 and VCAM1 gene.

ELAM1 and VCAM1 transcriptional promoters have a number of uses. First, they are useful to construct vectors inducible by cytokines (such as TNF or IL-1), and bacterial lipopolysaccharide (LPS), or any other agent found to induce expression of ELAMs in endothelial cells. Such vectors may be useful, for example, in gene transfer assays, wherein the inducible promoter is positioned so that it drives transcription of a reporter gene such as chloramphenicol acetyltransferase, beta-galactosidase, luciferase, etc. This construct will then be introduced transiently or stably into an appropriate mammalian cell line. Potential inhibitors or stimulators of induction can then be assayed by measuring their effect on induction by any or all of the inducers listed above.

We have also isolated a hybridoma producing monoclonal antibodies recognizing ELAM1, designated BB11. We describe its production in Example V, *infra*.

VCAM1 is involved in T and B cell binding to endothelial cells. T cells activated by lectin stimulation or by a specific antigen bind to HUVECs in vitro. This binding is mediated in part by the ICAM/LFA1 pathway, since monoclonal antibodies that bind to an inhibitory epitope on CD18 (the common β chain of LFA1) partially inhibit T cell binding. We found that anti-CD18 and anti-VCAM1 monoclonals completely inhibited binding. Coupled with the observations that humans deficient in CD18 exhibit normal recruitment of lymphocytes to sites of inflammation, and that activated T cells do not recirculate through the lymphatic system (i.e., they will not exit from the blood stream except at sites of

- 18 -

inflammation), this implies that VCAM1 is central to activated T cell migration in vivo. Thus, VCAM1 serves to focus all activated T cells into an inflammatory site. Since the presence of activated T cells is the
5 hallmark of numerous inflammatory and autoimmune diseases, this in turn implies that inappropriate expression of VCAM1 might be the fundamental pathochemical characteristic of such diseases. Therefore, the VCAM1 pathway may provide a key
10 intervention point for diseases where activated T cell recruitment is involved, e.g., arthritis, lupus, multiple sclerosis, etc. Therefore, we disclose a therapeutic treatment to inhibit T cell binding to the endothelium by blocking the VCAM1 binding pathway.
15 This may be accomplished by any of the means we describe herein.

The DNA sequence of VCAM1 reveals that the molecule has no structural similarity to ELAM1 but is a member of the immunoglobulin supergene family. Three
20 of the Ig superfamily members are established cell-cell adhesion molecules. These are NCAM, CEA, and ICAM1. NCAM binds to itself on the surface of other cells (homotypic adhesion) thus promoting adhesion between cells of the same type. The function of CEA
25 was unknown until recently, when it was discovered to function as an adhesion molecule, mediating homotypic aggregation of colon tumor cells as well as cells transfected with the cDNA for CEA. (Benchimol et al., 1989.) ICAM1 is a ligand for the leukocyte surface
30 protein, LFA1, and mediates both leukocyte-leukocyte and leukocyte-endothelial cell adhesion. (Staunton et al., 1988.) ICAM1 and VCAM1 possess some functional similarities, e.g., both are induced in endothelial cells after treatment with cytokines, and
35 both mediate adhesion of lymphocytes and related cell

- 19 -

lines. The ligand for ICAM1, LFA-1, has been well-characterized. The ligand for VCAM1 has been identified as VLA4 (see, infra). ICAM1 is believed to play a role not only in the migration of lymphocytes to sites of inflammation in vivo but also in numerous lymphocyte functions related to the immune response. Additionally, ICAM1 has recently been shown to be the receptor for many of the rhinoviruses. Receptors for other viruses (e.g., polio, HIV) are also members of the Ig superfamily. (White and Littmann, 1989.) Thus, VCAM1 may play a critical role in both immune regulation and viral infection.

Both CEA and ICAM1 are expressed on tumor cells. CEA has been used as a diagnostic marker for colon cancer for many years. Recent diagnostic techniques include the use of radioimmunoconjugates, in which anti-CEA antibodies are bound to radioactive markers and introduced into the patient. Using this method, clinicians have been able to identify tumors as small as three millimeters. (Goldenberg, 1989.)

Investigators are also exploring radioimmunotherapy and immunotoxin therapy. Radioimmunotherapy involves the use of radioimmunoconjugates in which nuclides such as ^{125}I , ^{90}Y , ^{186}Re and the like are bound to antibodies recognizing a particular surface antigen. Immunotoxins are antibodies conjugated with cell toxins, such as Pseudomonas exotoxin and the like. Upon injection, these conjugated antibodies target the toxic agents to cells expressing the antigen. In accordance with this invention, radioactive markers, nuclides and cellular toxins may be conjugated with VCAM1 and 1b or antibodies recognizing them to target cells expressing VCAM1 ligands (e.g., VLA4) or VCAM1.

- 20 -

The discovery of new ELAMs or the future discovery of ELAMs or MILAs being expressed on other cells, such a tumor cells, also makes possible new TIL therapies. For example, where a tumor is discovered which expresses an ELAM on its surface, the tumor can be biopsied and infiltrated lymphocytes can be removed. A gene for a tumorcidal agent, such as TNF in a retroviral expression vector, is then used to transfect the tumor infiltrating lymphocytes (TILs), which are then expanded with IL-2. When the transfected TILs are injected back into the patient, the TILs are specifically directed to the original tumor and migrate back into the tumor, where the tumorcidal gene product is released for local effect. (See, Thomas and Sikora, 1989.) Since all ELAMs bind some form of leukocyte and thereby mediate infiltration, modified TIL therapies in which infiltrated leukocyte cells are isolated, transfected for expression of a particular desired gene product, amplified and reintroduced to the patient are contemplated herein.

An alternative TIL therapy takes advantage of the fact that certain cell types, notably some forms of cancer cells, express ELAMs or MILAs. For example, colon carcinomas are known to express CDX and melanomas express VLA4.

Employing the DNA sequences disclosed herein, a therapy can be designed to enhance and improve the cytolytic activity of leukocytes by transfecting them to express surface ELAMs or MILAs, thereby improving their binding to target cells expressing the corresponding ligand. Where the cytolytic activity of a leukocyte cell type is increased as a function of stronger cell-to-cell adhesion, such a method would improve the ability of leukocytes to destroy targeted cells. For example, in the case of colon carcinoma or

- 21 -

melanoma, leukocytes (preferably infiltrating leukocytes, which already have an affinity for the target cancer cell) may be transfected with an expression vector including a gene for ELAM1 (in the case of colon carcinoma) or VCAM1 or VCAM1b (in the case of melanoma). Introducing such leukocytes into the patient provides a population of leukocytes capable of homing in on the carcinoma or melanoma cells, respectively, which leukocytes have enhanced ability to adhere to those cells to produce the desired cytolytic effect.

We have also found that incubating HUVECs with TNF and IFN- γ together increases VCAM1 expression about one-hundred percent over incubation with TNF alone. Activated T cells secrete IFN- γ , and therefore may promote their own recruitment to inflammatory sites through a positive feedback system: VCAM causes T cell binding, T cells further stimulate VCAM production via IFN- γ secretion. Thus, we have devised a new treatment for VCAM-dependent pathologies which involves inhibition of this feedback mechanism. The treatment comprises inhibiting cytokines such as IL-1, TNF or IFN- γ , for example with monoclonal antibodies, to block cytokine-stimulated production of VCAM.

We have also isolated a MILA, CDX, that is involved in ELAM1-mediated adhesion and, in fact, is probably the (or an) ELAM1 ligand, as our most recent evidence indicates. The isolation involved, as a first step, the production of monoclonal antibodies against the CDX molecule. We immunized mice with whole HL-60 cells, a PMN-related cell line, that was known to bind to ELAM1. Alternatively, one could immunize with any cell line that binds to ELAM1, including PMNs themselves and, as we shall show, U937 cells. In

- 22 -

addition, to isolate MILAs involved in adhesion to other ELAMs, one could immunize with any cell line that binds to the appropriate ELAM. For example, in isolating VCAM1, we have identified two such cell
5 lines: The B-lymphocyte-like cell line, RAMOS, and the T-lymphocyte-like cell line, JURKAT.

After finding that immune serum from the immunized mice inhibited binding of HL-60 cells to HUVECs in the adhesion assay we will describe, we
10 created hybridomas from spleen cells in a manner well known to the art. (Goding, 1983.) Then we identified those hybridomas that produced monoclonal antibodies (Moabs) against CDX by testing their ability in the adhesion assay to inhibit binding of HL-60 cells to
15 induced HUVECs. We used several of these hybridomas to produce ascites fluid containing monoclonal antibodies.

One can also generate monoclonal Fab fragments recognizing these antigens using the technique of Huse et al. (1989). (See also Skerra and
20 Plückthun, 1988.) Alternatively, one can produce single domain antibodies as described by Ward et al. (1989).

Our monoclonal antibodies against CDX possess the following characteristics: First, they inhibit
25 binding of HL-60 cells or PMNs to cells that express ELAM1. Second, these antibodies exhibit a specific cell-binding pattern -- they recognize cells that bind to ELAM1, but they do not recognize cells that do not bind to ELAM1. Third, they have a recognition pattern
30 for human cell lines that is distinct from the pattern of antibodies against other cell-surface molecules, such as anti-LFA-1, anti-LFA-3, anti-CD44, anti-ICAM, anti-CD4, and anti-Leu8.

We used these Moabs to isolate CDX. We
35 radioactively labeled HL-60 surface proteins and

- 23 -

surface proteins from neutrophils (isolated from human blood) with iodine using a modification of a method described by Kurzinger (Kurzinger et al., 1981) or metabolically with ³⁵S-methionine. We solubilized the
5 membrane proteins and incubated them with an anti-CDX monoclonal (α -CDX Moabs) bound through a μ chain-specific rabbit anti-mouse IgG to Protein A sepharose (ARX), and then we isolated the antibody-bound proteins. The protein appears on SDS-PAGE as a
10 single, diffuse band of about 150 kD. A 90 kD protein band was sometimes observed in the bound proteins from HL-60 cells and always in the proteins from neutrophils. We believe this 90 kD band represents a CDX degradation product. We also sometimes observed
15 higher molecular weight bands (i.e., around 170 kD). These may be non-specific bands. When the isolated 150 kD protein was treated with N-glycanase, the molecular weight was reduced to approximately 70 kD. When the 150 kD band was treated with N-glycanase and
20 O-glycanase, the molecular weight was further reduced to approximately 45 kD. We believe this represents the protein core of a very heavily glycosylated protein. This protein is CDX isolated substantially free of normally associated animal proteins.

25 We have also isolated a DNA sequence that codes on expression for CDX using techniques known to the art. Some practical techniques involve using expression systems to express cloned DNA. As we have mentioned, a variety of eukaryotic expression systems
30 are available. We created a cDNA library from mRNA of a cell line, HL-60, that expresses CDX. We enriched this library for CDX DNA sequences by using subtraction techniques, as we have described, with a cell line that does not express CDX, in this case HeLa cells. We
35 transfected a cell line, COS 7, with the subtracted

- 24 -

library and obtained about 2100 clones, from which those cells expressing CDX were investigated in a number of ways.

We incubated the transfected cells with the
5 α -CDX Moabs and panned them on plates coated with anti-mouse IgG or IgM; cells binding to the plates would be those expressing CDX. In this manner, a 2.1 kb DNA insert coding for CDX was identified, subcloned into a sequencing vector and designated pSQ219.

10 An alternative method for isolating CDX (or another MILA) would employ fluorescent-antibody labeling. In this method, CDX-expressing cells are incubated with α -CDX Moabs and then the Moabs are labeled with, e.g., fluorescently tagged anti-mouse
15 antibody. Cells binding the fluorescent antibodies may then be sorted with a fluorescence activated cell sorter (FACS). The DNA from the sorted cells may be used to transform a bacterial host such as E.coli. DNA from the resulting colonies may then be used to
20 transfect COS 7 cells, and this procedure may be repeated until a single CDX-expressing clone is identified.

A third method is to pan the transfected cells as described above on plates coated with
25 recombinant soluble ELAM1 (rSELAM1). We describe a method to coat plates with rSELAM1 in Example VIII. Cells binding to the plates will be those expressing CDX. Other soluble ELAMs can similarly be used to isolate cells expressing their ligands or MILAs
30 involved in their adhesion pathways.

An expression library may also be created in E.coli. For example, a λ ZAP[®](Stratagene)/HL-60 library may be constructed and used to express the inserted DNA in E.coli. After plating, the plaques can
35 be directly screened with, e.g., radioactively labeled

- 25 -

α -CDX monoclonals. (Young and Davis, 1983 and Young and Davis, 1984.) The plaques to which the monoclonals bind can be picked and the DNA insert isolated from them.

5 Another method we are using to identify ELAM ligands, not based on antibody recognition, is to transfect COS 7 cells with an appropriate library, that may be subtracted, and then pan them directly onto ELAM-expressing cells (such as induced HUVECS, ELAM-
10 expressing COS 7 cells, or ELAM-expressing CHO cells). Once again, multiple rounds of panning are required to enrich the library sufficiently to isolate the pertinent clones.

Another technique for isolating the DNA
15 sequences coding for CDX (or other MILAs) involves screening a cDNA library with oligonucleotide probes. If sufficient CDX protein is purified, for example by affinity chromatography using immobilized antibody to CDX or immobilized ELAM1, one may determine a partial
20 amino acid sequence and synthesize oligonucleotide probes that correspond to at least a portion of the CDX gene. These probes may then be used to screen the cDNA library. Alternatively, the oligonucleotides may be used as primers to generate long probes to be used in
25 screening the library for CDX (MILA) genes.

After isolating a cDNA insert including the coding sequence for CDX, we accumulated further evidence that CDX was the ligand (or at least one ligand) for ELAM1. COS 7 cells transfected with the
30 CDX insert adhered to beads coated with rsELAM1. This interaction is cation dependent and was inhibited by prior incubation with BB11, a monoclonal antibody recognizing ELAM1. In addition, the COS 7 cells transfected with the CDX insert assayed positive on a
35 FACS after incubation with fluorescently labeled α -CDX

- 26 -

Moabs. The CDX-transfected COS 7 cells also form rosettes with α -CDX-coated sepharose beads. (Seed and Aruffo, 1987.) Also, a protein of about 125 kD can be iodinated and immunoprecipitated from the CDX COS 7
5 cells using ARX beads (i.e., α -CDX bound through a μ chain-specific rabbit anti-mouse IgG to Protein A sepharose).

In view of the heavy carbohydrate component apparently associated with naturally produced CDX, it
10 was also illuminating to observe that treatment of HL-60 cells (CDX-expressing) with sialidase resulted in loss of binding to ELAM1. This may be a direct effect, for example that sialic acid moieties on the CDX sugars are directly involved in ELAM 1 binding.
15 Alternatively, it may be an indirect effect, for example that cleavage of sialic acid moieties may cause a radical change in the charge of CDX, which, in turn, inhibits binding to ELAM1.

We have also identified a ligand for VCAM1
20 and VCAM1b. It is the integrin VLA4. (Hemler, 1988; Hemler et al., 1987a; and Hemler et al., 1987b.) The integrins are a group of cell-extracellular matrix and cell-cell adhesion receptors exhibiting an $\alpha\beta$ heterodimeric structure. (Hynes, 1987; Marcantonio and
25 Hynes, 1988.) Investigators have identified three subfamilies of integrins categorized according to the β subunit. The VLA (Very Late Antigen) proteins belong to the β_1 subfamily, many of whose members are specialized for cell-extracellular matrix attachment.
30 (Hynes, 1987 and Ruoslahti, 1988.) VLA4 is expressed in relatively high levels on lymphoid cells (such as B and T cells) and myeloid cells, but is hardly detectable in other cells (Hemler et al., supra.) The binding of B and T cells to the extracellular matrix is
35 mediated by VLA4 and its ligand, human fibronectin

- 27 -

(FN). (Wayner et al., 1989.) The discovery that VLA4 is a ligand for VCAM1 is important because it now defines one binding pathway of B and T lymphocytes to activated endothelial cells. Therefore, we describe
5 the use of VLA4 and VCAM1 and 1b as ligand and receptor in the methods described below.

We contemplate several uses for ELAM and MILA DNA sequences and molecules in the present invention. First, one may use ELAMs and MILAs to produce
10 monoclonal antibody preparations that are reactive for these molecules. The Moabs may be used in turn as therapeutic agents to inhibit leukocyte binding to endothelial cells.

Second, one may use a soluble form of ELAM,
15 soluble ELAM ligand, or fragments of either as binding inhibitors. The ELAM peptides would bind to the ELAM ligand on leukocytes, and the ELAM ligand would bind to ELAM on endothelial cells. Both methods would thereby inhibit leukocyte binding to endothelial cells. To
20 produce recombinant soluble ELAM (rsELAM) or rsELAM ligand one preferably would alter a DNA encoding those molecules to eliminate the transmembrane region. Thus, DNAs for soluble molecules would include all or part of the extracellular domain, perhaps attached to the
25 cytoplasmic domain. This approach has already been validated using soluble CD4, the surface protein on T-cells that binds to the AIDS virus. (Fisher et al., 1988.) This approach also avoids the problems of antibody therapy, since the polypeptides used would be
30 less likely to induce an immune response.

One problem investigators have encountered with soluble recombinant molecules is a short in vivo plasma half-life. (Capon et al., 1989.) Because such molecules are quickly cleared from the system, large
35 doses or frequent injections are necessary to have a

- 28 -

therapeutic effect. Therefore, investigators have sought methods to increase the half-life of soluble molecules. A potential solution is to link the soluble molecule to another molecule known to have a longer
5 half-life in the blood stream. Due to their long half life, immunoglobulin molecules are promising candidates. Capon et al. (1989) have described the linking of soluble CD4 to an immunoglobulin molecule using recombinant DNA techniques. In this approach,
10 one replaces the variable region of an immunoglobulin molecule with the soluble protein, forming a protein/immunoglobulin fusion protein.

It is expected that the rsELAM/immunoglobulin fusion proteins will have greater plasma half-life than
15 rsELAM alone. Such fusion proteins are preferably produced with recombinant constructs, fusing a DNA sequence encoding the soluble molecule to a DNA sequence encoding the constant domain of an immunoglobulin molecule. The recombinant DNA may then
20 be expressed in an appropriate host cell, preferably an animal cell, to produce the fusion protein.

We expect ELAM/immunoglobulin fusion proteins to have another advantage. Because immunoglobulin molecules are normally bivalent (i.e., they have two
25 binding sites) an ELAM/immunoglobulin fusion protein would have two ELAMs and so, two ELAM ligand binding sites. Therefore, one would expect them to have greater affinity or avidity for cells displaying ELAM ligands.

30 Third, one may use molecules binding to ELAMs (such as anti-ELAM antibodies, or markers such as the ligand or fragments of it) to detect inflammation. This involves, for example, making a molecule detectable by fluorescence or radioactivity,
35 administering it to a patient and determining where in

- 29 -

the body it accumulates. In this way one could also identify the type of inflammation. For example, binding to ELAM1 would indicate acute, as opposed to chronic inflammation.

5 Fourth, if an ELAM binds to its ligand through a carbohydrate moiety or some other post-translational modification, one could use ELAM to identify the carbohydrate on the ELAM ligand to which it bound.

10 Fifth, one could use ELAMs and MILAs as part of a system to screen small molecules for adhesion inhibitors. For example, one could create an assay system in which small molecules are tested for the ability to inhibit the interaction between CDX and
15 ELAM1. Small molecule inhibitors identified in this way would provide candidates for anti-inflammatory drugs.

Sixth, one could use these molecules to identify endogenous proteins that inhibit leukocyte
20 binding to ELAMs. Investigators have tentatively identified one such molecule, leukocyte adhesion inhibitor (LAI), that is involved in detaching bound PMNs from endothelium. (Wheeler et al., 1988.)

Seventh, one can generate VCAM/ICAM fusion
25 proteins. We know that both proteins are composed of several structural domains. (Simmons et al., 1988.) DNA sequences encoding various domains of each protein are fused using, for example, the genetic fusion techniques we describe for making ELAM/immunoglobulin
30 fusion proteins. The domains chosen are those having the ability to bind VCAM1 or VCAM1b ligands and ICAM1 ligands, respectively. Domains binding VLA4 and LFA1, the known ligands, are preferable. The polypeptides produced on expression of these DNA sequences are
35 useful because they would block adhesion of any cell

- 30 -

having a ligand to either VCAM1 or VCAM1b, or ICAM1 or both.

Finally, one could use ELAM and ELAM ligand DNA sequences to produce nucleic acid molecules that intervene in ELAM or ELAM ligand expression at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme. These methods will be useful in treating inflammatory conditions.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into ELAM-producing cells. Antisense methods have been used to inhibit the expression of many genes in vitro. (Marcus-Sekura, 1988; Hambor et al., 1988.)

Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific

- 31 -

nucleotide sequences in an RNA molecule and cleave it. (Cech, 1988.) Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

Investigators have identified two types of
5 ribozymes, Tetrahymena-type and "hammerhead"-type. (Hasselhoff and Gerlach, 1988.) Tetrahymena-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the
10 more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to Tetrahymena-type ribozymes for inactivating a specific mRNA species, and eighteen-base recognition sequences are preferable to shorter
15 recognition sequences.

The DNA sequences described herein may thus be used to prepare antisense molecules against, and ribozymes that cleave, mRNAs for ELAM1, VCAM1 and VCAM1b, CDX and VLA4.

20 Antisense molecules and ribozymes may be used in methods to treat inflammation by introducing into cells molecules that interfere with the expression of adhesion molecules. Since ELAMs are induced on endothelial cells during inflammatory episodes, and
25 since therapeutic agents can be delivered to vascular endothelium easily by intravenous injection, endothelial cells are attractive targets for such therapies, provided the antisense molecules or ribozymes can be delivered effectively to the
30 appropriate cells.

Investigators have suggested two approaches which could be used to deliver these molecules to target cells. The first involves transfecting the target cell with a vector that expresses the anti-ELAM
35 antisense nucleic acid or the ELAM-specific ribozyme as

- 32 -

an mRNA molecule. (Hambor et al., supra.) While this approach is very useful when dealing with cell lines in vitro, it may not be as effective in vivo. A second approach that is more promising for in vivo delivery involves loading liposomes with anti-ELAM antisense molecules, ELAM-specific ribozymes or vectors which express them. These liposomes could also contain anti-ELAM monoclonal antibodies to direct the liposome to sites of inflammation. This form of delivery would provide a negative feedback system, since appearance of an ELAM on a cell would make the cell a target for suppression; and successful penetration of the antisense or ribozyme component would halt ELAM production, thereby eliminating the cell as a target.

Another feature of this invention is the expression of the ELAM and MILA DNA sequences disclosed herein. As is well known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.

Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E.coli plasmids col E1, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g.,

- 33 -

the numerous derivatives of phage λ , e.g., NM989, and other phage DNA, e.g., M13 and Filamentous single stranded phage DNA; yeast plasmids such as the 2 μ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast α -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi such as yeasts, and animal cells, such as CHO, R1.1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

- 34 -

It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

Considering these and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

- 35 -

The existence of antibodies against ELAM1, VCAM1 and 1b, CDX and VLA4 makes possible another method for isolating other ELAMs and ELAM ligands. The method takes advantage of an antibody characteristic known as idiotype. Each antibody contains a unique region that is specific for an antigen. This region is called the idiotype. Antibodies, themselves, contain antigenic determinants; the idiotype of an antibody is an antigenic determinant unique to that molecule. By immunizing an organism with antibodies, one can raise "anti-antibodies" that recognize them, including antibodies that recognize the idiotype. Antibodies that recognize the idiotype of another antibody are called anti-idiotypic antibodies. Some anti-idiotypic antibodies mimic the shape of the original antigen that the antibody recognizes and are said to bear the "internal image" of the antigen. (Kennedy, 1986.) When the antigen is a ligand, certain anti-idiotypes can bind to that ligand's receptor. Investigators have identified several of these, including anti-idiotypes that bind to receptors for insulin, angiotensin II, adenosine I, β -adrenalin, and rat brain nicotine and opiate receptors. (Carlsson and Glad, 1989.)

Taking advantage of this phenomenon, other ELAMs and ELAM ligands may be isolated using anti-idiotypic antibodies. Anti-idiotypes may be used to screen for molecules binding to the original antigen. For example, one may use this technique to identify other ELAM ligands.

We have demonstrated that related ELAMs exist with similar domain structures (i.e. VCAM1 and VCAM1b.) As a result of gene shuffling, there may be several adhesion molecules on the cell surface that share one or more domains. Anti-idiotypic antibodies, which recognize any shared domains, are useful to isolate

- 36 -

immunochemically ELAMs or ELAM-ligands not identified by bioassay, which relies on the protein's function, rather than structure.

In order that one may better understand this invention, we set forth the following examples. These examples are for purposes of illustration and are not to be construed as limiting the scope of the invention in any manner.

10 EXAMPLE I -- PREPARATION OF A cDNA SUBLIBRARY
ENRICHED FOR ELAM SEQUENCES

We prepared a cDNA sublibrary enriched for ELAM sequences as follows:

We isolated human umbilical vein endothelial cells (HUVECs) from umbilical cords, grew the cells in primary culture, and serially passaged them as described in Gimbrone (1976). We used HUVECs for library construction at passages 4 or 5. To induce the cells to produce mRNA for ELAMs we incubated confluent monolayers for 2.5 hours at 37°C with recombinant human IL-1 β (10 units/ml). We isolated the mRNA from these cells and reverse-transcribed it into cDNA using techniques well known to the art. (Gubler and Hoffman, 1983.) Using standard procedures, we ligated double stranded cDNA to a NotI-BstXI linker/adaptor having the following sequence:

5' GCG GCC GCT TTA GAG CAC A 3'
3' CGC CGG CGA AAT CTC 5'

We then size-selected the cDNA on a 4.2 ml 5-20% potassium acetate gradient, 2 mM EDTA, 1 μ g/ml ethidium bromide, in a Beckman® SW60 Rotor for 3 hours at 50,000 rpm at 22°C according to the protocols of Brian Seed. (See also Maniatis, 1982, p. 278.) We pooled the cDNA fragments of greater than 500 base pairs. Then we prepared the vector, pCDM8 (a gift from Brian Seed). We digested this plasmid with BstXI. To remove the 400

- 37 -

base pair stuffer fragment we centrifuged the mixture on a potassium acetate gradient, as above, and isolated the large fragment. We further purified this fragment by agarose gel electrophoresis, and then ligated the
5 cDNA to the vector. In this way we created recombinant DNA molecules containing DNA sequences for mRNA expressed in induced HUVECs. We used these plasmids to transform E.coli MC1061 P3. The result was a collection of over 7×10^6 recombinant clones
10 comprising a cDNA library for IL-1 β -induced HUVEC mRNA.

In order to prepare from this cDNA library a sublibrary enriched for ELAM cDNA sequences, we first prepared a subtracted probe enriched for ELAM sequences. We prepared cDNA as above from HUVECs
15 induced with IL-1 β and labeled it with ^{32}P . (Davis, 1986.) Then we isolated mRNA from HUVECs that had not been induced. To subtract uninduced cDNA sequences from induced sequences we hybridized the mRNA with the cDNA and isolated cDNA that had not hybridized to mRNA,
20 as described by Davis (1986). We subjected the isolated cDNA to another round of subtraction to increase the level of enrichment. In all, we prepared three batches of subtracted probes enriched for ELAM sequences.

25 We tested the level of purification of the probe by Northern blot. (Lehrach et al., 1977.) We ran a gel with parallel lanes of polyA+ mRNA from induced and uninduced HUVECs and blotted it on Gene Screen® (New England Nuclear). Hybridization and
30 subsequent autoradiography revealed that the probe bound strongly to a 4 kb band in the induced lane but did not bind, beyond background, to the uninduced lane. Occasionally we noted less intense hybridization bands to other messages in the induced lane.

- 38 -

We used the subtracted probe to create a cDNA sublibrary in E.coli MC1061 P3 enriched for IL-18 induced sequences. We began by plating-out one million clones of the IL-18-induced HUVEC cDNA library. We
5 plated one million colonies on Gene Screen Plus® filters (New England Nuclear) on LB agar containing 12.5 µg/ml ampicillin and 7.5 µg/ml tetracycline, and grew them at 37°C for 12 hours. We made two replicate filters (lifts) from each master. We grew these on LB
10 agar containing 12.5 µg/ml ampicillin and 7.5 µg/ml tetracycline for 4 hours and amplified them on LB agar containing 250 µg/ml chloramphenicol for 16 hours. We lysed the filters according to manufacturer's protocol and then prehybridized them in Plaque Screen® Buffer
15 (0.05M TRIS-HCl pH7.5, 1M NaCl, 1% SDS, 0.1% sodium pyrophosphate, 0.2% polyvinylpyrrolidone (PVP), 0.2% Ficoll-400, 0.2% BSA). We hybridized the filters at 65°C for 40 hours in 50 ml Plaque Screen® Buffer containing 10% dextran sulfate and 100 µg/ml yeast tRNA
20 and approximately 1×10^7 cpm of the subtracted IL-18-induced HUVEC cDNA. We then washed the filters twice with Plaque Screen® Buffer, twice with 2x SSC, 1% SDS, and twice with 1x SSC, 1% SDS at 65°C. We then exposed the filters to film for 5 days.

25 We selected colonies that hybridized to the probe by aligning the master filters with the autoradiographs and scraping the colonies off the filters with sterile toothpicks. We placed each scraping in one well of a 96-well microtiter plate
30 filled with LB broth containing 7.5 µg/ml tetracycline and 12.5 µg/ml ampicillin. After inoculation, we incubated the microtiter plates overnight at 37°C. When the cells had grown we added glycerol to each well to a final concentration of 20% and stored the plates
35 at -70°C. In this way we isolated from the master

- 39 -

library filters 864 colonies comprising the cDNA sublibrary enriched for ELAM sequences. We point out that because of the plating density, not all the colonies of the enriched sublibrary were pure.

5 We carried out two sets of procedures in parallel with the enriched cDNA sublibrary.

EXAMPLE II -- ISOLATION OF A CLONE EXPRESSING ELAM1

In a first procedure we isolated from the enriched sublibrary a clone expressing ELAM1. We chose to transfect this sublibrary into a cell line competent for high-level transient expression, the African Green Monkey kidney cell line, COS 7. We plated the cells and transfected the sublibrary by spheroplast fusion. (Sandri-Goldin et al., 1981.) Forty-eight hours after transfection, we assayed the COS 7 cells for expression of ELAM1 by their ability to bind HL-60 cells, a cell line known to bind to endothelial cells stimulated with inflammatory agents.

20 We performed the assay as follows: We labeled HL-60 cells with carboxyfluorescein diacetate according to the Brenan and Parish method. (Brenan and Parish, 1984.) Briefly, we resuspended HL-60 cells in RPMI/10% FCS at a concentration of 1×10^7 cells/ml, and added carboxyfluorescein diacetate to a final concentration of 0.1 mg/ml from a stock solution of 10 mg/ml in acetone. We incubated COS 7 cells with labeled HL-60 cells for 15 minutes at room temperature. We washed the cells 3-4 times with RPMI/1% FCS. We examined the petri dish by fluorescence microscopy for clusters of adherent HL-60 cells. We picked regions of the cell plates with clusters of HL-60 cells and lysed the cells in 0.6% SDS, 10mM EDTA, pH 8, then rescued the plasmids according to the method of Hirt. (Hirt, 1967.) We used these pooled plasmids to transform

- 40 -

E.coli MC1061 P3. We grew colonies from these transformants and performed a second round of spheroplast fusion with COS 7 cells with subsequent assay for HL-60 adhesion. From among the cells that
5 were positive for adhesion we selected one and isolated the plasmid from it. We designated a culture containing this plasmid ELAM pCDM8 clone 6. We deposited this plasmid under the Budapest Treaty with In Vitro International, Inc., 611 P. Hammonds Ferry
10 Rd., Linthicum, Md., 21090 (USA) on April 20, 1989. It is identified as:

ELAM pCDM8 clone 6 / E.coli MC1061 P3
Accession Number IVI-10204

15 EXAMPLE III -- ISOLATION OF cDNA INSERTS FOR ELAM1 SEQUENCES

In a second procedure, we isolated cDNA inserts for IL-18-induced cDNA sequences. We selected at random twenty-four of the 864 colonies of the enriched library and isolated plasmids from them using
20 the alkaline miniprep procedure of Maniatis. (Maniatis, 1982.) We digested the plasmid DNA with XhoI or NotI and separated the fragments on 1% agarose gels. We identified from this gel two plasmids with inserts of greater than 3 kb, isolated these inserts
25 and labeled them with ^{32}P . (See, Feinberg and Vogelstein, 1983 and 1984.)

We then performed Northern blots with these inserts, as described above. Both inserts hybridized to bands at 4 kb in the induced HUVEC mRNA lane but did
30 not hybridize to the uninduced HUVEC mRNA lane. The inserts cross-hybridized with the ELAM1 expressing plasmid ELAM pCDM8 clone 6 (described above) as well. We subcloned these inserts into NotI-digested pNN11 that had been treated with calf intestinal alkaline
35 phosphatase. We constructed the sequencing plasmid

- 41 -

pNN11 by removing the synthetic polylinker from the commercially available plasmid pUC8 (Pharmacia PL Biochemicals) by restriction digestion and replacing it with a new synthetic segment. The 2.5 kb backbone
5 common to the pUC plasmids, that provides an origin of replication and confers ampicillin resistance, remained unchanged. The novel synthetic portion of pNN11 is shown in Figure 2. We called these new constructs pSQ148 and pSQ149, respectively.

10 EXAMPLE IV -- A DNA SEQUENCE FOR ELAM1

We determined the entire DNA sequence for the inserts of plasmids pSQ148 and pSQ149 and 624 nucleotides of the sequence at the 5' end of the insert of ELAM pCDM8 clone 6. We used the Maxam-Gilbert
15 method. (Maxam and Gilbert, 1980.) Because the sequences have significant overlap, we obtained a composite sequence of ELAM cDNA, a sequence of 3863 nucleotides. This sequence consists of 140 nucleotides of the 5' untranslated region, 1830 nucleotides
20 encoding 610 amino acids, and 1893 nucleotides of the 3' untranslated region (including a translational stop codon and a polyadenylation signal). The mature protein derived from the deduced amino acid sequence has been designated ELAM1, and the coding sequence has
25 been designated the ELAM1 DNA sequence. The cDNA sequence of ELAM1 is shown in Figure 1.

A search of the Genbank Data Base, release 58, December 1988, revealed that the DNA sequence for ELAM1 has no significant homologies to known DNA
30 sequences.

We used this cDNA sequence to deduce the ELAM1 amino acid sequence, that is also presented in Figure 1. Our analysis of the sequence revealed the following properties: The protein possesses a

- 42 -

hydrophobic N-terminal sequence characteristic of a signal sequence. (von Heijne, 1986.) We have not yet determined the signal cleavage site and the mature N-terminus through protein sequencing, however based on
5 von Heijne we predict that the mature N-terminal amino acid will be tryptophan, at nucleotide number 204 in Figure 1. The extracellular domain of the polypeptide is approximately 554 amino acids including the signal sequence and is followed by a hydrophobic transmembrane
10 region of 24 amino acids. The protein possesses a short, charged cytoplasmic tail of 32 amino acids. We note that the protein is cysteine-rich and contains eleven potential N-glycosylation sites.

When we compared the amino acid sequence of
15 ELAM1 to other proteins in the NBRF and NEW protein data bases we found significant homology with several proteins, including complement C2 precursor, β -2-glycoprotein I, C4b-binding protein, complement factor B, complement factor H, Drosophila notch
20 protein, the IgE receptor Hepatic lectin, and Coagulation factors IX and X precursors. Thus, we can divide ELAM1 into at least three domains based on homology to the above-mentioned proteins: (1) a lectin-like domain (nucleotides 204-563 of Figure 1);
25 (2) an EGF-like domain (nucleotides 564-668); and (3) a consensus cysteine repeat unit of 59-63 amino acids containing six cysteine residues per repeat (nucleotides 669-1793). Other invariable amino acids in each repeat are proline, glycine, and tryptophan.

30 EXAMPLE V -- MONOCLONAL ANTIBODIES RECOGNIZING ELAM1

To make monoclonal antibodies that recognize ELAM1 we prepared hybridomas in essentially the same manner as we did in Example X, *infra*. However, we immunized the mice with ELAM1-expressing COS cells and

- 43 -

identified mice producing anti-ELAM1 antibodies by testing their antiserum for the ability to block HL-60 cell adhesion to IL-1 β induced HUVECs.

We screened hybridomas produced in this manner for those producing anti-ELAM1 monoclonals using several assays. First, we tested the culture supernatants for antibodies having the ability to bind to a cell line that stably expressed ELAM1. This cell line was a line of CHO-DHFR⁻ cells transfected with the ELAM1 animal cell expression vector, pBG341jod.ELAM. We created this plasmid by introducing the DNA sequence encoding ELAM1 from pCDM8 clone 6 into the NotI site of pBG341.jod (described in Example VIII, infra). The ELAM1 expressing CHO-DHFR⁻ derived cell line was detected using an adhesion assay to HL-60 cells.

Second, we screened hybridoma culture supernatants for the ability to bind cytokine-induced, but not control, HUVECs.

Third, we tested them for their ability to inhibit HL-60 cell adhesion to cytokine-induced HUVEC monolayers.

We identified one hybridoma clone, BB11, which produced a positive result in all three assays. BB11 immunoprecipitates proteins with molecular weights of about 110 kD and 96 kD from ELAM1-expressing HUVECs and COS cells, representing variably glycosylated forms of ELAM1. (Bevilacqua et al., 1989.) It also completely blocked adhesion of HL-60 cells to ELAM1-expressing COS and CHO cells. It produced immunoglobulins of the IgG_{2b} class. We deposited a subclone of this hybridoma under the Budapest Treaty with In Vitro International, Inc., 611 P. Hammonds Ferry Rd., Linthicum, Md. 21090 (USA) on December 13, 1989. It is identified as:

Monoclonal antibody CDB.BB11.BC6

- 44 -

Accession Number IVI-10220.

EXAMPLE VI -- ISOLATION OF CLONES EXPRESSING
VCAM1 and VCAM1b

We have also characterized and cloned two
5 different ELAMs that bind to lymphocytes and
lymphocyte-like cell lines. As a first step, we
characterized the binding pathways of RAMOS, a B-
lymphocyte-like line, and JURKAT, a T-lymphocyte-like
line, to HUVECs induced with IL-1 β or TNF for 4, 24, or
10 48 hours. We found that both RAMOS and JURKAT binding
was maximal at 4 hours after induction with either IL-
1 β or TNF, and binding was maintained at 24 hours and
48 hours after induction. RAMOS binding was
temperature-sensitive, occurring at room temperature
15 but not at 4°C. JURKAT binding was reduced but not
completely eliminated at 4°C, and thus JURKAT exhibited
both a temperature-sensitive and temperature-
insensitive component. Antisera from mice immunized
with JURKAT cells inhibited binding from both JURKAT
20 and RAMOS cells to HUVECs, indicating that RAMOS and
JURKAT share a MILA. Neither RAMOS nor JURKAT bound to
COS or CHO cells expressing ELAM1, indicating the
presence of at least one other inducible ELAM on
HUVECs, at 4 to 48 hours after induction.
25 In order to isolate clones expressing the
ELAMs involved in RAMOS and JURKAT binding to HUVECs,
we screened the previously described ELAM-enriched
HUVEC cDNA sublibrary by the method described in
Example II, supra. We incubated carboxy-fluorescein
30 diacetate-labeled RAMOS and JURKAT cells with
sublibrary-transfected COS 7 cells. Regions of the
cell plates with clusters of bound cells were picked
and lysed, and the plasmids were rescued, transformed
into E.coli, and reassayed in COS 7 cells as previously
35 described. Plasmids were isolated from individual

- 45 -

bacteria colonies from the transformants that were positive on reassay. These plasmids were transfected individually into COS 7 cells, and a plasmid that tested positive for adhesion to RAMOS and JURKAT was identified. The cDNA insert from this plasmid was excised, radioactively labeled, and used to probe a Northern blot according to the procedures of Lehrach (1979). The probe hybridized to an RNA species approximately 3.4 kb in length. The RNA was undetectable in uninduced HUVEC RNA, barely detectable at 5, 10, 30 or 60 minutes after treatment with IL-1 β , but abundant at 2, 24, 48 and 72 hours after treatment with IL-1 β .

We designated the plasmid AM pCDM8 clone 41. We deposited this plasmid under the Budapest Treaty with In Vitro International, Inc., Linthicum, Md. (USA) on May 24, 1989. It is identified as:

AM pCDM 8 clone 41 / E. coli MC1061 P3
Accession Number IVI-10206

We have also isolated a cDNA for another VCAM. We screened the IL-1 β -induced HUVEC cDNA library (Example I) with a labeled VCAM1-encoding insert from AM pCDM 8 clone 41. We sequenced one of these, clone 1E11. We found several clones that were longer than the clone 41 insert as analyzed by restriction mapping with XbaI. We sequenced one of these, clone 1E11. We deposited it under the Budapest Treaty with In Vitro International, Inc., Linthicum, Md. (USA) on December 7, 1989. It is identified as:

VCAM 1B Clone 1E11 pCDM8/E. coli MC1061p3
Accession Number IVI-10216.

We are also isolating DNA sequences for other ELAMs. We are collecting mRNA from HUVECs around forty-eight hours after IL-1 β induction. We will isolate the ELAM cDNA sequences in a manner similar to

- 46 -

the one we used to isolate the cDNA sequences for ELAM1 and VCAM1 and 1b.

Alternatively, one may identify other ELAMs by inducing cells with other inflammatory agents, such as TNF, LT, LPS, interferons, or combinations of such agents.

EXAMPLE VII -- DNA SEQUENCES FOR VCAM1 and VCAM1b

We determined the entire DNA sequence for the insert of plasmid AM pCDM8 clone 41 by the method of Maxam and Gilbert (1980). This sequence consists of 106 nucleotides of the 5' untranslated region, 1941 nucleotides encoding 647 amino acids, and 764 nucleotides of the 3' untranslated region including a translational stop codon. The protein derived from the cDNA sequence has been designated VCAM1, and the coding sequence has been designated the VCAM1 DNA sequence. We have presented the cDNA sequence of VCAM1 in Figure 3. The putative amino acid sequence of VCAM1 is also indicated in Figure 3.

We also determined the entire DNA sequence for the insert of plasmid VCAM1b pCDM8 1E11 by the method of Maxam and Gilbert (1980). This sequence consists of 99 nucleotides of the 5' untranslated region, 2217 nucleotides encoding 739 amino acids and 764 nucleotides of the 3' untranslated region including a translational stop codon. We have designated the mature protein derived from the cDNA sequence as VCAM1b and the coding sequence as the VCAM1b DNA sequence. We have presented the cDNA sequence and putative amino acid sequence of VCAM1b in Figure 4.

Comparison of the DNA and amino acid sequences of VCAM1 and VCAM1b revealed that they are virtually identical except for one significant difference: VCAM1b contains an insertion of 276

- 47 -

nucleotides near the middle of the coding region. These nucleotides encode 92 additional amino acids which form an extra domain of 84 amino acids situated between the end of VCAM1 domain 3 and the beginning of
5 VCAM1 domain 4. We discuss the significance of this domain, designated VCAM1 domain 3B, below.

Our analysis of the sequences revealed the following properties: The VCAM1 polypeptide possesses a hydrophobic N-terminal sequence characteristic of a
10 signal sequence. (von Heijne, 1986.) We have not yet determined the signal cleavage site and the mature N-terminus through protein sequencing, however based on von Heijne we predict that the N-terminal amino acid of the mature protein will be phenylalanine, at nucleotide
15 number 179 in Figure 3. The extracellular domain of the polypeptide is approximately 606 amino acids including the signal sequence and is followed by a hydrophobic transmembrane region of 22 amino acids. The protein possesses a short, charged cytoplasmic tail
20 of 19 amino acids. We note that the protein contains six potential N-glycosylation sites.

Similarly, the N-terminal amino acid of the mature VCAM1b protein should be the phenylalanine, at nucleotide number 172 of Figure 4. The extracellular
25 domain of the polypeptide, which is longer than VCAM1, is approximately 698 amino acids including the signal sequence and is followed by a hydrophobic transmembrane region of 22 amino acids. The protein possesses a short, charged cytoplasmic tail of 19 amino acids. We
30 note that the protein contains seven potential N-glycosylation sites.

Comparison of the amino acid sequences of VCAM1 and VCAM1b with other proteins in the NBRF and NEW protein databases revealed significant homologies
35 with several proteins, including non-specific cross-

- 48 -

reactive antigen (NCA), biliary glycoprotein 1 (BG1),
neural cell adhesion molecule (NCAM), carcinoembryonic
antigen (CEA), immunoglobulin alpha chain constant
region, the T cell receptor (TCR) alpha and beta chain
5 variable regions, and myelin associated glycoprotein
(MAG). Lesser homology is seen with myosin light chain
kinase, ribulose biphosphate carboxylase, adenovirus
E1A 28K protein, pseudouridine synthetase, and
xylulokinase. VCAM1 and 1b and the VCAM1 and 1b DNA
10 sequences show no homology with, and are distinct from,
the previously described ELAM1 (supra).

Importantly, NCA, BG1, NCAM, CEA, MAG, and
TCR are members of the immunoglobulin gene superfamily.
(Williams and Barclay, 1988; Hunkapiller and Hood,
15 1989.) Members of this family are defined by the
presence of one or more regions homologous to the basic
structural unit of immunoglobulin (Ig) molecules, the
Ig homology unit. (Hunkapiller and Hood, 1989.) These
units are characterized by a primary amino acid
20 sequence of about 70-110 residues in length, with an
essentially invariant disulfide bridge spanning 50-70
residues, and several other relatively conserved
residues involved in establishing a tertiary structure
referred to as the "antibody fold". These units may be
25 further subdivided into three groups, i.e., V, C1, and
C2 (Williams and Barclay, 1988), or V, C, and H
(Hunkapiller and Hood, 1989), based on various
criteria, including intercysteine spacing, number of
beta strands, and type of conserved residues. When
30 these criteria are applied to the predicted primary
sequence of VCAM1, the sequence can be divided into six
Ig units, designated domains 1-6, all of which fall
into the C2 or H subset, each of about 100 amino acids
in length. The invariant disulfide bridges of the six
35 domains, referring to Figure 3, occur between cysteines

- 49 -

47 and 95 (domain 1), 137 and 195 (domain 2), 246 and 291 (domain 3), 333 and 391 (domain 4), 442 and 487 (domain 5), and 531 and 576 (domain 6).

As we stated above, VCAM1b has seven domains. We have designated the additional domain as domain 3B. This domain is included in the additional 276 nucleotides of VCAM1b that begin at nucleotide 1027 and end at nucleotide 1305 of Figure 4. The DNA sequence encompassing domains 1-3 is 72% homologous to the DNA sequence encompassing domains 3B-5. At the polypeptide level, there is significant homology between domains 1 and 3B, 2 and 4, and 3 and 5, respectively. We present the domain structures of VCAM1 and VCAM1b in Figures 5 and 6.

mRNAs for VCAM1 and VCAM1b could arise by two mechanisms: They could represent alternately spliced forms of the same gene product, or they could be the products of separate VCAM alleles. To help distinguish between these possibilities, we examined VCAM1 and mRNA from three individuals, at different time-points after cytokine induction. HUVECs were prepared from umbilical cords from three different individuals, the cord samples being labeled #1, #2 and #3. Each preparation was split into four separate flasks for treatment with TNF for 0 (untreated), 2.5, 24, and 48 hours. Relative amounts of VCAM1 and VCAM1b mRNA were determined by Northern blotting and probing with synthetic oligonucleotides specific for each form. VCAM1b was clearly the major mRNA present in all three umbilical cord preparations. VCAM1 was present in cords #1 and #3, most prominently at the 2.5 hour induction time-point, although in cord #3 VCAM1 was also present at 24 and 48 hours. Cord #2 cells had little or no VCAM1 mRNA, although amounts of VCAM1b mRNA were comparable to those in HUVECs from cords #1

- 50 -

and #3. The mechanism by which these two products arise is still unclear, although alternate splicing seems likely because the two mRNAs are identical except for the deletion of one domain, at a point likely to be a splice junction, judging by its position between domains (Hunkapillar and Hood, 1989) and by the presence of the dinucleotide AG, typical of splice junctions (Breathnach and Chambon, 1981). Furthermore, alternate splicing is common among other members of the Ig gene superfamily to which VCAM1 is most clearly related. (Hunkapillar and Hood, 1989.)

Functionally, differences between the two forms of VCAM1 appear to be minimal. Both forms, when expressed transiently in COS 7 cells, bound RAMOS cells, and this binding was completely inhibited by Moab 14B9, indicating that the same epitope is relevant to binding in each case. Furthermore, we have shown that this epitope is located within the first three domains, which are common to both forms (see Example VIII, supra).

EXAMPLE VIII -- RECOMBINANT SOLUBLE ELAM1 AND VCAM1b

We constructed a vector expressing recombinant soluble ELAM1 (rsELAM1). We called this vector pSAB108. The rsELAM1 expressed by pSAB108 contains the portion of the extracellular domain of ELAM1 encoded by the DNA sequence of Figure 1 from nucleotide 141 to nucleotide 1790.

To construct pSAB108 we first created a DNA fragment which encoded an rsELAM1. We digested ELAM pCDM8 clone 6 with MluI and NotI. This yielded a 3.8 kb DNA fragment including a DNA sequence encoding ELAM1. We subcloned this fragment into NotI-digested pNN11 that had been treated with calf intestinal

- 51 -

alkaline phosphatase (described in Example III). We called this vector pNNELAM1.

We used site specific mutagenesis to eliminate the transmembrane and intracellular regions of ELAM1. (Peden and Nathans, 1982; Kalderon et al., 1982; Oostra et al., 1983.) Accordingly, we digested a sample of pNNELAM1 with EcoRI and isolated the large fragment. We linearized another sample of pNNELAM1 with ScaI. Then we synthesized an oligonucleotide having the sequence 5' TGT GAA GCT CCC TAA ATT CCC. When this sequence hybridizes to an ELAM1 antisense sequence it introduces a stop codon and a BamHI restriction site into the ELAM1 DNA sequence after nucleotide number 1790. We created a heteroduplex using these three fragments according to the methods of Morinaga et al. (1984) and Chang et al. (1984). We filled in the single stranded gaps with Klenow fragment and T4 ligase and used the mixture to transform E. coli MC1061. We screened the resulting colonies by checking for a BamHI site and selected mutagenized clones. Consequently on expression, the transmembrane region of the polypeptide is eliminated and the C-terminal amino acid is proline. We called this plasmid pSAB100.

Then we digested pSAB100 with AatII and NcoI and isolated the 5.2 kb fragment. We also digested pNNELAM1 with these two enzymes and isolated the 1.4 kb fragment. NcoI cuts at nucleotide 927 of Figure 1, about the middle of the ELAM1 coding area. We ligated these two DNA fragments and called the plasmid pSAB108. We made this construction because site-directed mutagenesis sometimes causes mutations in other parts of the molecule and we wanted to avoid any such mutations in the coding region of rsELAM1. We digested pSAB108 with NotI and isolated the 3.8 kb fragment. We

- 52 -

ligated this fragment to a 7819 bp fragment of pBG341.jod, created as follows.

First we obtained pSV2-DHFR, ATCC 37146, from the American Type Culture Collection, Bethesda, Md. (USA). (Subramani et al., 1981.) We digested this with ApaI and EcoRI and isolated the 4420 bp fragment. Then, we produced a synthetic double stranded DNA sequence having an ApaI overhang, a DNA sequence encoding nucleotides +190 to +233 of the human gastrin gene (Sato et al., 1986, Figure 4), an XhoI site, and an EcoRI overhang. We ligated this oligonucleotide with the 4420 bp fragment of pSV2-DHFR and called the resulting plasmid pDT4. We digested this plasmid with AatII and XhoI and isolated the 4391 bp fragment.

Then we cleaved the Mullerian Inhibiting Substance expression vector pD1 (Cate et al., 1986) with AatII and SalI and isolated the 5462 bp fragment. We ligated this fragment with the 4391 bp fragment of pDT4 to make pJOD-10.

We digested pJOD-10 with HindIII and BstEII and isolated the large fragment which did not encode Mullerian Inhibiting Substance. We blunt-ended the fragment ends, ligated SalI linkers to the ends and self-ligated the vector. This produced pJOD-s.

Then we digested pJOD-s with AatI and NotI and isolated the 6750 bp fragment. We ligated this to a 1100 bp NotI fragment from pBG341, which we created as follows.

We created pBG341 by replacing the SmaI site of pBG312 (Cate et al., 1986) with a NotI site. We linearized pBG312 with BglII, blunt-ended the fragment by filling in with Klenow, and self-ligated it. We linearized this plasmid with BamHI and again blunt-ended and self-ligated it. We linearized this plasmid with SmaI and ligated to the ends a NotI linker having

- 53 -

the sequence 5' GCGGCGC. We called the resulting plasmid pBG341.

We digested pBG341 with AatII and NotI and isolated the 1100 bp fragment. We ligated this
5 fragment to a 6750 bp fragment of pJOD-s. We called the resulting plasmid pBG341.jod. This plasmid contains the SV40 early and the adenovirus major late promoter. Genes inserted into the plasmid at the NotI site are transcribed from either of these promoters.

10 Then we linearized pBG341.jod with NotI and isolated the linear 7819 bp fragment. We ligated this fragment with the 3.8 kb fragment of pSAB108, which encoded rsELAM1, generating plasmid pSAB110.

We transfected CHO-DHFR⁻ cells by
15 electroporation with plasmid pSAB110 linearized with AatII. We performed electroporation with a Biorad® Gene Pulser at 270V and 960 μ FD using 10^7 cells/ml in 20 mM HEPES pH 7.05, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂HPO₄, and 6 mM dextrose with 20 μ g plasmid and 200 μ g
20 sonicated salmon sperm DNA. Following transfection we cultured the cells in selective medium, alpha⁻ MEM containing 500nM methotrexate and 10% dialyzed FCS. We picked colonies, plated them onto 96-well cluster plates and detected rsELAM1-expressing cells using the
25 monoclonal antibody BB11. After growing cells to confluence in complete medium containing 10% fetal calf serum (FCS) we maintained them in medium containing 2% FCS in which the cells produced rsELAM1. We harvested medium and replaced it with fresh 2% serum every three
30 or four days.

We isolated rsELAM1 from this conditioned medium to at least 95% purity. This involved concentrating the medium and incubating it overnight with Moab BB11 (Example V) covalently coupled to
35 Protein A sepharose. (Schneider et al., 1982.) Then we

- 54 -

washed this resin with PBS to remove unbound protein, eluted bound material with 0.1 M glycine, pH 2.7, neutralized the eluate with sodium phosphate and dialyzed it against PBS. We further purified the
5 rseLAM1 by chromatography with Protein A sepharose in PBS.

Using the following assay, we demonstrated that we had produced rseLAM1. To a 6 cm diameter Petri dish of bacteriologic plastic (e.g., Falcon #10070) we
10 added 2.5 ml of 50 mM Tris buffer, pH 9.5. To this we added 10 μ g of pure rseLAM1. We incubated the plate for 60 minutes at room temperature to allow the rseLAM1 to bind to the plate. Then we aspirated the medium and replaced it with PBS containing 10 mg/ml bovine serum
15 albumin. We incubated the plates overnight at 4° in this solution to block remaining protein binding sites on the plates. We warmed the plates to room temperature, washed them with medium containing 10% fetal calf serum, and incubated them with 2 ml of cells
20 (2×10^6 ml⁻¹) for 20 minutes. We aspirated the medium and washed the plates twice with 3 ml each of medium (RPMI 1640 with 10% serum). Then we examined the plates by microscopy.

We found that cells which bind ELAM1, such as
25 HL-60 cells, bind to rseLAM1-coated plates, while cells which do not bind to ELAM1, e.g., the B cell line RAMOS, do not bind to these plates.

In addition, we found that the specific Moab BB11 blocks the binding of HL-60 cells to rseLAM1
30 coated plates. Together, these results show first, that we have produced rseLAM1, and, second, that like ELAM1, rseLAM1 possesses the ability to bind to leukocytes.

We also constructed a vector expressing
35 recombinant soluble VCAM1b (rsVCAM1b). This vector was

- 55 -

named pBN1006, and the rsVCAM1b expressed by pBN1006 contains the portion of the extracellular domain of VCAM1b encoded by the DNA sequence shown in Figure 4 from nucleotide 107 to nucleotide 2193.

5 In order to generate a cell line capable of constitutively expressing full length soluble VCAM1b, we first created a vector derived from pJOD-s having a unique NotI site downstream from the adenovirus major late promoter, so that NotI fragments could be inserted
10 into the expression vector. pJOD-s was linearized by NotI cleavage of the plasmid DNA. The protruding 5' termini were blunt-ended using Mung bean nuclease and the linearized DNA fragment was purified by low melting temperature agarose (LMA) gel electrophoresis. The DNA
15 fragment was religated using T4 DNA ligase. The ligated molecules were then transformed into E. coli JA221 (ATTC accession no. 33875). Colonies were screened for the absence of a NotI site. The resulting vector was designated as pJOD-s delta Not1. pJOD-s
20 delta Not1 was linearized using SalI and the 5' termini were dephosphorylated using calf intestine alkaline phosphatase. The linearized DNA fragment was purified by LMA gel electrophoresis and ligated in the presence of phosphorylated oligonucleotide ACE 175 (5'
25 pTCGACGCGGCCGCG). The ligation mixture was transformed into E. coli JA221 and colonies were screened for the presence of a NotI site. The correct plasmid was named PMDR901.

Soluble VCAM1b was obtained by truncating
30 VCAM1b clone 1E11 at nucleotide 2193 by digestion with AluI, thus eliminating the transmembrane and intracellular portion as well as the 3' untranslated region. A stop codon-NotI linker was added, and the insert was religated into pCDM8. The insert was
35 excised from pCDM8 with NotI and ligated into PMDR901

- 56 -

at the NotI site. This construct, designated pBN1006, encodes full length soluble VCAM1b, having amino acids 1-698 as shown in Figure 4.

Using materials and methods already
5 described, we have also constructed plasmids expressing truncated forms of the rsELAM1 and rsVCAM1b molecules described above. These truncated forms, comprising the amino acid sequences of one or more of the particular domains of the extracellular regions of ELAM1 and
10 VCAM1b, were used to investigate which domain or domains are involved most directly in cell-to-cell adhesion. Our initial experiments have investigated the domains of ELAM1 and VCAM1 and 1b that are recognized by antibodies against those molecules, i.e.,
15 antibodies BB11 and 4B9, respectively.

A soluble ELAM1 construct designated CH101 was prepared comprising the lectin-like domain of ELAM1. Referring to Figure 1, CH101 was the expression product of a cDNA sequence including nucleotides 1-557
20 (coding for amino acids 1 through 139 of ELAM1) and a stop codon. Another soluble construct designated CH102 was prepared comprising the lectin-like domain and the EGF-like domain of ELAM1. Referring to Figure 1, CH102 was the expression product of a cDNA sequence that
25 included nucleotides 1-671 (coding for amino acids 1 through 177 of ELAM1) and a stop codon. The soluble ELAM1 construct CH102 was found to immunoprecipitate the anti-ELAM1 monoclonal antibody, BB11.

The following soluble VCAM1 and 1b constructs
30 were similarly prepared:

(A) domain 1 (nucleotides 1-430 of Figure 3, coding for amino acids 1-108);

(B) domain 1 + domain 2 (nucleotides 1-757 of Figure 3, coding for amino acids 1-217);

- 57 -

(C) domain 1 + domain 2 + domain 3
(nucleotides 1-1036 of Figure 3, coding for amino acids
1-310);

(D) domain 1 + domain 2 + domain 3 (from a
5 hybrid of VCAM1 and VCAM1b cDNA, coding for amino acids
1-317 as depicted in Figure 4);

(E) full length soluble VCAM1 (nucleotides
1-1924 of Figure 3, coding form amino acids 1-606); and

(F) full length soluble VCAM1b (nucleotides 1-2193 of
10 Figure 4, coding for amino acids 1-698).

Of the foregoing VCAM1 constructs, B, C, D, E
and F (but not A) were immunoprecipitated with the
anti-VCAM1 antibody 4B9. Constructs B, D, E and F were
also found to produce protein functional for cell
15 adhesion. Conditioned media containing protein encoded
by constructs B, D, E and F were concentrated, passed
over an immunoaffinity column of immobilized 4B9
antibody, and the bound protein eluted and neutralized
as described for rSELAM1. The eluted proteins were
20 immobilized on plastic as described for rSELAM1 and
found to support specific adhesion of RAMOS and JURKAT
cells. These results indicate that the first two
domains of VCAM1 are sufficient to support adhesion of
certain VLA4-expressing human lymphoid cell lines.

25 EXAMPLE IX -- ISOLATION OF THE ELAM1 AND VCAM1 PROMOTER

We have isolated and characterized genomic
clones for the ELAM1 and VCAM1 genes. We isolated the
ELAM1 clones as follows:

We selected as probes either the entire ELAM
30 pCDM8 clone 6 insert or a 400 base pair fragment from
its 5' end. We labeled these molecules with ³²P by
random priming. Then we screened a human genomic EMBL3
library with the ELAM cDNA probes. We isolated and
characterized a genomic ELAM1 clone from the library

and designated it EL1-07. It includes approximate kb of 5' flanking sequence including the transcriptional promoter for ELAM1 and approximately 100 base pairs of coding sequence at the 5' end of the gene. Current knowledge suggests that the relevant control sequences for induction will be included within the DNA sequence represented by this phage clone. (Leonardo and Baltimore, 1989.) We sequenced a region including 840 bp of 5' flanking sequence and 720 bp of the 5' end of the ELAM1 gene, including the first two exons, the first intron and part of the second intron. We present this sequence in Figure 7. The 5' flanking region displays a classical promoter structure including TATAAA and CAAT sequences. It also contains the sequence GGGGATTTCC about 95 base pairs upstream from the presumed start of transcription. This sequence is an NF- κ B binding sequence identical to that found in the human κ immunoglobulin (Ig) gene enhancer. NF- κ B is an inducible DNA binding protein known or suspected to stimulate transcription of a number of genes relevant to inflammation and the immune response (such as the immunoglobulins, the interleukin-2 receptor, and β -interferon, among others). It can be activated by TNF, IL-1, and LPS, the same inducers known to stimulate production of ELAM1, VCAM1, and ICAM1. (Leonardo and Baltimore, 1989; Osborn et al., 1989.) We have demonstrated that NF- κ B DNA binding activity is stimulated in endothelial cells by IL-1 and TNF, and we are currently engaged in defining minimal DNA sequences necessary for inducible transcription from the ELAM1 promoter, by transfection of promoter/reporter gene constructs into endothelial and other cell types.

- 59 -

We deposited clone EL1-07 under the Budapest Treaty with In Vitro International, Inc., Linthicum, Md. (USA) on December 7, 1989. It is identified as:

5 EL1-07
 Accession Number IVI-10218.

We also isolated an EMBL3 genomic clone representing the VCAM1 gene by probing the previously mentioned EMBL3 human genomic library with a ³²p-labeled 30 base oligomer probe homologous to the 5' end of the VCAM1 cDNA. We designated this clone VC1-16 and deposited it under the Budapest Treaty with In Vitro International, Inc., Linthicum, Md. (USA) on December 7, 1989. It is identified as:

15 VC1-16
 Accession Number IVI-10217.

We sequenced a region including approximately 300 bp of 5' flanking sequence and 900 bp of the 5' end of the VCAM1 gene, including the first exon, the first intron, and part of the second exon. We present this sequence in Figure 8. The 5' flanking region has a classical TATAAA sequence, and two NF- κ B consensus sequences: AGGGATTTC on the sense strand from about -63 to -54 from the start of transcription, and GGGGAAACCC on the reverse complement strand from about -69 to -78. This sequence will be used for studies analogous to those proposed for the ELAM1 promoter sequence.

EXAMPLE X -- ANTIBODIES RECOGNIZING CDX

We isolated CDX, a MILA involved in ELAM1-mediated adhesion. As a first step, we prepared monoclonal antibodies that recognized an antigen on the leukocyte cell surface and that interfered with leukocyte-endothelial cell binding. In order to assure that the antigen that these monoclonals recognized was involved in ELAM1-mediated adhesion, we tested the

- 60 -

monoclonals in systems in which ELAM1-mediated binding was the exclusive cell-cell binding pathway.

1. Preparation and Analysis of Monoclonal Antibodies Against CDX

a. Adhesion assay

To identify Moabs that inhibit leukocyte-endothelial cell binding, we developed an improved assay to detect endothelial cell-leukocyte adhesion. We performed this assay using HL-60 cells and HUVECs. It should be clear that one can perform such an assay using any cell line that expresses a MILA and with any cell line that expresses an ELAM. In 48-well tissue-culture plates we grew HUVECs to confluence (8×10^4 cells/well). We washed the cells once with RPMI/1% FCS and added 0.5 ml RPMI/1% FCS with 13 U/ml of IL- 1β to each well (except the control wells). We incubated these cells for 4 hours at 37°C. Just before use, we washed them once with RPMI/1% FCS. The HL-60 cells we used in the assay had been labeled overnight with 1 μ Ci/ml of 35 S-methionine. We washed these cells once and then resuspended them in RPMI/1% FCS at 5×10^6 cells/ml. We took 100 μ l of the HL-60 cells and incubated them for 30 min at 0°C with 50 μ l of Moab (1 μ g/ml). Then we added the 150 μ l to each well of HUVECs. We allowed the cells to bind for 10 min at 20°C and then washed the wells gently once with RPMI/1% FCS. We filled the wells with RPMI/1% FCS, sealed the plates, inverted them, and centrifuged them for 2 min at 500 x g. We removed the media and washed the wells two more times with PBS⁻. (PBS⁻ is PBS without Ca⁺⁺ and without Mg⁺⁺.) We determined the number of HL-60 cells bound to the HUVECs by solubilizing the cells in each well with 200 μ l of 0.2N NaOH/1% SDS, adding 4.5 ml of

- 61 -

scintillant (Ready Protein, Beckman), and counting with a scintillation counter.

b. Preparation of hybridomas

To make monoclonal antibodies against CDX we
5 prepared hybridomas in the following manner. We
injected BALB C mice with whole, live HL-60 cells.
Initially, each mouse received 2×10^7 cells in PBS⁼
intraperitoneally (IP). We injected complete Freund's
adjuvant intraperitoneally at a different site 2-24
10 hours later. We boosted the mice with 2×10^7 cells IP
every second week for six weeks. Four days before
fusing we injected the mice intravenously with 5×10^6
cells and IP with 5×10^6 cells.

We tested immune serum from these animals for
15 the ability to inhibit binding of the HL-60 cells to
IL- 1β stimulated HUVECs by the adhesion assay described
above. The immune serum tested positive after the
third boost and we proceeded to produce hybridomas from
the spleen cells of the immunized animals. We
20 performed fusion of spleen cells and myeloma cells in a
manner standard to the art. (See, Goding, 1983.)

Using the adhesion assay we described above,
we screened the hybridomas for those producing
monoclonal antibodies that inhibited the binding of HL-
25 60 cells to IL- 1β -induced HUVECs. In this way we
identified hybridomas that produced monoclonal
antibodies that recognized CDX. We used five of these
hybridomas to produce ascites fluid. We deposited one
of them, designated SGB₃B₄, under the Budapest Treaty
30 with In Vitro International, Inc., Linthicum, Md. (USA)
on April 25, 1989. It is identified as:

SGB₃B₄

Accession number: IVI-10205

- 62 -

c. FACS analysis

To identify to which cell types our monoclonals bound, we performed FACS analysis. This involved taking 2×10^5 cells, washing them one time with PBS⁻, and then blocking Fc receptors by incubation in 25 μ l of RPMI, 1% FCS, 0.1 mg/ml human IgG, and 0.1% sodium azide for 10 min at 0°C. We then added antibody (25 μ l at 1 μ g/ml) and incubated the cells 30 min at 0°C. We centrifuged the cells at 250 x g for 5 min, washed them two times with Buffer A (PBS⁻, 5% FCS, 0.1% azide) and resuspended them in 25 μ l Buffer A containing 0.1 mg/ml human IgG. We added fluorescein-conjugated anti-mouse IgG (25 μ l at 5 μ g/ml in Buffer A (Cappel)) and incubated the mixture 30 min at 0°C. We centrifuged the cells, washed them once with Buffer A, and resuspended them in 250 μ l Buffer A. Then we analyzed them on a Beckton-Dickinson FACStar Cell Sorter.

We performed cell binding studies with the ELAM1-expressing COS cells essentially as described for the HL-60 cell-HUVEC adhesion assay.

2. Demonstration That Hybridoma SGB₃B₄ Produced Monoclonal Antibodies That Recognize CDX

We have developed several lines of evidence that demonstrate the specific recognition of monoclonals from hybridoma SGB₃B₄ for a MILA involved in ELAM1-mediated binding, specifically, CDX.

First, the α -CDX antibodies should inhibit binding of cells expressing CDX to ELAM1-expressing cells. Using the adhesion assay, we showed that these monoclonals do indeed inhibit the binding of HL-60 cells and PMNs to IL-1 β -induced HUVECs and ELAM1-expressing COS 7 cells. In the presence of 60.3, a

- 63 -

monoclonal antibody against the β_2 integrin chain, the only binding pathway for HL-60 cells and PMNs that is utilized in ELAM1-expressing COS 7 cells is ELAM1 itself. Therefore, antibody inhibition of cell-cell
5 adhesion in this system must be through the ELAM1 pathway via CDX.

Second, α -CDX monoclonals should recognize those cells that bind to ELAM1-expressing cells in an adhesion assay, but should not recognize those cells
10 that do not bind to ELAM1 in this assay. Using FACS analysis, we determined the binding pattern of our Moabs. These monoclonals bound to the following cell types: HL-60, U937, HT-29, THP-1, SW620, SW948, SW1417, monocytes, eosinophils, and PMNs. They did
15 not bind to these cells: RAJI, DAUDI, RAMOS, HeLa, or JY. (We isolated the non-transformed cells by fractionating peripheral blood leukocytes.) This binding pattern precisely parallels the binding of these cells to ELAM1-expressing COS 7 cells and to
20 rsELAM1-coated plates.

Third, α -CDX monoclonals should exhibit a different recognition pattern than monoclonals against other leukocyte cell-surface antigens, such as LFA-1, LFA-3, CD44, ICAM1 and CD4. In fact, no other
25 monoclonal of which we are aware exhibits the same cell-recognition pattern as our antibodies.

In sum, it is apparent that the monoclonals produced by hybridoma SGB₃B₄, and by other hybridomas we isolated, recognize CDX. Consequently, we used these
30 monoclonals to isolate CDX itself.

- 64 -

EXAMPLE XI -- ISOLATION OF CDX1. Iodination of HL-60 Cell Surface Proteins

We washed 1×10^7 HL-60 cells three times with PBS⁻, resuspended them in 0.5 ml PBS⁻ and added them to a tube coated with 50 μ g 1,3,4,6-tetrachloro-3 α ,6 α -diphenylglycouril (Sigma Chemical Co.). To this we added 1 mCi of ¹²⁵I. We incubated the mixture for 30 min at 0°C. We transferred labeled cells to a tube containing 10 ml of RPMI/10% FCS and centrifuged them at 1000 x g for 5 min. Then we washed them first with another 10 ml of RPMI/10% FCS and second with 2 ml of PBS⁻. (Alternatively, we have labeled the cells metabolically with ³⁵S-methionine or ³⁵S-cysteine.) We lysed the cells by addition of 1.0 ml PBS⁻ containing 1% NP40, 2 mM PMSF, 1 mM EDTA, soybean Trypsin inhibitor (50 mg/ml), and Leupeptin (1 mM) (Sigma Chemical Co.). Then we incubated them for 30 min at 0°C. We centrifuged the lysate for 10 min at 10,000 x g to remove particulate matter. We precleared the supernatant containing labeled solubilized membrane proteins with 10 μ g of rabbit anti-mouse IgM (Jackson Immuno-Research Labs) and 50 μ l of Protein A sepharose (Zymed, 2 mg Protein A/ml) for 2 hours at 0°C. We stored the lysate at 4°C.

2. Immunoprecipitation of CDX

We purified CDX away from the other labeled proteins using the Moabs to immunoprecipitate it. We performed the immunoprecipitation as follows:

We incubated precleared lysate (50-100 μ l) with 10 λ of ARX beads for 2 hours at 4°C. We washed the sepharose four times with 2 ml PBS⁻ containing 0.75% NP40, 0.2% DOC, and 1 mM EDTA. Then we

- 65 -

resuspended the ARX beads in non-reducing SDS sample buffer. We heated the sample for 10 min at 85°C and removed the supernatant. To this we added β -ME to 5%, heated for 5 min, and separated the molecules on a 10% SDS polyacrylamide gel. We dried the gel and autoradiographed it.

CDX appeared on the autoradiograph as a single, diffuse band with molecular weight of approximately 150 kD.

10 EXAMPLE XII -- ISOLATION OF CLONE EXPRESSING CDX

Following the general procedure of Example I, we prepared two cDNA libraries in the pCDM8 vector from the two types of CDX-expressing cells, HL-60 cells and U937 cells. We then prepared an enriched CDX cDNA library by first creating a ^{32}P -labeled cDNA probe from 1 microgram of HL-60 poly A+ mRNA, then subtracted non-CDX cDNA sequences from the probe by hybridizing with 30 micrograms of poly A+ mRNA from HeLa cells, which do not express CDX. (See, Davis, 1986.) We used the subtracted probe to create an enriched sublibrary from HL-60 cells in E.coli MC1061 P3 and grew about 2100 clones in twenty-two 96-well plates. A V937 enriched CDX sublibrary was prepared in a similar manner, and 1400 clones were obtained.

25 Following the general procedure of Example II, we divided the colonies into 22 pools for transfection of COS 7 cells by spheroplast fusion. We assayed transfected COS 7 cells for CDX expression by panning with α -CDX monoclonal antibodies from hybridoma SGC₂E₅ (isolated in Example X) according to the method of Seed and Aruffo (1987). Pool #7 assayed positive, yielding two clones with a 2.1 kb cDNA insert, which were designated 7.1 and 7.2.

- 66 -

A DNA sequence for CDX was obtained by the Maxam and Gilbert technique (1980) from CDX pCDM8 clone 7.2 and from a portion of the 7.2 insert subcloned into the sequencing vector, pNN11. The latter plasmid was
5 designated pSQ219. The DNA sequence obtained is set forth in Figure 9.

We deposited a culture containing the plasmid CDX pCDM8 clone 7.2 under the Budapest Treaty with In Vitro International, Inc., 611 P. Hammonds Ferry Rd.,
10 Linthicum, Md. 21090 (USA) on April 26, 1990. The deposit is identified as:

CDX pCDM8 / E. coli MC1061 P3

Accession Number IVI-10242

We also transfected CDX clones 7.1 and 7.2
15 into COS 7 cells to confirm expression of CDX. At 48 hours after transfection these cells expressed a protein on their cell surface to which α -CDX antibodies bound, as assayed by FACS. This cell surface protein could be labeled with 125 I and immunoprecipitated. The
20 apparent molecular weight of the immunoprecipitated doublet was approximately 125 kD. The CDX-expressing COS 7.2 cells also form rosettes around sepharose beads coated with rsELAM1, the rosetting was cation dependent and was inhibited by BB11 (anti-ELAM1 antibody), and
25 COS cells transfected with pCDM8 alone (without the inserted CDX gene) did not rosette to rsELAM1 beads. Also, the COS 7.2 cells did not rosette to beads coated with bovine serum albumin. All of the foregoing evidence indicates that CDX is a ligand for ELAM1.

30 Preliminary analysis of the deduced amino acid sequence of CDX indicates a 405-amino acid protein (nucleotides 66-1280 in Figure 9). Using UWGCG Sequence Analysis Software Package (version 6.1, Aug. 1989), we searched the NBRF Protein database (release
35 23, Dec. 1989) using the program FASTA for homology to

- 67 -

other proteins. We also searched Genbank (release 63, Mar. 1990) and EMBL (release 19, May 1989) using TFASTA. In these searches we found short regions (e.g., about 23 amino acids) of homology to certain
5 viral envelope proteins including Herpes simplex virus type 1, Dengue virus, yellow fever and other flaviviruses. In general the homology to known proteins was low, and we conclude that CDX is a novel protein.

10 EXAMPLE XIII -- ANTIBODIES RECOGNIZING MILAS FOR VCAM1

Polyclonal antisera were obtained from three mice that had been immunized with whole JURKAT cells. The serum from one mouse completely inhibited both RAMOS and JURKAT binding to 4 hour-induced HUVECs at
15 room temperature. The sera from the two other mice completely inhibited RAMOS but only partially inhibited JURKAT binding under the same conditions. These data indicate that RAMOS and JURKAT share a MILA, and that JURKAT exhibits at least one other MILA not shared by
20 RAMOS.

To prepare Moabs to lymphocyte MILAS, we immunized mice against whole live RAMOS and JURKAT cells and performed fusion of spleen cells from JURKAT-immunized mice and myeloma cells in the manner
25 described in Example VIII, above. We are screening the resulting hybridomas by the method described in Example VII, which we used successfully to obtain monoclonal antibodies to CDX. To date we have screened the conditioned medium from about 260 hybridomas for
30 inhibition of RAMOS adhesion to HUVECs treated with TNF for 24 hours. About 25 hybridomas have shown consistent partial inhibition of adhesion, and these are currently being subcloned for re-screening. Such

- 68 -

antibodies may be used to both isolate and clone lymphocyte MILAs.

EXAMPLE XIV -- EVIDENCE THAT VLA4 IS A VCAM1 LIGAND

We and other colleagues have performed
5 several studies that demonstrate that VLA4 is a VCAM1 ligand and that VLA4 has separate binding sites for VCAM1 and fibronectin.

First, we showed that monoclonal antibodies against the subunits of VLA4 inhibited the attachment
10 of VLA4-expressing cells to activated HUVECs and to COS cells transfected with VCAM1. VLA4 is composed of the subunits β_1 and α^4 . (Hemler, 1988.) We found that a monoclonal antibody against β_1 , designated B1E11, and goat anti- β_1 heteroantiserum completely inhibited the
15 adhesion of RAMOS cells to activated HUVECs and transfected COS cells. A control antibody did not inhibit adhesion. Furthermore, a monoclonal antibody against the α^4 subunit, designated HP2/1, also blocked attachment of RAMOS to these cells. Similarly, these
20 antibodies inhibited the attachment of the VLA4-expressing T lymphoblastoid cell line HPB-ALL.

Next, we showed that transfecting cells that do not ordinarily express VLA4 with α^4 enabled them to bind to VCAM1-expressing cells. We transfected two
25 sets of K-562 erythroleukemic cells. One set was transfected with a cDNA coding for α^4 . (Takada et al., 1989.) The other was transfected with α^2 , which is not part of VLA4. (Takada and Hemler, 1989.) We showed that K-562 cells transfected with α^4 were now able to
30 bind with a monolayer of VCAM1-transfected COS cells or TNF-activated HUVECs, but parent K-562 cells and K-562 α^2 -transfected cells were not. In addition, monoclonal antibodies against α^4 or β_1 abolished the adhesion of

- 69 -

α^4 -transfected K-562 cells (that normally express the β_1 subunit) to these VCAM1-expressing cells.

Recent studies have shown that VLA4 mediates cell attachment to human plasma fibronectin (FN) through the FN CS-1 site. (Wayner et al., 1989.) We have shown that the VLA4 binding site for VCAM1 is different than its binding site for FN. First, we found that preincubation of RAMOS cells or α^4 -transfected K-652 cells with FN-40 (a soluble FN fragment) inhibited their binding with FN-40, but not with VCAM1-transfected COS cells or TNF α activated HUVECs. Second, we found that a monoclonal against VLA4, HP1/3, inhibited the binding of these cells to transfected COS cells or activated HUVECs, but not to FN-40.

EXAMPLE XV - INHIBITOR SCREENING

One can use ELAMs and their ligands in three basic adhesion assays to screen for potential inhibitors of adhesion, such as synthetic organic chemicals, natural fermentation products, peptides, etc.:

1. Cell-Cell Adhesion Assays

A first assay would test the ability of molecules to inhibit cell-cell adhesion. One could perform this assay in 96-well microtiter plates. First, one creates a cell line that stably expresses an ELAM, for example, as described in Example V. Then one plates out these cells and adds HL-60 cells. Inhibitors are identified by their ability to inhibit HL-60 binding to the ELAM-expressing cells. One would perform an assay exactly as described for screening for monoclonal antibodies to the ELAM ligand.

2. Cell-Adhesion Protein Assays

- 70 -

A second assay would test the ability of a small molecule to inhibit cell binding to ELAM itself. We have developed such an assay with rsELAM1 which works in 96 well microtiter plates. These plates, made of bacteriologic plastic (e.g. Linbro/Titertek #76-232-05®), are incubated with 0.5 µg per well of rsELAM1 in 50 µl of 15 mM sodium carbonate/35mM sodium bicarbonate, pH 9.2, overnight at 4°. The plates are then blocked for one hour at room temperature with PBS containing 10 mg/ml of bovine serum albumin, and then adhesion assays performed as described in Example VIII using, e.g., HL-60 cells, 2×10^6 /ml, 50 µl per well. Under these conditions HL-60 cells bind well to rsELAM1, providing a convenient microassay for screening. One would identify inhibitors by their ability to inhibit HL-60 binding to the plate. Alternatively, one could use an ELAM ligand in this assay, using as the probe a cell line that stably expresses an ELAM.

Another alternative assay in this category would examine the binding of a soluble ELAM or ELAM ligand to monolayers of cells stably expressing an ELAM ligand or ELAM, respectively. The soluble molecule would be labeled with a reporter group (e.g., radioactivity, fluorescent probe, enzyme, etc.)

3. Adhesion Protein-Adhesion Protein Assays

This assay tests the ability of a small molecule to inhibit the binding of an ELAM to its ligand. One of the two molecules in soluble form, e.g., a soluble ELAM, is immobilized in the wells of a 96-well microtiter plate, and adhesion is measured by binding of the other member of the pair, e.g., an ELAM ligand labeled with a reporter group.

- 71 -

In each of these three assays, one detects inhibitors by their ability to inhibit adhesion.

EXAMPLE XVI -- VCAM1/IMMUNOGLOBULIN CONSTRUCT

We have prepared a DNA sequence which, on
5 expression, produces an rsVCAM1/immunoglobulin fusion protein. The DNA sequence contains, from 5' to 3', VCAM1 domains 1-3 and the constant region of an IgG₁ heavy chain gene.

We produced a DNA fragment containing the
10 VCAM1 domains 1-3 through nucleotide 1035 of Figure 3 by polymerase chain reaction (PCR). (Sambrook et al., 1989) The 3'-5' primer had the sequence 5' GA GCT CGA GGC CGC ACC ATG CCT GGG AAG ATG. It is complementary to nucleotides 100-114 in Figure 3 and contains the
15 VCAM1 initiation codon and recognition sites for XhoI and NotI. The 5'-3' primer had the sequence 5' CT AGC TAG CGC GTT TTA CTT CAC. It is complementary to nucleotides 1016-1035 in Figure 3, at the end of domain 3, and contains an NheI recognition site. We used
20 these primers to amplify a segment from a plasmid containing VCAM1 coding region of AM pCDM8 clone 41. The product of this process was a DNA sequence encoding VCAM1 domains 1-3. We digested this DNA fragment with XhoI and NheI and inserted it into pAB53, which we made
25 as follows.

We digested pJOD-s (Example VIII) with SalI and inserted a cDNA sequence encoding human rsCD4. We called this plasmid pJOD-rsT4. We partially digested pJOD-rsT4 with PvuII and SphI to delete the fragment
30 containing the two SV40 enhancer repeats in the SV40 promoter which control transcription of the DHFR cDNA. We religated the plasmid and designated it pJOD-rsT4 delta E. Then we digested pJOD-rsT4 delta E with NheI and NotI and inserted two DNA fragments: first, an

- 72 -

NheI-HindIII linker containing a 5' mRNA splice site and second, a DNA fragment encoding the constant region of an IgG heavy chain gene. We obtained these fragments as follows.

5 We synthesized an NheI-HindIII linker having the following sequence:

```
                    5' splice
5' CTA GCT TTC CAA GGT GAG TCC TA      3'
3'      GA AAG GTT CCA CTC AGG ATT CGA 5'
```

10 The DNA sequence of an IgG heavy chain gene is described in Ellison et al. (1982). We isolated a fragment of this gene from an EMBL3 human genomic library (Example VIII) using an oligonucleotide probe. We digested the fragment with HindIII and NotI and
15 isolated the fragment which included the constant heavy domains and the associated introns.

We ligated these two fragments into pJOD-rsT4 delta E and called the resulting plasmid pAB53. We digested pAB53 with XhoI and NheI to delete the rsT4
20 coding region. We inserted in its place the XhoI-NheI fragment encoding VCAM1 domains 1-3. We called this plasmid VCAM1-IgG₁.

An rsVCAM1/IgG fusion protein is expressed using this plasmid. The plasmid is transfected into
25 CHO cells for stable expression. After transcription of this gene, the mRNA is spliced to remove the introns and upon translation, the cell produces rsVCAM-IgG fusion protein.

30 EXAMPLE XVII -- INHIBITING VCAM1 EXPRESSION WITH AN ANTISENSE NUCLEIC ACID

We describe here an antisense nucleic acid against VCAM1 and a method for testing its ability to inhibit VCAM1 expression in induced HUVECs. An effective nucleic acid sequence for an antisense
35 nucleic acid is one that is complementary to the coding

- 73 -

region of the mRNA and, more particularly, to either the initiation codon, AUG, or the splice sites. (Marcus-Sekura, 1988.) Also, oligomers of about 15 nucleotides are most preferred. Thus, an effective
5 antisense nucleic acid against VCAM1 is an oligomer with the DNA sequence 5' CCC AGG CAT TTT AAG. This would bind to nucleotides 94-108 of Figure 3 (CAT is the antisense initiation codon.) This DNA sequence is synthesized, for example, by an automated DNA
10 synthesizer.

The ability of this antisense nucleic acid to inhibit VCAM1 expression is tested as follows. HUVECs are grown to confluence as in Example V except that the serum used for cell growth would be heat inactivated
15 for 30 min. at 60° to inactivate nucleases. Cells are preincubated with the oligomers at concentrations between 10µM and 100µM, most preferably the highest concentration having no effect on cell viability, for four to forty-eight hours. These ranges are required
20 for effective inhibition. (Marcus-Sekura, 1988; Becker et al., 1989.) The HUVECs are then treated with 10 ng/ml TNF to induce VCAM1. About four hours later the presence of VCAM1 on the surface of the cells is tested by the adhesion assay.

25 EXAMPLE XVIII -- A HAMMERHEAD RIBOZYME WHICH RECOGNIZES VCAM1 mRNA

A hammerhead-type ribozyme which recognizes VCAM1 mRNA is prepared according to the rules of Haselhoff and Gerlach (1988) as follows. First, a
30 cleavage site on the target mRNA is identified. Hammerhead ribozymes cleave after the sequence 5' GUX, where X is any nucleotide. The first instance of this sequence in the coding region of VCAM1 mRNA is the sixth codon: 5' AUG CCU GGG AAG AUG GUC GUG AUC CUU.
35 An appropriate recognition sequence includes about six

- 74 -

nucleotides of the 5' and 3' regions flanking the cleavage site. An eighteen-base recognition sequence which contains the cleavage site is 5' AAG AUG GUC GUG AUC CUU.

5 Then, one designs an RNA sequence for the ribozyme containing the recognition sequence and a sequence for the catalytic "hammerhead." Such a sequence is 5' AAG GAU CAC [CUGAUGAGUCCGUGAGGACGAA] AC CAU CUU. The sequence in brackets generates the
10 catalytic "hammerhead" and the 5' and 3' flanking sequences are complementary to and bind to the recognition sequence. In a similar way, one can also design shorter recognition sequences or those for other cleavage sites in VCAM1 mRNA or the other ELAM or ELAM
15 ligand mRNAs.

EXAMPLE XIX -- ANTI-IDIOTYPIC ANTIBODIES
RECOGNIZING ELAM1 LIGANDS

We have prepared anti-idiotypic antibodies against anti-ELAM1 antibodies that bind to the ligand
20 of ELAM1 on HL-60 cells. We immunized rabbits with protein-A-purified CDB.BB11.BC6 monoclonal (Example V) emulsified 1:1 in complete Freund's adjuvant. Twenty-six days after immunization we bled the rabbits and analyzed the anti-sera for specific antibodies using
25 FACS. We incubated the antibody preparation with either HL-60 cells, which express a ligand for ELAM1, or RAMOS cells, which do not. We found that this antibody preparation specifically bound to the HL-60 cells and not to the RAMOS cells, indicating that it
30 contained antibodies that recognize the ELAM1 ligand. Control anti-serum did not react with either cell line.

- 75 -

EXAMPLE XX -- EVIDENCE OF A NEW ELAM

The binding of U937 cells (which are monocyte-like) to induced HUVECs is not blocked by specific Moabs to the ELAM1, VCAM1, and/or ICAM1 pathways. U937 binding is blocked, however, by a monoclonal antibody to CD29, the β_1 integrin subunit. This leads us to postulate the existence of a new adhesion molecule on HUVECs that interacts with leukocytes via a β_1 integrin. The new molecule is induced with a time-course similar to VCAM1, remaining at maximal levels 48 hours after induction. We have generated a subtracted library from 48-hour TNF-treated HUVECs, using the methods previously described for the 2.5-hour IL-1 induced HUVEC subtracted sublibrary. We are attempting to clone the new molecule using the direct expression protocol described previously.

While we have described herein a number of embodiments of this invention, it is apparent that one of skill in the art could alter our procedures to provide other embodiments that utilize the processes and compositions of this invention. Therefore, one will appreciate that the scope of this invention is to be defined by the claims appended hereto rather than by the specific embodiments that we have presented by way of example.

- 76 -

CITED PUBLICATIONS

Arfors, K.-E., et al., "A Monoclonal Antibody to the Membrane Glycoprotein Complex CD18 Inhibits Polymorphonuclear Leukocyte Accumulation and Plasma Leakage In Vivo", Blood, 69, pp. 338-40 (1987)

Aruffo, A., and Seed, B., "Molecular Cloning of a CD28 cDNA by a High Efficiency COS Cell Expression System", Proc. Natl. Acad. Sci. USA, 84, pp. 8573-77 (1987)

Becker, D., et al., "Proliferation of Human Malignant Melanomas Is Inhibited by Antisense Oligodeoxynucleotides Targeted Against Basic Fibroblast Growth Factor", EMBO J., 8, pp. 3685-91 (1989)

Benchimol, S., et al., "Carcinoembryonic Antigen, A Human Tumor Marker, Functions as an Intercellular Adhesion Molecule", Cell, 57, pp. 327-34 (1989)

Bevilacqua, M.P., and M.A. Gimbrone, "Inducible Endothelial Functions in Inflammation and Coagulation", Seminars in Thrombosis and Hemostasis, 13, pp. 425-33 (1987)

Bevilacqua, M.P., et al., "Interleukin 1 Acts on Cultured Human Vascular Endothelium to Increase the Adhesion of Polymorphonuclear Leukocytes, Monocytes, and Related Leukocyte Cell Lines", J. Clin. Invest., 76, pp. 2003-11 (1985) ("Bevilacqua I")

Bevilacqua, M.P., et al., "Endothelial-Dependent Mechanisms of Leukocyte Adhesion: Regulation by Interleukin-1 and Tumor Necrosis Factor", Leukocyte Emigration and Its Sequelae (S. Karger A.G., Switzerland, 1987a), pp. 79-93 ("Bevilacqua II")

Bevilacqua, M.P., et al., "Identification of an Inducible Endothelial-Leukocyte Adhesion Molecule", Proc. Natl. Acad. Sci. USA, 84, pp. 9238-42 (1987b) ("Bevilacqua III")

- 77 -

- Bevilacqua, M.P., et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins", Science, 243, pp. 1160-5 (1989) ("Bevilacqua IV")
- Breathnach, R. and P. Chambon, "Organization and Expression of Eucaryotic Split Genes Coding for Proteins", Ann. Rev. Biochem., 50, pp. 349-83 (1981)
- Brenan, M. and C.R. Parish, "Intracellular Fluorescent Labelling of Cells for Analysis of Lymphocyte Migration", J. Immun. Meth., 74, pp. 31-38 (1984)
- Capon, D.J., et al., "Designing CD4 Immuno adhesins for AIDS Therapy", Nature, 337, pp. 525-31 (1989)
- Carlsson, R., and C. Glad, "Monoclonal Antibodies into the '90s", Bio/Technology, 7, pp. 567-73 (June 1989)
- Cate, R., et al., "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells", Cell, 45, pp. 685-98 (1986)
- Cech, T.R., "Ribozymes and Their Medical Implications", J. Amer. Med. Assn., 260, pp. 3030-4 (1988)
- Chang et al., "Recombination Following Transformation of Escherichia coli by Heteroduplex Plasmid DNA Molecules", Gene, 29, pp. 255-61 (1984)
- Cotran, R.S., et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo", J. Exp. Med., 164, pp. 661-66 (1986)
- Cotran, R.S., and J.S. Pober, "Endothelial Activation: Its Role in Inflammatory and Immune Reactions," in Endothelial Cell Biology, Simionescu and Simionescu, Eds., Plenum Press, New York (1988), pp. 335-47
- Dana, N., et al., "Mol Surface Glycoprotein: Structure, Function and Clinical Importance", Pathol. Immunopathol. Res., 5, pp. 371-83 (1986)
- Davis, M.M., "Subtractive cDNA Hybridizaion and the T-Cell Receptor Gene", Handbook of Experimental Immunology In Four Volumes, 4th ed. Blackwell Scientific Publications, Oxford, England (1986), pp. 76.1-76.13

- 78 -

Davis, M.M., et al., "Cell Type-Specific cDNA Probes and the Murine I Region: The Localization and Orientation of Ad", Proc. Natl. Acad. Sci. USA, 81, pp. 2194-98 (1984)

Devereux, J., et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," Nucl. Acids Res., 12, pp. 387-95 (1984)

Duguid, J.R., et al., "Isolation of cDNAs of Scrapie-Modulated RNAs by Subtractive Hybridization of a cDNA Library", Proc. Natl. Acad. Sci. USA, 85, pp. 5738-42 (1988)

Dustin, M.L., and T.A. Springer, "Lymphocyte Function-Associated Antigen-1 (LFA-1) Interaction with Intercellular Adhesion Molecule 1 (ICAM1) Is One of at Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells," J. Cell. Biol., 107, pp. 321-33 (1988)

Dustin, M.L., et al., "Induction by IL1 and Interferon-gamma: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1), J. Immunol., 137, pp. 245-254 (1986)

Ellison, J.W., et al., "The Sequence of a Human Immunoglobulin C-gamma-1 Gene," Nucl. Acids Res., 10, pp. 4071-79 (1982)

Feinberg, A.P., and B. Vogelstein, "A Technique for Radiolabeling DNA Restriction Endonuclease Fragments to High Specific Activity", Anal. Biochem., 132, pp. 6-13 (1983)

Feinberg, A.P., and B. Vogelstein, "A Technique for Radiolabeling DNA Restriction Endonuclease Fragments to High Specific Activity", Anal. Biochem., 137, pp. 266-67 (1984) (Addendum)

Fisher, R.A., et al., "HIV Infection Is Blocked In Vitro by Recombinant Soluble CD4", Nature, 331, pp. 76-78 (1988)

Gimbrone, M.A., "Culture of Vascular Endothelium", Prog. Hemostasis Thromb., 3, pp. 1-28 (1976)

Goding, W., ed., Monoclonal Antibodies: Principles and Practice, (Academic Press, New York, 1983)

Goldenberg, D.M., "Targeted Cancer Treatment," Immunology Today, 10, pp. 286-88 (1989)

- 79 -

Gubler, U. and Hoffman, B.J., "A Simple and Very Efficient Method for Generating cDNA Libraries", Gene, 25, pp. 263-69 (1983)

Hambor, J.E., et al., "Functional Consequences of Anti-Sense RNA-Mediated Inhibition of CD8 Surface Expression in a Human T Cell Clone," J. Exp. Med., 168, pp. 1237-45 (1988)

Harlan, J.M., "Leukocyte-Endothelial Interactions," Blood, 65, pp. 513-25 (1985) ("Harlan I")

Harlan, J.M., "Neutrophil-Mediated Vascular Injury", Acta Med. Scand., Suppl., 715, pp. 123-29 (1987) ("Harlan II")

Harlan, J.M., et al., "The Role of Neutrophil Membrane Proteins in Neutrophil Emigration," in Leukocyte Emigration and Its Sequelae, H. Movat, ed. (S. Karger AG, Basel, Switzerland, 1987), pp. 94-104

Haselhoff, J., and W.L. Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," Nature, 334, pp. 585-591 (1988)

Hedrick, S.M., et al., "Isolation of cDNA Clones Encoding T Cell-Specific Membrane-Associated Proteins," Nature, 308, pp. 149-53 (1984)

Hemler, M.E., "Adhesion Protein Receptors on Hematopoietic Cells", Immunol. Today, 9, pp. 109-113 (1988)

Hemler, M.E., et al., "The VLA Protein Family (Characterization of Five Distinct Cell Surface Heterodimers Each with a Common 130,000 Molecular Weight β Subunit)," J. Biol. Chem., 262, pp. 3300-09 (1987a)

Hemler, M.E., et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides," J. Biol. Chem., 262, pp. 11478-85 (1987b)

Hirt, B., "Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures", J. Mol. Biol., 26, pp. 365-69 (1967)

Hough, A. and L. Sokoloff, "Pathology", Chap. 4, Rheumatoid Arthritis, P.D. Ustinger, N.J. Zugifler, and Ehrlich, G.E., eds., (Lippencott, Philadelphia, 1985), pp. 49-69

- 80 -

Hunkapiller, T. and L. Hood, "Diversity of the Immunoglobulin Gene Superfamily", Adv. Immunol., 44, pp. 1-63 (1989)

Huse, W.D., et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, 246, pp. 1275-81 (1989)

Hynes, R.O., "Integrins: A Family of Cell Surface Receptors", Cell, 48, pp. 549-554 (1987)

Kaldoron et al., Nucl. Acids Res., 10, pp. 5161-71 (1982)

Kennedy, R.C., et al., "Anti-idiotypes and Immunity," Sci. Am., 255, pp. 48-56 (July 1986)

Kurzinger, K., et al., "A Novel Lymphocyte Function-Associated Antigen (LFA-1): Cellular Distribution, Quantitative Expression, and Structure", J. Immunol., 127, pp. 596-602 (1981)

Lehrach, H., et al., "RNA Molecular Weight Determinations by Gel Electrophoresis under Denaturing Conditions, a Critical Reexamination", Biochem., 16, pp. 4743-51 (1977)

Lenardo, M.J. and D. Baltimore, "NF- κ B: A Pleiotropic Mediator of Inducible and Tissue Specific Gene Control," Cell, 58, pp.227-30 (1989)

Malech, H.L. and Gallin, J.I., "Neutrophils in Human Diseases", N. Eng. J. Med., 317, pp. 687-94 (1987)

Maniatis, T., et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982)

Marcantonio, E.E., and R.O. Hynes, "Antibodies to the Conserved Cytoplasmic Domain of the Integrin β -1 Subunit React with Proteins in Vertebrates, Invertebrates and Fungi," J. Cell. Biol., 106, pp. 1765-72 (1988)

Marcus-Sekura, C.J., "Techniques for Using Antisense Oligonucleotides to Study Gene Expression," Anal. Biochem., 172, pp. 289-95 (1988)

Marlin, S.D., and T.A. Springer, "Purified Intercellular Adhesion Molecule-1 (ICAM-1) Is a Ligand for Lymphocyte Function-Associated Antigen 1 (LFA-1)," Cell, 51, pp. 813-9 (1987)

- 81 -

Maxam, A. and W. Gilbert, "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages", Methods in Enzymol., 65, pp. 499-560 (1980)

Morinaga et al., "Improvement of Oligonucleotide-Directed Site-Specific Mutagenesis Using Double-Stranded Plasmid DNA," Bio/Technology, 2, pp. 636-9 (1984)

Oostra et al., "Transforming Activity of Polyoma Virus Middle-T Antigen Probed by Site-Directed Mutagenesis," Nature, 304, pp. 456-60 (1983)

Osborn, L., et al., "Tumor Necrosis Factor α and Interleukin 1 Stimulate the Human Immunodeficiency Virus Enhancer by Activation of the Nucleus Factor κ B," Proc. Natl. Acad. Sci., U.S.A., 86, pp. 2336-40 (1989)

Peden, K.W.C. and D. Nathans, "Local Mutagenesis Within Deletion Loops of DNA Heteroduplexes," Proc. Natl. Acad. Sci., U.S.A., 79, 7214-17 (1982)

Pober, J.S., et al., "Overlapping Patterns of Activation of Human Endothelial Cells by Interleukin 1, Tumor Necrosis Factor, and Immune Interferon," J. Immunol., 137, pp. 1895-6 (1986)

Ross, R., "The Pathogenesis of Atherosclerosis - An Update", N. Eng. J. Med., 314, pp. 488-500 (1986)

Rothlein, R., et al., "A Human Intercellular Adhesion Molecule (ICAM-1) Distinct from LFA-1," J. Immunol., 137, pp. 1270-4 (1986)

Ruoslahti, E., "Fibronectin and its Receptors", Ann. Rev. Biochem., 57, pp. 375-413 (1988)

Sambrook, J., et al., "In Vitro Amplification of DNA by Polymerase Chain Reaction," Chapter 14 in Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)

Sandri-Goldin, R.M., et al., "High Frequency Transfer of Cloned Herpes Simplex Virus Type I Sequences to Mammalian Cells by Protoplast Fusion", Molec. and Cell Biol., 1, pp. 743-52 (1981)

Sargent, T.D., "Isolation of Differentially Expressed Genes", Methods in Enzymol., 152, pp. 423-47 (1987)

- 82 -

Sato, K., et al., "A Specific DNA Sequence Controls Termination of Transcription in the Gastrin Gene," Molec. and Cell Biol., 6, pp. 1032-43 (1986)

Schneider, C., et al., "A One-Step Purification of Membrane Proteins Using a High Efficiency Immunomatrix" J. Biol. Chem., 257, pp. 10766-69 (1982)

Seed, B., "An LFA-3 cDNA Encodes a Phospholipid-Linked Membrane Protein Homologous to Its Receptor CD2", Nature, 329, pp. 840-42 (1987)

Seed, B. and A. Aruffo, "Molecular Cloning of the CD2 Antigen, the T-Cell Erythrocyte Receptor, by a Rapid Immunoselection Procedure", Proc. Natl. Acad. Sci. USA, 84, pp. 3365-69 (1987)

Skerra, A. and A. Pluckthun, "Assembly of a Functional Immunoglobulin F₁ Fragment in Escherichia coli," Science, 240, pp. 1038-1043 (1988)

Simmons et al., "ICAM, an Adhesion Ligand of LFA-1, Is Homologous to the Neural Cell Adhesion Molecule NCAM," Nature, 331, pp. 624-47 (1988)

Smith, C.W., et al., "Cooperative Interactions of LFA-1 and Mac-1 with Intercellular Adhesion Molecule 1 in Facilitating Adherence and Transendothelial Cell Migration of Human Neutrophils in Vitro," J. Clin. Invest., 83, pp. 2008-17 (1989)

Springer, T.A., et al., "The Lymphocyte Function-Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune System", Ann. Rev. Immunol., 5, pp. 223-252 (1987)

Staunton, D.E., et al., "Primary Structure of ICAM-1 Demonstrates Interaction Between Members of the Immunoglobulin and Integrin Supergene Families", Cell, 52, pp. 925-33 (1988)

Subramani, S., et al., "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simina Virus 40 Vectors," Molec. Cell. Biol., 1, pp. 854-64 (1981)

Takada, Y., and M.E. Hemler, "The Primary Structure of the VLA-2/Collagen Receptor α^2 Subunit (Platelet GP Ia): Homology to Other Integrins and the Presence of a Possible Collagen-Binding Domain," J. Cell. Biol., 109, pp. 397-407 (1989)

- 83 -

Takada, Y., et al., "The Primary Structure of the $\alpha 4$ Subunit of VLA-4: Homology to Other Integrins and a Possible Cell-Cell Adhesion Function," EMBO J., 8, pp. 1361-68 (1989)

Thomas, H. and Sikora, K., "Biological Approaches to Cancer Therapy", J. Intl. Med. Res., 17, pp. 191-204 (1989)

Todd III, R.F., et al., "The Anti-Inflammatory Properties of Monoclonal Anti-Mol (CD11B/CD18) Antibodies in Vitro and in Vivo," in Structure and Function of Molecules Involved in Leukocyte Adhesion, Rosenthal et al., Eds., Springer - Verlag, New York (1989) in press

Vedder, N.B., et al., "A Monoclonal Antibody to the Adherence-Promoting Leukocyte Glycoprotein, CD18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits", J. Clin. Invest., 81, pp. 939-44 (1988)

von Heijne, G., "A Method for Predicting Signal Sequence Cleavage Sites", Nucl. Acids Res., 14, pp. 4693-90 (1986)

Ward, E.S., et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli," Nature, 341, pp. 544-46 (1989)

Wallis, W.J., and J.M. Harlan, "Effector Functions of Endothelium in Inflammatory and Immunologic Reactions," Pathol. Immunopathol. Res., 5, pp. 73-103 (1986)

Wayner, E.A., et al., "Identification and Characterization of the Lymphocyte Adhesion Receptor for an Alternative Cell Attachment Domain in Plasma Fibronectin," J. Cell. Biol., in press (1989)

Weintraub, H.M., "Antisense RNA and DNA," Sci. Am., 262, pp. 40-46 (Jan. 1990)

Wheeler, M.E., et al., "Cultured Human Endothelial Cells Stimulated with Cytokines or Endotoxin Produce an Inhibitor of Leukocyte Adhesion", J. Clin. Invest., 82, pp. 1211-18 (1988)

White, J. and D. Littmann, "Viral Receptors of the Immunoglobulin Superfamily", Cell, 56, pp. 725-28 (1989)

- 84 -

Williams, A. and Barclay, A.N., "The Immunoglobulin Superfamily -- Domains for Cell Surface Recognition", Ann. Rev. Immunol., 6, pp. 381-405 (1988)

Wysocki, L.J. and V.L. Sato, "'Panning' for Lymphocytes: A Method for Cell Selection", Proc. Natl. Acad. Sci. USA, 75, pp. 2844-48 (1978)

Yamasaki, K., et al., "Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNB2) Receptor", Science, 241, pp. 825-28 (1988)

Young, R.A. and R.W. Davis, "Efficient Isolation of Genes by Using Antibody Probes", Proc. Natl. Acad. Sci. USA, 80, pp. 1194-98 (1983) ("Young I")

Young, R.A. and R.W. Davis, "Yeast RNA Polymerase II Genes: Isolation with Antibody Probes", Science, 222, pp. 778-82 (1984) ("Young II")

Foreign Patent Application

Hemler, M.E. and Y. Takada, "VLA Proteins," EP 330,506, published August 30, 1989.

- 85 -

CLAIMS:

1. A DNA sequence encoding an endothelial cell-leukocyte adhesion molecule (ELAM) or a fragment thereof selected from the group consisting of:

(a) the ELAM1 DNA sequence of Figure 1 from nucleotide number 141 to number 1970;

(b) the ELAM1 DNA sequence of Figure 1 from nucleotide number 144 to number 1970;

(c) a DNA sequence encoding an amino acid sequence of a mature ELAM1;

(d) the DNA sequence of Figure 1 from nucleotide number 204 to number 1970, optionally including an ATG start codon at its 5' end;

(e) a DNA sequence encoding a soluble ELAM1;

(f) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(g) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

2. A recombinant DNA molecule comprising a DNA sequence encoding an endothelial cell-leukocyte adhesion molecule (ELAM) or a fragment thereof, wherein said DNA sequence is selected from the group consisting of:

(a) the ELAM1 DNA sequence of Figure 1 from nucleotide number 141 to number 1970;

(b) the ELAM1 DNA sequence of Figure 1 from nucleotide number 144 to number 1970;

(c) a DNA sequence encoding an amino acid sequence of a mature ELAM1;

- 86 -

(d) the DNA sequence of Figure 1 from nucleotide number 204 to number 1970, optionally including an ATG start codon at its 5' end;

(e) a DNA sequence encoding a soluble ELAM1;

(f) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(g) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

3. A recombinant DNA molecule according to claim 2 wherein said DNA sequence is operatively linked to an expression control sequence.

4. The recombinant DNA molecule of claim 3, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase and the promoters of the yeast α -mating factors.

5. A recombinant DNA molecule according to claim 3 comprising plasmid ELAM pCDM8 clone 6.

6. A unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence encoding an endothelial cell-leukocyte adhesion molecule (ELAM) or fragment thereof, wherein said DNA sequence is selected from the group consisting of:

- 87 -

(a) the ELAM1 DNA sequence of Figure 1 from nucleotide number 141 to number 1970;

(b) the ELAM1 DNA sequence of Figure 1 from nucleotide number 144 to number 1970;

(c) a DNA sequence encoding an amino acid sequence of a mature ELAM1;

(d) the DNA sequence of Figure 1 from nucleotide number 204 to number 1970 optionally containing an ATG start codon at its 5' end;

(e) a DNA sequence encoding a soluble ELAM1;

(f) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(g) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences; wherein said DNA sequence is operatively linked to an expression control sequence.

7. A unicellular host according to claim 6, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase and the promoters of the yeast α -mating factors.

8. A transformed host according to claim 6, comprising plasmid ELAM pCDM8 clone 6.

- 88 -

9. A transformed host according to claim 6 wherein the unicellular host is selected from the group consisting of E.coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, and human cells in tissue culture.

10. A method for producing ELAM1 comprising the step of culturing a transformed host according to claim 7.

11. A cytokine-inducible expression control sequence derived from the nucleotide sequence of Figure 7.

12. A cytokine-inducible expression control sequence of claim 11 comprising nucleotides 740-1307 of Figure 7.

13. An ELAM or fragment thereof essentially free of normally associated animal proteins selected from the group consisting of ELAM1, the lectin-like domain of ELAM1, the EGF-like domain of ELAM1, the consensus cysteine repeat unit of ELAM1, soluble ELAM1, mature ELAM1, and ELAM1 fragments capable of binding to an ELAM1 ligand.

14. A molecule according to claim 13 comprising the amino acid sequence of Figure 1 from amino acid number 22 (Trp) to amino acid number 609 (Leu) optionally including an N-terminal methionine residue.

15. Hybridoma CDB.BB11.BC6 anti-ELAM1.

- 89 -

16. The monoclonal antibodies produced by hybridoma CDB.BB11.BC6 anti-ELAM1.

17. A DNA sequence encoding a MILA for ELAM1 or fragment thereof.

18. The DNA sequence of claim 17, or fragments thereof, selected from the group consisting of:

(a) the CDX DNA sequence of Figure 9 from nucleotide 66 to 1280;

(b) the CDX DNA sequence of Figure 9 from nucleotide 69 to 1280;

(c) a CDX DNA sequence encoding a mature CDX amino acid sequence;

(d) a CDX DNA sequence encoding a soluble CDX amino acid sequence;

(e) DNA sequences that hybridize to any of the foregoing CDX DNA sequences under standard hybridization conditions; and

(f) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

19. The DNA sequence of claim 17, wherein the MILA is an ELAM1 ligand.

20. A recombinant DNA molecule comprising a DNA sequence encoding a MILA for ELAM1 or a fragment thereof.

21. The recombinant DNA molecule of claim 20, wherein the DNA sequence is selected from the group consisting of:

- 90 -

(a) the CDX DNA sequence of Figure 9 from nucleotide 66 to 1280;

(b) the CDX DNA sequence of Figure 9 from nucleotide 69 to 1280;

(c) a CDX DNA sequence encoding a mature CDX amino acid sequence;

(d) a CDX DNA sequence encoding a soluble CDX amino acid sequence;

(e) DNA sequences that hybridize to any of the foregoing CDX DNA sequences under standard hybridization conditions; and

(f) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

22. The recombinant DNA molecule of claim 20, wherein the MILA is an ELAM1 ligand.

23. The recombinant DNA molecule of claim 20 wherein said DNA sequence is operatively linked to an expression control sequence.

24. A unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence encoding a MILA for ELAM1 or fragment thereof.

25. The unicellular host of claim 24, wherein the MILA is CDX.

26. The unicellular host of claim 24, wherein the MILA is an ELAM1 ligand.

27. A unicellular host of claim 24 selected from the group consisting of E.coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M,

- 91 -

COS 1, COS 7, BSC1, BSC40, BMT10, insect cells, plant cells, and human cells in tissue culture.

28. A MILA for ELAM1 or a fragment thereof, substantially free of normally associated animal proteins.

29. The MILA of claim 28 comprising CDX.

30. The MILA of claim 28 having the amino acid sequence depicted in Figure 9.

31. A fragment of a MILA according to claim 28 that binds to ELAM1.

32. The MILA fragment according to claim 31, wherein said fragment is a soluble polypeptide.

33. Hybridoma SGB,B..

34. The monoclonal antibodies produced by hybridoma SGB,B..

35. An antibody preparation that is reactive to a MILA for ELAM1 but non-reactive to other proteins on the leukocyte cell surface.

36. The antibody preparation of claim 35 wherein the MILA is CDX.

37. The antibody preparation of claim 35 consisting essentially of monoclonal antibodies.

38. A method for producing an antibody preparation reactive to a MILA for ELAM1 comprising the

- 92 -

step of immunizing an organism with CDX or an antigenic fragment thereof.

39. A DNA sequence encoding an endothelial cell-leukocyte adhesion molecule or fragment thereof selected from the group consisting of

(a) the VCAM1 DNA sequence of Figure 3 from nucleotide number 107 to number 2047;

(b) the VCAM1 DNA sequence of Figure 3 from nucleotide number 110 to number 2047;

(c) a DNA sequence encoding an amino acid sequence of a mature VCAM1;

(d) the VCAM1 DNA sequence of Figure 3 from nucleotide number 179 to 2047, optionally including an ATG start-codon at its 5' end;

(e) a DNA sequence encoding a soluble VCAM1;

(f) the VCAM1b DNA sequence of Figure 4 from nucleotide number 100 to number 2316;

(g) the VCAM1b DNA sequence of Figure 4 from nucleotide number 103 to number 2316;

(h) a DNA sequence encoding an amino acid sequence of mature VCAM1b;

(i) a DNA sequence encoding a soluble VCAM1b;

(j) the VCAM1b DNA sequence of Figure 4 from nucleotide number 172 to 2316, optionally including an ATG start codon at its 5' end;

(k) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(l) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

- 93 -

40. A recombinant DNA molecule comprising a DNA sequence encoding an endothelial cell-leukocyte adhesion molecule (ELAM) or a fragment thereof wherein said DNA sequence is selected from the group consisting of:

(a) the VCAM1 DNA sequence of Figure 3 from nucleotide number 107 to number 2047;

(b) the VCAM1 DNA sequence of Figure 3 from nucleotide number 110 to number 2047;

(c) a DNA sequence encoding an amino acid sequence of mature VCAM1;

(d) the VCAM1b DNA sequence of Figure 4 from nucleotide number 172 to 2316, optionally including an ATG start codon at its 5' end;

(e) a DNA sequence encoding a soluble VCAM1;

(f) the VCAM1b DNA sequence of Figure 4 from nucleotide number 100 to number 2316;

(g) the VCAM1b DNA sequence of Figure 4 from nucleotide number 103 to number 2316;

(h) a DNA sequence encoding an amino acid sequence of mature VCAM1b;

(i) a DNA sequence encoding a soluble VCAM1b;

(j) the VCAM1b DNA sequence of Figure 4 from nucleotide number 172 to 2316, optionally including an ATG start codon at its 5' end;

(k) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(l) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.

- 94 -

41. The recombinant DNA molecule of claim 40 wherein said DNA sequence is operatively linked to an expression control sequence.

42. The recombinant DNA molecule of claim 41, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter of 3-phosphoglycerate kinase, the promoters of acid phosphatase and the promoters of yeast α -mating factors.

43. A recombinant DNA molecule according to claim 41, comprising plasmid AM pCDM 8 clone 41 or plasmid VCAM 1B clone 1E11 pCDM8.

44. A unicellular host transformed with a recombinant DNA molecule comprising a DNA sequence encoding an endothelial cell-leukocyte adhesion molecule (ELAM) or a fragment thereof, wherein said DNA sequence is selected from the group consisting of:

(a) the VCAM1 DNA sequence of Figure 3 from nucleotide number 107 to number 2047;

(b) the VCAM1 DNA sequence of Figure 3 from nucleotide number 110 to number 2047;

(c) a DNA sequence encoding an amino acid sequence of mature VCAM1;

(d) the VCAM1b DNA sequence of Figure 4 from nucleotide number 172 to 2316, optionally including an ATG start codon at its 5' end;

(e) a DNA sequence encoding a soluble VCAM1;

- 95 -

(f) the VCAM1b DNA sequence of Figure 4 from nucleotide number 100 to number 2316;

(g) the VCAM1b DNA sequence of Figure 4 from nucleotide number 103 to number 2316;

(h) a DNA sequence encoding an amino acid sequence of mature VCAM1b;

(i) a DNA sequence encoding a soluble VCAM1b;

(j) the VCAM1b DNA sequence of Figure 4 from nucleotide number 172 to 2316, optionally including an ATG start codon at its 5' end;

(k) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and

(l) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences; and wherein said DNA sequence is operatively linked to an expression control sequence.

45. A unicellular host according to claim 44, wherein the recombinant DNA molecule comprises plasmid AM pCDM 8 clone 41 or clone VCAM 1B pCDM8 clone 1E11.

46. A unicellular host of claim 44, selected from the group consisting of E.coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10, insect cells, plant cells, and human cells in tissue culture.

47. A method for producing VCAM1 comprising the step of culturing a unicellular host according to claim 44.

- 96 -

48. VCAM1 or VCAM1b or a fragment thereof essentially free of normally associated animal proteins.

49. A VCAM1 or VCAM1b polypeptide selected from the group consisting of domain 1 of VCAM1, domain 2 of VCAM1, domain 3 of VCAM1, domain 4 of VCAM1, domain 5 of VCAM1, domain 6 of VCAM1, domain 3 of VCAM1b, domain 3B of VCAM1b, domain 4 of VCAM1b, and combinations thereof.

50. A VCAM1 according to claim 48, comprising the amino acid sequence of Figure 3 from amino acid number 25 to amino acid number 647, optionally including an N-terminal methionine residue.

51. An antibody preparation that is reactive for VCAM1 or VCAM1b but non-reactive for other adhesion molecules expressed on the endothelial cell surface.

52. The antibody preparation of claim 51 wherein said antibody preparation consists essentially of monoclonal antibodies.

53. A hybridoma producing monoclonal antibodies that recognize VCAM1.

54. A method for producing antibodies which recognize VCAM1 or VCAM1b, comprising the step of immunizing an organism with VCAM1 or VCAM1b or an antigenic fragment thereof.

55. A method for identifying molecules which inhibit binding of leukocytes to endothelial cells comprising the steps of:

- 97 -

(a) contacting a molecule with an ELAM or with ELAM-expressing cells to create a first mixture;

(b) contacting said first mixture with an ELAM ligand or with MILA-expressing cells to create a second mixture; and

(c) testing said second mixture for the amount of said ELAM or ELAM-expressing cells bound to said ELAM ligand or MILA-expressing cells.

56. A method for identifying molecules which inhibit binding of leukocytes to endothelial cells comprising the steps of:

(a) contacting a molecule with an ELAM ligand or with MILA-expressing cells to create a first mixture;

(b) contacting said first mixture with an ELAM or with ELAM-expressing cells to create a second mixture; and

(c) testing said second mixture for the amount of said ELAM ligand or ELAM-expressing cells bound to said ELAM or ELAM-expressing cells.

57. The method of claim 55 or 56, wherein and the ELAM is ELAM1.

58. The method of claim 55 or 56, wherein the ELAM ligand is ELAM1 ligand.

59. The method of claim 55 or 56, wherein the MILA is CDX.

60. The method of claim 55 or 56, wherein the ELAM is VCAM1 or VCAM1b.

- 98 -

61. The method of claim 55 or 56, wherein the MILA is a VCAM1 or VCAM1b ligand.

62. The method of claim 55 or 56 wherein the MILA is VLA4.

63. A method of inhibiting adhesion between leukocytes and endothelial cells in a system containing them comprising the step of introducing an effective amount of an inhibitory agent into said system, wherein said inhibitory agent is selected from the group consisting of ELAMs or fragments thereof capable of binding to ELAM ligands, antibodies recognizing MILAs, ELAM ligands or fragments thereof capable binding to ELAMs, carbohydrates binding to ELAMs, and antibodies recognizing ELAMs.

64. The method of claim 63, wherein the inhibitory agent is ELAM1 or a fragment of an ELAM selected from the group consisting of the lectin-like domain of an ELAM1, the EGF-like domain of ELAM1, the consensus cysteine repeat of ELAM1, and a soluble ELAM1.

65. The method of claim 63, wherein the inhibitory agent is a preparation of monoclonal antibodies recognizing ELAM1 ligand.

66. The method of claim 63, wherein the inhibitory agent is a monoclonal antibody which recognizes CDX.

67. The method of claim 66, wherein the monoclonal antibody is that produced by hybridoma SGB,B..

- 99 -

68. The method of claim 63, wherein said inhibitory agent is an ELAM1 ligand or a fragment thereof capable of binding to ELAM1.

69. The method of claim 63, wherein the inhibitory agent is a monoclonal antibody recognizing ELAM1.

70. The method of claim 69 wherein the monoclonal antibody is that produced by hybridoma CDB.BB11.BC6 anti-ELAM1.

71. The method of claim 63 wherein said inhibitory agent is selected from the group consisting of VCAM1, VCAM1b and fragments thereof that bind to VLA4.

72. The method of claim 63 wherein said inhibitory agent is a monoclonal antibody which recognizes a VCAM1 ligand.

73. The method of claim 63 wherein said inhibitory agent is a VCAM1 ligand or a fragment thereof that binds to VCAM1 or VCAM1b.

74. The method of claim 73 wherein the VCAM1 ligand is VLA4.

75. The method of claim 63, wherein said inhibitory agent is a monoclonal antibody that recognizes VCAM1 or VCAM1b.

76. A method of detecting inflammation comprising the step of administering a detectably

- 100 -

labelled compound selected from the group consisting of ELAM ligands, ELAM-binding fragments of an ELAM ligand, and antibodies which recognize an ELAM.

77. A method of detecting inflammation comprising the steps of:

(a) contacting a sample of blood, serum, or other bodily fluid with detectably labelled ELAM ligands, ELAM-binding fragments of an ELAM ligand, or antibodies which recognize an ELAM, to create a mixture, and

(b) testing said mixture for the amount of ELAM ligand, ELAM-binding fragment of an ELAM ligand, or antibodies bound to an ELAM.

78. The method of claims 76 or 77, wherein the ELAM ligand is ELAM1 ligand.

79. The method of claims 76 or 77 wherein the ELAM ligand is a VCAM1 ligand or VCAM1b ligand.

80. The method of claim 79 wherein the VCAM1 ligand is VLA4.

81. The method of claims 76 or 77 wherein the antibodies are those produced by hybridoma CDB.B11.BC6 anti-ELAM1.

82. A recombinant DNA molecule coding on expression for an ELAM/immunoglobulin fusion protein comprising a DNA sequence coding on expression for an ELAM or fragment thereof and a DNA sequence coding on expression for the constant region of an immunoglobulin molecule.

- 101 -

83. The DNA sequence of claim 82 wherein the ELAM is ELAM1, VCAM1 or VCAM1b.

84. A recombinant DNA molecule according to claim 82 comprising VCAM1 domains 1-3 and the constant regions of human immunoglobulin C-gamma-1.

85. An antisense nucleic acid against an ELAM or MILA mRNA comprising a nucleic acid sequence hybridizing to said mRNA.

86. The antisense oligonucleotide of claim 85 which binds to the initiation codon of any of said mRNAs.

87. The antisense nucleic acid of claim 85 wherein the ELAM is ELAM1, VCAM1 or VCAM1b.

88. The antisense nucleic acid of claim 85, wherein the MILA is an ELAM1 ligand.

89. The antisense nucleic acid of claim 85, wherein the MILA is CDX.

90. The antisense nucleic acid of claim 85, wherein the MILA is VLA4.

91. The antisense nucleic acid of claim 85 comprising DNA.

92. An antisense nucleic acid of claim 85, comprising RNA.

93. The antisense nucleic acid of claim 85 having the DNA sequence 5' CCC AGG CAT TTT AAG.

- 102 -

94. A recombinant DNA molecule having a DNA sequence which, on transcription, produces an antisense ribonucleic acid against an ELAM or MILA mRNA, said antisense ribonucleic acid comprising a nucleic acid sequence hybridizing to said mRNA.

95. An ELAM-producing or MILA-producing cell line transfected with a recombinant DNA molecule having a DNA sequence which, on transcription, produces an antisense ribonucleic acid against an ELAM or MILA mRNA, said antisense ribonucleic acid comprising a nucleic acid sequence hybridizing to said mRNA.

96. A method for creating a cell line which exhibits reduced expression of an ELAM or MILA comprising transfecting an ELAM-producing or MILA-producing cell line with a recombinant DNA molecule having a DNA sequence which, upon transcription, produces an antisense ribonucleic acid against an ELAM or MILA mRNA, said antisense ribonucleic acid comprising a nucleic acid sequence hybridizing said mRNA.

97. A method of treating inflammation comprising the step of administering an amount of an antisense nucleic acid according to claim 82 effective to reduce production of one or more ELAMs or MILAs.

98. A ribozyme which cleaves an ELAM or MILA mRNA.

99. A ribozyme according to claim 98 that cleaves ELAM1, VCAM1 or VCAM1b mRNA.

- 103 -

100. A ribozyme according to claim 98 that cleaves an ELAM ligand mRNA.

101. A ribozyme according to claim 98 that cleaves CDX mRNA.

102. A ribozyme according to claim 98 that cleaves VLA4 mRNA.

103. A ribozyme according to claim 98 further comprising a Tetrahymena-type ribozyme.

104. A ribozyme according to claim 98 further comprising a hammerhead-type ribozyme.

105. A recombinant DNA molecule comprising a DNA sequence which, upon transcription, produces a ribozyme that cleaves an ELAM or MILA mRNA.

106. The ribozyme according to claim 98 comprising the RNA sequence 5' AAGGAUCACC UGAUGAGUCC GUGAGGACGA AACCAUCUU.

107. An ELAM-producing or MILA-producing cell line transfected with a recombinant DNA molecule comprising a DNA sequence which, upon transcription, produces a ribozyme that cleaves an ELAM or MILA mRNA.

108. A method for creating a cell line which exhibits reduced expression of an ELAM or MILA comprising transfecting an ELAM-producing or MILA-producing cell line with a recombinant DNA molecule that produces on transcription a ribozyme that cleaves an ELAM or MILA mRNA.

- 104 -

109. A method of treating inflammation comprising the step of administering an amount of a ribozyme that cleaves an ELAM mRNA or an ELAM ligand mRNA effective to reduce the production of ELAM or ELAM ligand.

110. An anti-idiotypic antibody preparation reactive to an ELAM or MILA.

111. An anti-idiotypic antibody preparation of claim 110 reactive to ELAM1, VCAM1 or VCAM1b.

112. An anti-idiotypic antibody preparation of claim 110 reactive to an ELAM1 ligand.

113. An anti-idiotypic antibody preparation of claim 110 reactive to VLA4.

114. An anti-idiotypic antibody preparation of claim 110 reactive to CDX.

115. An anti-idiotypic antibody preparation of claim 110 reactive to domains 1, 2, 3, 4, 5 or 6 of VCAM1 or domains 3, 3B or 4 of VCAM1b.

116. A method for identifying an ELAM or ELAM-ligand which binds to any one of ELAM1, CDX, VCAM1, VCAM1b, or VLA4, comprising the steps of:

(a) screening a mixture of proteins for proteins that bind to anti-idiotypic antibodies recognizing antibodies that recognize any one of ELAM1, CDX, VCAM1, VCAM1b, or VLA4;

(b) isolating those molecules which bind to said anti-idiotypic antibodies; and

- 105 -

(c) testing the ability of those proteins to bind to ELAM1, CDX, VCAM1, VCAM1b, or VLA4.

117. A method for identifying ELAM ligands which bind to any of the domains of VCAM1 or VCAM1b comprising the steps of:

(a) screening a mixture of proteins for proteins that bind to anti-idiotypic antibodies recognizing antibodies which recognize any of said domains of VCAM1 or VCAM1b;

(b) isolating those proteins that bind to said anti-idiotypic antibodies; and

(c) testing the ability of those proteins to bind to any of said domains of VCAM1 or VCAM1b.

118. A method for inhibiting VCAM1 or VCAM1b expression comprising the step of administering an effective dose of an antibody which recognizes IL-1, TNF, or IFN- γ .

119. A radioimmunoconjugate comprising an antibody recognizing VCAM1 or VCAM1b conjugated to a nuclide.

120. The radioimmunoconjugate of claim 119 wherein the nuclide is selected from the group consisting of ^{125}I , ^{90}Y , and ^{186}Re .

121. An immunotoxin comprising an antibody recognizing VCAM1 or VCAM1b conjugated to a cell toxin.

122. The immunotoxin of claim 121 wherein the cell toxin is Pseudomonas exotoxin.

- 106 -

123. A method for detecting VCAM1 or VCAM1b-producing cancer cells comprising the step of administering a radioimmunoconjugate having an antibody which recognizes VCAM1 or VCAM1b.

124. A method for treating cancer comprising the step of administering an effective dose of a radioimmunoconjugate or immunotoxin having an antibody which recognizes VCAM1 or VCAM1b.

125. A DNA sequence encoding a VCAM/ICAM fusion protein comprising DNA sequences for VCAM1 or VCAM1b domains binding a VCAM1 ligand and ICAM1 domains binding an ICAM1 ligand.

126. A DNA sequence according to claim 125 wherein the VCAM1 ligand is VLA4 and the ICAM1 ligand is LFA1.

127. A VCAM/ICAM fusion protein comprising VCAM1 or VCAM1b domains binding a VCAM1 ligand and ICAM1 domains binding an ICAM1 ligand.

128. A fusion protein according to claim 127 wherein the VCAM1 ligand is VLA4 and the ICAM1 ligand is LFA1.

129. A method for treating tumors expressing ELAM1, VCAM1, VCAM1b or a ligand thereof comprising:

- (1) removing a sample of tumor tissue from a mammal having such a tumor,
- (2) isolating from said sample one or more leukocytes that have infiltrated the tumor tissue,
- (3) transfecting said one or more infiltrating leukocytes with a recombinant expression

- 107 -

vector including a gene coding for a tumorcidal agent and capable of expressing in said leukocytes a tumorcidal gene product,

(4) introducing the transfected leukocytes into said mammal.

130. A method according to claim 129, wherein the tumorcidal gene product is TNF or lymphotoxin.

131. A method according to claim 130, wherein the mammal is a human.

132. A method according to claim 129, wherein the recombinant expression vector is a retroviral vector.

133. A method according to claim 129, wherein, prior to introduction of the transfected leukocytes into the mammal, said transfected leukocytes are expanded with IL-2.

134. A method according to claim 129, wherein the tumor is a malignant tumor.

135. A method according to claim 129, wherein the tumor expresses VLA4 or CDX.

136. A method according to claim 135, wherein the tumor is melanoma or colon carcinoma.

137. A method for enhancing the cytolytic properties of leukocytes against target cells expressing ELAMs or MILAs comprising transfecting said leukocytes with a recombinant expression vector including a gene coding for an ELAM or MILA molecule

- 108 -

that binds to the ELAM or MILA expressed by said target cells, which recombinant expression vector is capable of expressing said gene in said leukocyte.

138. A method according to 137, wherein the target cell is a melanoma or a colon carcinoma.

139. A method according to claim 138, wherein the gene encodes VCAM1 or VCAM1b, or encodes ELAM1.

140. A method according to claim 137, wherein the recombinant expression vector is a retroviral vector.

141. A method according to claim 140, wherein the recombinant expression vector also includes a gene encoding a tumorcidal agent.

142. A method according to claim 140, wherein the leukocytes are tumor infiltrating leukocytes.

FIGURE 1A

1/21

1	TTCACATCAAACTCCTATACTGACCTGAGACAGAGGCAGCAGTGATACC	50
51	CACCTGAGAGATCCTGTGTTTGAACAACTGCTTCCCAAACGGAAAGTAT	100
101	TTCAAGCCTAACCTTTGGGTGAAAAGAACTCTTGAAGTCATGATTGCTT MetIleAlaS	150
151	CACAGTTTCTCTCAGCTCTCACTTTGGTGCTTCTCATTAAAGAGAGTGGA erGlnPheLeuSerAlaLeuThrLeuValLeuLeuIleLysGluSerGly	200
201	GCCTGGTCTTACAACACCTCCACGGAAGCTATGACTTATGATGAGGCCAG AlaTrpSerTyrAsnThrSerThrGluAlaMetThrTyrAspGluAlaSe	250
251	TGCTTATTGTGAGCAAAGGTACACACACCTGGTTGCAATTCAAAACAAAG rAlaTyrCysGlnGlnArgTyrThrHisLeuValAlaIleGlnAsnLysG	300
301	AAGAGATTGAGTACCTAACTCCATATTGAGCTATTCACCAAGTTATTAC luGluIleGluTyrLeuAsnSerIleLeuSerTyrSerProSerTyrTyr	350
351	TGGATTGGAATCAGAAAAGTCAACAATGTGTGGGTCTGGGTAGGAACCCA TrpIleGlyIleArgLysValAsnAsnValTrpValTrpValGlyThrGl	400
401	GAAACCTCTGACAGAAGAAGCCAAGAAGTGGCTCCAGGTGAACCCAACA nLysProLeuThrGluGluAlaLysAsnTrpAlaProGlyGluProAsnA	450
451	ATAGGCAAAAAGATGAGGACTGCGTGAGATCTACATCAAGAGAGAAAAA snArgGlnLysAspGluAspCysValGluIleTyrIleLysArgGluLys	500
501	GATGTGGGCATGTGGAATGATGAGAGGTGCAGCAAGAAGAAGCTTGCCCT AspValGlyMetTrpAsnAspGluArgCysSerLysLysLysLeuAlaLe	550
551	ATGCTACACAGCTGCCTGTACCAATACATCCTGCAGTGGCCACGGTGAAT uCysTyrThrAlaAlaCysThrAsnThrSerCysSerGlyHisGlyGluC	600
601	GTGTAGAGACCATCAATAATTACACTTGCAAGTGTGACCCTGGCTTCAGT ysValGluThrIleAsnAsnTyrThrCysLysCysAspProGlyPheSer	650
651	GGAICTAAGTGTGAGCAAATTGTGAACTGTACAGCCCTGGAATCCCCTGA GlyLeuLysCysGluGlnIleValAsnCysThrAlaLeuGluSerProGl	700
701	GCATGGAAGCCTGGTTTGCAGTCACCCACTGGGAACTTCAGCTACAATT uHisGlySerLeuValCysSerHisProLeuGlyAsnPheSerTyrAsnS	750
751	CTTCCTGCTCTATCAGCTGTGATAGGGGTTACCTGCCAAGCAGCATGGAG erSerCysSerIleSerCysAspArgGlyTyrLeuProSerSerMetGlu	800

THIS PAGE BLANK (USPTO)

FIGURE 1B

2/21

801	ACCATGCAGTGTATGTCCTCTGGAGAATGGAGTGCTCCTATTCCAGCCTG ThrMetGlnCysMetSerSerGlyGluTrpSerAlaProIleProAlaCy	850
851	CAATGTGGTTGAGTGTGATGCTGTGACAAATCCAGCCAATGGGTTTCGTGG sAsnValValGluCysAspAlaValThrAsnProAlaAsnGlyPheValG	900
901	AATGTTTCCAAAACCCTGGAAGCTTCCCATGGAACACAACCTGTACATTT luCysPheGlnAsnProGlySerPheProTrpAsnThrThrCysThrPhe	950
951	GACTGTGAAGAAGGATTTGAACTAATGGGAGCCCAGAGCCTTCAGTGTAC AspCysGluGluGlyPheGluLeuMetGlyAlaGlnSerLeuGlnCysTh	1000
1001	CTCATCTGGGAATTGGGACAACGAGAAGCCAACGTGTAAAGCTGTGACAT rSerSerGlyAsnTrpAspAsnGluLysProThrCysLysAlaValThrC	1050
1051	GCAGGGCCGTCCGCCAGCCTCAGAATGGCTCTGTGAGGTGCAGCCATTCC ysArgAlaValArgGlnProGlnAsnGlySerValArgCysSerHisSer	1100
1101	CCTGCTGGAGAGTTCACCTTCAAATCATCCTGCAACTTCACCTGTGAGGA ProAlaGlyGluPheThrPheLysSerSerCysAsnPheThrCysGluGl	1150
1151	AGGCTTCATGTTGCAGGGACCAGCCCAGGTTGAATGCACCACTCAAGGGC uGlyPheMetLeuGlnGlyProAlaGlnValGluCysThrThrGlnGlyG	1200
1201	AGTGGACACAGCAAATCCCAGTTTGTGAAGCTTTCAGTGCACAGCCTTG lnTrpThrGlnGlnIleProValCysGluAlaPheGlnCysThrAlaLeu	1250
1251	TCCAACCCCGAGCGAGGCTACATGAATTGTCTTCTAGTGCTTCTGGCAG SerAsnProGluArgGlyTyrMetAsnCysLeuProSerAlaSerGlySe	1300
1301	TTTCCGTTATGGGTCCAGCTGTGAGTTCTCCTGTGAGCAGGGTTTTGTGT rPheArgTyrGlySerSerCysGluPheSerCysGluGlnGlyPheValL	1350
1351	TGAAGGGATCCAAAAGGCTCCAATGTGGCCCCACAGGGGAGTGGGACAAC euLysGlySerLysArgLeuGlnCysGlyProThrGlyGluTrpAspAsn	1400
1401	GAGAAGCCCACATGTGAAGCTGTGAGATGCGATGCTGTCCACCAGCCCCC GluLysProThrCysGluAlaValArgCysAspAlaValHisGlnProPr	1450
1451	GAAGGGTTTGGTGAGGTGTGCTCATTCCCCTATTGGAGAATTCACCTACA oLysGlyLeuValArgCysAlaHisSerProIleGlyGluPheThrTyrL	1500
1501	AGTCCTCTTGTGCCTTCAGCTGTGAGGAGGGATTTGAATTACATGGATCA ysSerSerCysAlaPheSerCysGluGluGlyPheGluLeuHisGlySer	1550
1551	ACTCAACTTGAGTGCACATCTCAGGGACAATGGACAGAAGAGGTTCTTTC ThrGlnLeuGluCysThrSerGlnGlyGlnTrpThrGluGluValProSe	1600

THIS PAGE BLANK (USPTO)

FIGURE 1C

3/21

1601	CTGCCAAGTGGTAAAATGTTCAAGCCTGGCAGTTCCGGGAAAGATCAACA rCysGlnValValLysCysSerSerLeuAlaValProGlyLysIleAsnM	1650
1651	TGAGCTGCAGTGGGGAGCCCGTGTGTTTGGCACTGTGTGCAAGTTCGCCTGT etSerCysSerGlyGluProValPheGlyThrValCysLysPheAlaCys	1700
1701	CCTGAAGGATGGACGCTCAATGGCTCTGCAGCTCGGACATGTGGAGCCAC ProGluGlyTrpThrLeuAsnGlySerAlaAlaArgThrCysGlyAlaTh	1750
1751	AGGACACTGGTCTGGCCTGCTACCTACCTGTGAAGCTCCCACTGAGTCCA rGlyHisTrpSerGlyLeuLeuProThrCysGluAlaProThrGluSerA	1800
1801	ACATTCCCTTGGTAGCTGGACTTTCTGCTGCTGGACTCTCCCTCCTGACA snIleProLeuValAlaGlyLeuSerAlaAlaGlyLeuSerLeuLeuThr	1850
1851	TTAGCACCATTCTCCTCTGGCTTCGGAAATGCTTACGGAAAGCAAAGAA LeuAlaProPheLeuLeuTrpLeuArgLysCysLeuArgLysAlaLysLy	1900
1901	ATTTGTTCTGCCAGCAGCTGCCAAAGCCTTGAATCAGATGGAAGCTACC sPheValProAlaSerSerCysGlnSerLeuGluSerAspGlySerTyrG	1950
1951	AAAAGCCTTCTTACATCCTTTAAGTTCAAAGAATCAGAAACAGGTGCAT lnLysProSerTyrIleLeu	2000
2001	CTGGGGAAGTAGAGGGATACACTGAAGTTAACAGAGACAGATAACTCTCC	2050
2051	TCGGGTCTCTGGCCCTTCTTGCCCTACTATGCCAGATGCCTTTTATGGCTGA	2100
2101	AACCGCAACACCCATCACCACCTTCAATAGATCAAAGTCCAGCAGGCAAGG	2150
2151	ACGGCCTTCAACTGAAAAGACTCAGTGTTCCCTTTCCTACTCTCAGGATC	2200
2201	AAGAAAGTGTTGGCTAATGAAGGGAAAGGATATTTTCTTCCAAGCAAAGG	2250
2251	TGAAGAGACCAAGACTCTGAAATCTCAGAATTCCTTTTCTAACTCTCCCT	2300
2301	TGCTCGCTGTAAAATCTTGGCACAGAAACACAATATTTTGTGGCTTTCTT	2350
2351	TCTTTTGCCCTTCACAGTGTTTCGACAGCTGATTACACAGTTGCTGTCTAT	2400
2401	AAGAATGAATAATAATTATCCAGAGTTTAGAGGAAAAAAATGACTAAAAA	2450
2451	TATTATAACTTAAAAAATGACAGATGTTGAATGCCACAGGCAAATGCAT	2500
2501	GGAGGGTTGTTAATGGTGCAAATCCTACTGAATGCTCTGTGCGAGGGTTA	2550
2551	CTATGCACAATTTAATCACTTTCATCCCTATGGGATTCAGTGCTTCTTAA	2600

THIS PAGE BLANK (USPTO)

FIGURE 1D

4/21

2601	AGAGTTCTTAAGGATTGTGATATTTTACTTGCATTGAATATATTATAAT	2650
2651	CTTCCATACTTCTTCATTCAATACAAGTGTGGTAGGGACTTAAAAAACTT	2700
2701	GTAAATGCTGTCAACTATGATATGGTAAAAGTTACTTATTCTAGATTACC	2750
2751	CCCTCATTGTTTATTAACAAATTATGTTACATCTGTTTTAAATTTATTTT	2800
2801	AAAAAGGGAAACTATTGTCCCCTAGCAAGGCATGATGTTAACCAGAATAA	2850
2851	AGTTCTGAGTGTTTTTTACTACAGTTGTTTTTTGAAAACATGGTAGAATTG	2900
2901	GAGAGTAAAACTGAATGGAAGGTTTGTATATTGTCAGATATTTTTTTCAG	2950
2951	AAATATGTGGTTTCCACGATGAAAACTTCCATGAGGCCAAACGTTTTGA	3000
3001	ACTAATAAAAGCATAAATGCAAACACACAAAGGTATAATTTTATGAATGT	3050
3051	CTTTGTTGGAAAAGAATACAGAAAGATGGATGTGCTTTGCATTCTCTACAA	3100
3101	AGATGTTTGTCTAGATATGATATGTAAACATAATTCTTGTATATTATGGAA	3150
3151	GATTTTAAATTCACAATAGAACTCACCATGTAAAAGAGTCATCTGGTAG	3200
3201	ATTTTTAACGAATGAAGATGTCTAATAGTTATTCCCTATTTGTTTTCTTC	3250
3251	TGTATGTTAGGGTGCTCTGGAAGAGAGGAATGCCTGTGTGAGCAAGCATT	3300
3301	TATGTTTATTTATAAGCAGATTTAACAATTCCAAAGGAATCTCCAGTTTT	3350
3351	CAGTTGATCACTGGCAATGAAAAATTCTCAGTCAGTAATTGCCAAAGCTG	3400
3401	CTCTAGCCTTGAGGAGTGTGAGAATCAAACCTCTCCTACACTTCCATTAA	3450
3451	CTTAGCATGTGTTGAAAAAAAAGTTTCAGAGAAGTTCTGGCTGAACACTG	3500
3501	GCAACAACAAAGCCAACAGTCAAAACAGAGATGTGATAAGGATCAGAACA	3550
3551	GCAGAGGTTCTTTTAAAGGGGCAGAAAACTCTGGGAAATAAGAGAGAAC	3600
3601	AACTACTGTGATCAGGCTATGTATGGAATACAGTGTTATTTTCTTTGAAA	3650
3651	TTGTTTAAGTGTGTGTAATATTTATGTAAACTGCATTAGAAATTAGCTGT	3700
3701	GTGAAATACCAGTGTGGTTTGTGTTTGAGTTTTATTGAGAATTTTAAATT	3750
3751	ATAACTTAAATATTTTATAATTTTAAAGTATATATTTATTTAAGCTTA	3800

THIS PAGE BLANK (USPTO)

FIGURE 1E

5 / 2 1

3801 TGCAGACCTATTTGACATAACACTATAAAGGTTGACAATAAATGTGCTT 3850
3851 ATGTTTAAAAAAA 3863

THIS PAGE BLANK (USPTO)

6 / 2 1

FIGURE 2

N	D B E S S	N	s E E N	X	N	D S S B E S
h	s g a p a f		p a a o	h		s p a g a f
e	a l e b c l		l l e g t	o		a B c l e l
l	l 11221		l l l l	2		l 22 l l l
	///		//			/

401 GctAGCGGCCTCCGCGCCAGTCCAAAGCATTAGCGGACATGCGGCGCCGAAAGGATCAGCAGATCCTCACATCCCAATCCGAGCGCGGTTGCGCCG

510 CgaTCGCGCGGAGCGCGCGGTACAGTTGGTGGTTAGAGTTTCGTATCCGCTGTACGCGCGCGTTTGTCTAGTCTAGGAGTGTAGGCTCCGCGCGCCACCGCGG

THIS PAGE BLANK (USPTO)

FIGURE 3A

7/12/1

1	CGGGCCTCACTGGCTTCAGGAGCTGAATACCCTCCCAGGCACACACAGGT	50
51	GGGACACAAATAAGGGTTTTTGAACCACTATTTTCTCATCAGCAGCAA	100
101	CTTAAAATGCCTGGGAAGATGGTCGTGATCCTTGGAGCCTCAAATATACT MetProGlyLysMetValValIleLeuGlyAlaSerAsnIleLe	150
151	TTGGATAATGTTTGCAGCTTCTCAAGCTTTTAAAATCGAGACCACCCAG uTrpIleMetPheAlaAlaSerGlnAlaPheLysIleGluThrThrProG	200
201	AATCTAGATATCTTGCTCAGATTGGTGACTCCGTCTCATTGACTTGCAGC luSerArgTyrLeuAlaGlnIleGlyAspSerValSerLeuThrCysSer	250
251	ACCACAGGCTGTGAGTCCCCATTTTCTCTTGGAGAACCAGATAGATAG ThrThrGlyCysGluSerProPhePheSerTrpArgThrGlnIleAspSe	300
301	TCCACTGAATGGGAAGGTGACGAATGAGGGGACCACATCTACGCTGACAA rProLeuAsnGlyLysValThrAsnGluGlyThrThrSerThrLeuThrM	350
351	TGAATCCTGTTAGTTTTTGGGAACGAACACTCTTACCTGTGCACAGCAACT etAsnProValSerPheGlyAsnGluHisSerTyrLeuCysThrAlaThr	400
401	TGTGAATCTAGGAAATTGGAAAAAGGAATCCAGGTGGAGATCTACTCTTT CysGluSerArgLysLeuGluLysGlyIleGlnValGluIleTyrSerPh	450
451	TCCTAAGGATCCAGAGATTCAATTTGAGTGGCCCTCTGGAGGCTGGGAAGC eProLysAspProGluIleHisLeuSerGlyProLeuGluAlaGlyLysP	500
501	CGATCACAGTCAAGTGTTTCAGTTGCTGATGTATACCCATTTGACAGGCTG roIleThrValLysCysSerValAlaAspValTyrProPheAspArgLeu	550
551	GAGATAGACTTACTGAAAGGAGATCATCTCATGAAGAGTCAGGAATTTCT GluIleAspLeuLeuLysGlyAspHisLeuMetLysSerGlnGluPheLe	600
601	GGAGGATGCAGACAGGAAGTCCCTGGAAACCAAGAGTTTGGAAAGTAACCT uGluAspAlaAspArgLysSerLeuGluThrLysSerLeuGluValThrP	650
651	TTACTCCTGTCATTGAGGATATTGGAAAAGTTCTTGTTTCCGAGCTAAA heThrProValIleGluAspIleGlyLysValLeuValCysArgAlaLys	700
701	TTACACATTGATGAAATGGATTCTGTGCCACAGTAAGGCAGGCTGTAAA LeuHisIleAspGluMetAspSerValProThrValArgGlnAlaValLy	750
751	AGAATTGCAAGTCTACATATCACCCAAGAATACAGTTATTTCTGTGAATC sGluLeuGlnValTyrIleSerProLysAsnThrValIleSerValAsnP	800

THIS PAGE BLANK (USPTO)

FIGURE 3B

8 / 2 1

801	CATCCACAAAGCTGCAAGAAGGTGGCTCTGTGACCATGACCTGTTCCAGC	850
	roSerThrLysLeuGlnGluGlyGlySerValThrMetThrCysSerSer	
851	GAGGGTCTACCAGCTCCAGAGATTTTCTGGAGTAAGAAATTAGATAATGG	900
	GluGlyLeuProAlaProGluIlePheTrpSerLysLysLeuAspAsnGl	
901	GAATCTACAGCACCTTTCTGGAAATGCAACTCTCACCTTAATTGCTATGA	950
	yAsnLeuGlnHisLeuSerGlyAsnAlaThrLeuThrLeuIleAlaMeta	
951	GGATGGAAGATTCTGGAATTTATGTGTGTGAAGGAGTTAATTGATTGGG	1000
	rgMetGluAspSerGlyIleTyrValCysGluGlyValAsnLeuIleGly	
1001	AAAAACAGAAAAGAGGTGGAATTAATTGTTCAAGCATTCCCTAGAGATCC	1050
	LysAsnArgLysGluValGluLeuIleValGlnAlaPheProArgAspPr	
1051	AGAAATCGAGATGAGTGGTGGCCTCGTGAATGGGAGCTCTGTCACTGTAA	1100
	oGluIleGluMetSerGlyGlyLeuValAsnGlySerSerValThrValS	
1101	GCTGCAAGGTTCTAGCGTGTACCCCTTGACCGGCTGGAGATTGAATTA	1150
	erCysLysValProSerValTyrProLeuAspArgLeuGluIleGluLeu	
1151	CTTAAGGGGGAGACTATTCTGGAGAATATAGAGTTTTTGGAGGATACGGA	1200
	LeuLysGlyGluThrIleLeuGluAsnIleGluPheLeuGluAspThrAs	
1201	TATGAAATCTCTAGAGAACAAAAGTTTGGAAATGACCTTCATCCCTACCA	1250
	pMetLysSerLeuGluAsnLysSerLeuGluMetThrPheIleProThrI	
1251	TTGAAGATACTGGAAAAGCTCTTGTTTGTGAGGCTAAGTTACATATTGAT	1300
	leGluAspThrGlyLysAlaLeuValCysGlnAlaLysLeuHisIleAsp	
1301	GACATGGAATTCGAACCCAAACAAAGGCAGAGTACGCAAACACTTTATGT	1350
	AspMetGluPheGluProLysGlnArgGlnSerThrGlnThrLeuTyrVa	
1351	CAATGTTGCCCCAGAGATACAACCGTCTTGGTCAGCCCTTCCTCCATCC	1400
	lAsnValAlaProArgAspThrThrValLeuValSerProSerSerIleL	
1401	TGGAGGAAGGCAGTTCTGTGAATATGACATGCTTGAGCCAGGGCTTTCCT	1450
	euGluGluGlySerSerValAsnMetThrCysLeuSerGlnGlyPhePro	
1451	GCTCCGAAAATCCTGTGGAGCAGGCAGCTCCCTAACGGGGAGCTACAGCC	1500
	AlaProLysIleLeuTrpSerArgGlnLeuProAsnGlyGluLeuGlnPr	
1501	TCTTTCTGAGAATGCAACTCTCACCTTAATTTCTACAAAATGGAAGATT	1550
	oLeuSerGluAsnAlaThrLeuThrLeuIleSerThrLysMetGluAsps	
1551	CTGGGGTTTATTTATGTGAAGGAATTAACCAGGCTGGAAGAAGCAGAAAG	1600
	erGlyValTyrLeuCysGluGlyIleAsnGlnAlaGlyArgSerArgLys	

THIS PAGE BLANK (USPTO)

FIGURE 3C

9 / 21

1601 GAAGTGGAAATTAATTATCCAAGTTACTCCAAAAGACATAAACTTACAGC 1650
GluValGluLeuIleIleGlnValThrProLysAspIleLysLeuThrAl

1651 TTTTCCTTCTGAGAGTGTCAAAGAAGGAGACACTGTCATCATCTCTTGTA 1700
aPheProSerGluSerValLysGluGlyAspThrValIleIleSerCyst

1701 CATGTGGAAATGTTCCAGAAACATGGATAATCCTGAAGAAAAAGCGGAG 1750
hrCysGlyAsnValProGluThrTrpIleIleLeuLysLysLysAlaGlu

1751 ACAGGAGACACAGTACTAAAATCTATAGATGGCGCCTATACCATCCGAAA 1800
ThrGlyAspThrValLeuLysSerIleAspGlyAlaTyrThrIleArgLy

1801 GGCCCAAGTTGAAGGATGCGGGAGTATATGAATGTGAATCTAAAAACAAAG 1850
sAlaGlnLeuLysAspAlaGlyValTyrGluCysGluSerLysAsnLysV

1851 TTGGCTCACAAATTAAGAAGTTTAACACTTGATGTTCAAGGAAGAGAAAAC 1900
alGlySerGlnLeuArgSerLeuThrLeuAspValGlnGlyArgGluAsn

1901 AACAAAGACTATTTTTCTCCTGAGCTTCTCGTGCTCTATTTTGCATCCTC 1950
AsnLysAspTyrPheSerProGluLeuLeuValLeuTyrPheAlaSerSe

1951 CTTAATAATACCTGCCATTGGAATGATAATTTACTTTGCAAGAAAAGCCA 2000
rLeuIleIleProAlaIleGlyMetIleIleTyrPheAlaArgLysAlaA

2001 ACATGAAGGGGTTCATATAGTCTTGTAGAAGCACAGAAATCAAAGTGTAG 2050
snMetLysGlySerTyrSerLeuValGluAlaGlnLysSerLysVal

2051 CTAATGCTTGATATGTTCAACTGGAGACACTATTTATCTGTGCAAATCCT 2100

2101 TGATACTGCTCATCATTCCCTTGAGAAAAACAATGAGCTGAGAGGCAGACT 2150

2151 TCCCTGAATGTATTGAACTTGGAAGAAATGCCCATCTATGTCCCTTGCT 2200

2201 GTGAGCAAGAAGTCAAAGTAAAACCTTGCTGCCTGAAGAACAGTAACTGCC 2250

2251 ATCAAGATGAGAGAACTGGAGGAGTTCCTTGATCTGTATATACAATAACA 2300

2301 TAATTTGTACATATGTAAAATAAAATTATGCCATAGCAAGATTGCTTAAA 2350

2351 ATAGCAACACTCTATATTTAGATTGTTAAAATAACTAGTGTTGCTTGGAC 2400

2401 TATTATAATTTAATGCATGTTAGGAAAATTTACATTAATATTTGCTGAC 2450

2451 AGCTGACCTTTGTCATCTTTCTTCTATTTTATTCCCTTTACAAAATTTT 2500

2501 ATTCCTATATAGTTTATTGACAATAATTTTCAAGTTTTGTAAAGATGCCGG 2550

THIS PAGE BLANK (USPTO)

FIGURE 3D

10 / 21

2551 GTTTTATATTTTATAGACAAATAATAAGCAAAGGGAGC[·]ACTGGGTTGAC[·] 2600
2601 T[·]TCAGGTACTAAATACCTCAACCTATGGTATAATGGTTGACTGGGTTTC[·] 2650
2651 TCTGTATAGTACTGGCATGGTACGGAGATGTTTCACGAAGTTTGTTTCATC[·] 2700
2701 AGACTCCTGTGCAACTTTCCCAATGTGGCCTAAAAATGCAACTTCTTTTT[·] 2750
2751 ATTTTCTTTTGTAATGTTTAGGTTTTTTTGTATAGTAAAGTGATAATT[·] 2800
2801 CTGGAATTAAA 2811

THIS PAGE BLANK (USPTO)

FIGURE 4A

11 / 21

1 CACTGGCTTCAGGAGCTGAATACCCTCCCAGGCACACACAGGTGGGACAC 50
51 AAATAAGGGTTTTTGAACCACCTATTTTCTCATCACGACAGCAACTTAAAA 100
M
101 TGCCTGGGAAGATGGTCGTGATCCTTGGAGCCTCAAATATACTTTGGATA 150
etProGlyLysMetValValIleLeuGlyAlaSerAsnIleLeuTrpIle
151 ATGTTTGCAGCTTCTCAAGCTTTTAAATCGAGACCACCCAGAATCTAG 200
MetPheAlaAlaSerGlnAlaPheLysIleGluThrThrProGluSerAr
201 ATATCTTGCTCAGATTGGTGACTCCGTCTCATTGACTTGACAGCACCACAG 250
gTyrLeuAlaGlnIleGlyAspSerValSerLeuThrCysSerThrThrG
251 GCTGTGAGTCCCCATTTTCTCTTGGAGAACCAGATAGATAGTCCACTG 300
lyCysGluSerProPhePheSerTrpArgThrGlnIleAspSerProLeu
301 AATGGGAAGGTGACGAATGAGGGGACCACATCTACGCTGACAATGAATCC 350
AsnGlyLysValThrAsnGluGlyThrThrSerThrLeuThrMetAsnPr
351 TGTTAGTTTTGGGAACGAACACTCTTACCTGTGCACAGCAACTTGTAAT 400
oValSerPheGlyAsnGluHisSerTyrLeuCysThrAlaThrCysGluS
401 CTAGGAAATTGGAAAAGGAATCCAGGTGGAGATCTACTCTTTTCCTAAG 450
erArgLysLeuGluLysGlyIleGlnValGluIleTyrSerPheProLys
451 GATCCAGAGATTTCATTTGAGTGGCCCTCTGGAGGCTGGGAAGCCGATCAC 500
AspProGluIleHisLeuSerGlyProLeuGluAlaGlyLysProIleTh
501 AGTCAAGTGTTTCAGTTGCTGATGTATACCCATTTGACAGGCTGGAGATAG 550
rValLysCysSerValAlaAspValTyrProPheAspArgLeuGluIleA
551 ACTTACTGAAAGGAGATCATCTCATGAAGAGTCAGGAATTTCTGGAGGAT 600
spLeuLeuLysGlyAspHisLeuMetLysSerGlnGluPheLeuGluAsp
601 GCAGACAGGAAGTCCCTGGAAACCAAGAGTTTGGAAAGTAACCTTTACTCC 650
AlaAspArgLysSerLeuGluThrLysSerLeuGluValThrPheThrPr
651 TGTCATTGAGGATATTGGAAAAGTTCTTGTTTGCCGAGCTAAATTACACA 700
oValIleGluAspIleGlyLysValLeuValCysArgAlaLysLeuHisI
701 TTGATGAAATGGATTCTGTGCCCCACAGTAAGGCAGGCTGTAAAAGAATTG 750
leAspGluMetAspSerValProThrValArgGlnAlaValLysGluLeu

THIS PAGE BLANK (USPTO)

FIGURE 4B

12 / 21

751	CAAGTCTACATATCACCCAAGAATACAGTTATTTCTGTGAATCCATCCAC	800
	GlnValTyrIleSerProLysAsnThrValIleSerValAsnProSerTh	
801	AAAGCTGCAAGAAGGTGGCTCTGTGACCATGACCTGTTCCAGCGAGGGTC	850
	rLysLeuGlnGluGlyGlySerValThrMetThrCysSerSerGluGlyL	
851	TACCAGCTCCAGAGATTTTCTGGAGTAAGAAATTAGATAATGGGAATCTA	900
	euProAlaProGluIlePheTrpSerLysLysLeuAspAsnGlyAsnLeu	
901	CAGCACCTTTCTGGAAATGCAACTCTCACCTTAATTGCTATGAGGATGGÄ	950
	GlnHisLeuSerGlyAsnAlaThrLeuThrLeuIleAlaMetArgMetGl	
951	AGATTCTGGAATTTATGTGTGTGAAGGAGTTAATTTGATTGGGAAAAACA	1000
	uAspSerGlyIleTyrValCysGluGlyValAsnLeuIleGlyLysAsnA	
1001	GAAAAGAGGTGGAATTAATTGTTCAAGAGAAACCATTTACTGTTGAGATC	1050
	rgLysGluValGluLeuIleValGlnGluLysProPheThrValGluIle	
1051	TCCCCTGGACCCCGGATTGCTGCTCAGATTGGAGACTCAGTCATGTTGAC	1100
	SerProGlyProArgIleAlaAlaGlnIleGlyAspSerValMetLeuTh	
1101	ATGTAGTGTCTATGGGCTGTGAATCCCCATCTTTCTCCTGGAGAACCCAGA	1150
	rCysSerValMetGlyCysGluSerProSerPheSerTrpArgThrGlnI	
1151	TAGACAGCCCTCTGAGCGGGAAGGTGAGGAGTGAGGGGACCAATTCCACG	1200
	leAspSerProLeuSerGlyLysValArgSerGluGlyThrAsnSerThr	
1201	CTGACCCTGAGCCCTGTGAGTTTTGAGAAACGAACACTCTTATCTGTGCAC	1250
	LeuThrLeuSerProValSerPheGluAsnGluHisSerTyrLeuCysTh	
1251	AGTGACTTGTGGACATAAGAAACTGGAAAAGGGAATCCAGGTGGAGCTCT	1300
	rValThrCysGlyHisLysLysLeuGluLysGlyIleGlnValGluLeuT	
1301	ACTCATTCCCTAGAGATCCAGAAATCGAGATGAGTGGTGGCCTCGTGAAT	1350
	yrSerPheProArgAspProGluIleGluMetSerGlyGlyLeuValAsn	
1351	GGGAGCTCTGTCACTGTAAGCTGCAAGGTTCTAGCGTGTACCCCTTGA	1400
	GlySerSerValThrValSerCysLysValProSerValTyrProLeuAs	
1401	CCGGCTGGAGATTGAATTACTTAAGGGGGAGACTATTCTGGAGAATATAG	1450
	pArgLeuGluIleGluLeuLeuLysGlyGluThrIleLeuGluAsnIleG	
1451	AGTTTTTGGAGGATACGGATATGAAATCTCTAGAGAACAAAAGTTTGGAA	1500
	luPheLeuGluAspThrAspMetLysSerLeuGluAsnLysSerLeuGlu	
1501	ATGACCTTCATCCCTACCATTGAAGATACTGGAAAAGCTCTTGTTTGTCA	1550
	MetThrPheIleProThrIleGluAspThrGlyLysAlaLeuValCysGl	

THIS PAGE BLANK (USPTO)

FIGURE 4C

13 / 21

1551	GGCTAAGTTACATATTGATGACATGGAATTCGAACCCAAACAAAGGCAGAnAlaLysLeuHisIleAspAspMetGluPheGluProLysGlnArgGlnS	1600
1601	GTACGCAAACACTTTATGTCAATGTTGCCCCAGAGATACAACCGTCTTGerThrGlnThrLeuTyrValAsnValAlaProArgAspThrThrValLeu	1650
1651	GTCAGCCCTTCCTCCATCCTGGAGGAAGGCAGTTCTGTGAATATGACATGValSerProSerSerIleLeuGluGluGlySerSerValAsnMetThrCy	1700
1701	CTTGAGCCAGGGCTTTCCTGCTCCGAAAATCCTGTGGAGCAGGCAGCTCCsLeuSerGlnGlyPheProAlaProLysIleLeuTrpSerArgGlnLeuP	1750
1751	CTAACGGGGAGCTACAGCCTCTTTCTGAGAATGCAACTCTCACCTTAATTroAsnGlyGluLeuGlnProLeuSerGluAsnAlaThrLeuThrLeuIle	1800
1801	TCTACAAAAATGGAAGATTCTGGGGTTTATTTATGTGAAGGAATTAACCASerThrLysMetGluAspSerGlyValTyrLeuCysGluGlyIleAsnGl	1850
1851	GGCTGGAAGAAGCAGAAAGGAAGTGGAAATTAATTATCCAAGTTACTCCAAAlaGlyArgSerArgLysGluValGluLeuIleIleGlnValThrProL	1900
1901	AAGACATAAACTTACAGCTTTTCCTTCTGAGAGTGTCAAAGAAGGAGACysAspIleLysLeuThrAlaPheProSerGluSerValLysGluGlyAsp	1950
1951	ACTGTCATCATCTCTTGTACATGTGGAAATGTTCCAGAAACATGGATAATThrValIleIleSerCysThrCysGlyAsnValProGluThrTrpIleIl	2000
2001	CCTGAAGAAAAAAGCGGAGACAGGAGACACAGTACTAAAATCTATAGATGeLeuLysLysLysAlaGluThrGlyAspThrValLeuLysSerIleAspG	2050
2051	GCGCCTATACCATCCGAAAGGCCAGTTGAAGGATGCGGGAGTATATGAAllyAlaTyrThrIleArgLysAlaGlnLeuLysAspAlaGlyValTyrGlu	2100
2101	TGTGAATCTAAAAACAAAGTTGGCTCACAATTAAGAAGTTTAACTTGCACysGluSerLysAsnLysValGlySerGlnLeuArgSerLeuThrLeuAs	2150
2151	TGTTCAAGGAAGAGAAAAACAACAAAGACTATTTTCTCCTGAGCTTCTCGpValGlnGlyArgGluAsnAsnLysAspTyrPheSerProGluLeuLeuV	2200
2201	TGCTCTATTTTGCATCCTCCTTAATAATACCTGCCATTGGAATGATAATTalLeuTyrPheAlaSerSerLeuIleIleProAlaIleGlyMetIleIle	2250
2251	TACTTTGCAAGAAAAGCCAACATGAAGGGGTCATATAGTCTTGTAGAAGCTyrPheAlaArgLysAlaAsnMetLysGlySerTyrSerLeuValGluAl	2300
2301	ACAGAAATCAAAAGTGTAGCTAATGCTTGATATGTTCAACTGGAGACACTaGlnLysSerLysVal	2350

THIS PAGE BLANK (USPTO)

FIGURE 4D

14/21

2351	ATTTATCTGTGCAAATCCTTGATACTGCTCATCATTCCCTTGAGAAAAACA	2400
2401	ATGAGCTGAGAGGCAGACTTCCCTGAATGTATTGAACTTGGAAGAAATG	2450
2451	CCCATCTATGTCCCTTGCTGTGAGCAAGAAGTCAAAGTAAACTTGCTGC	2500
2501	CTGAAGAACAGTAACTGCCATCAAGATGAGAGAACTGGAGGAGTTCCTTG	2550
2551	ATCTGTATATACAATAACATAATTTGTACATATGTAAAATAAAATTATGC	2600
2601	CATAGCAAGATTGCTTAAAATAGCAACACTCTATATTTAGATTGTTAAAA	2650
2651	TAACTAGTGTTGCTTGGACTATTATAATTTAATGCATGTTAGGAAAATTT	2700
2701	CACATTAATATTTGCTGACAGCTGACCTTTGTTCATCTTCTTCTATTTTA	2750
2751	TTCCCTTTCACAAAATTTTATTCCTATATAGTTTATTGACAATAATTTCA	2800
2801	GGTTTTGTAAAGATGCCGGGTTTTATATTTTATAGACAAATAATAAGCA	2850
2851	AAGGGAGCACTGGGTTGACTTTCAGGTACTAAATACCTCAACCTATGGTA	2900
2901	TAATGGTTGACTGGGTTTCTCTGTATAGTACTGGCATGGTACGGAGATGT	2950
2951	TTCACGAAGTTTGTTTCATCAGACTCCTGTGCAACTTTCCCAATGTGGCCT	3000
3001	AAAAATGCAACTTCTTTTTATTTTCTTTTGTAATGTTTAGGTTTTTTTG	3050
3051	TATAGTAAAGTGATAATTTCTGGAATTAAA	3080

THIS PAGE BLANK (USPTO)

FIGURE 5

	*	G h f C	P	v p	P	D s G	o C	N	*
1		F K I E T T P E S R Y L A Q I G D S V S L T C S T T G C E S P P P S V R T Q I D S P L N G K						V T N E G T T S L T I M N P V S P G N E H S Y L C T A T C E S R K L E K G I	
2		Q V E I Y S F P K D P E I H L S G P L - E A G K P I T V K C S V A - D V Y P P D R L E I D L I K G D H L M K S Q E F L E D A D R K S L E T K S L E V T P T P V I E D I G K V L V C R A K L H I D E H D S V P T V R Q A V K E L							
3		Q V Y I S P K N T V I S V N P S T K L - Q E G G S V T H T C S S E G L P A P E I F V S K K L D N G M L Q H						L S G N A T L T L - I A H R M E D S G - I Y V C E G V N L I G K N R K E V E L I V Q A	
4		F P R D P E I E H S G G L - V N G S S V T V S C K V P - S V Y P L D R L E I E L I K G E T I L E N I E F L E D T D M K S L E N K S L E H T F I P T I E D T C K A L V C Q A K L H I D D H E F E P K Q R Q S T Q T L							
5		Y V N V A P R D T T V L V S P S S I L - E E G S S V N H T C L S Q G F P A P K I L V S R O L P N G E L Q P						L S E N A T L T L - I S T K H E D S G - V Y L C E G I N O A G R S R K E V E L I I Q V	
6		T P K D I K L T A F P S E S V - K E G D T V I I S C T C G N V -- P E T - V I I L K K K A E T G D T V L						S I D G A Y T T I R K A Q L K D A G - V Y E C E S K N K V G S Q L R S L T L D V Q G R E N	
		<p style="text-align: center;">N K D Y F S P E L L V L Y F A S S L I I P A I G H I I Y F A R K A N H K G S T S L V E A Q K S K V</p>							

THIS PAGE BLANK (USPTO)

FIGURE 6

G h f c P Wp P DsG o c N
 1 FK1ETTPESRYLAQIGDSVSLTCTTGCEBSPFFSVRTQIDSPLNCK-----VTNEGTTSTLTNPVSFCNEHSYLTCTATCESRKLEKGI
 2 QVEIYSFPKQPEIHLSGPL-EACKPITVKCSVA-DVYFPDRLEIDLKGBHLKMSQEFLEADARKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDENDSVPTTVROAVKEL
 3 QVYISPKNTVISVNPSTKL-QEGCSVHTCSSEGLPAPEIFVSKKLDNGLQH-----LSGNATLTL-IAMRMEDSG-IYVCEGVNLICKNRKEVELIVQEKP
 3B FTVEISPGPRIAAQIGDSVNLTCBVGCEBSPFFSVRTQIDSPLSGK-----VRSEGTNSTLTSPVSENEHSYLTCTVTCGHKLEKGI
 4 QVELYSFPROPEIEMSGGL-VNGSSVTVSCVP-SVYPLDRLEIELLKGETILENIEPLEDTDKMSLENKSLMENTPIPTIEDTGKALVCQAKLHIDMEPEPKQKQSTQTL
 5 YVNVAPRDTTVLVSPSSIL-BEGSSVNHTCLSQGPAPKILVSRQLPNGELQP-----LSENATLTL-ISTKMEDSG-VYLCEGINQAGRSRKEVELIIQV
 6 TPKDIKLTAFPSVSV-KEGDTVIIISCTCGNV--PET-VIILKKAETGDTVL-----SIDGAVTIRKAQLKDAG-VYECESKNKVGSQLSLTLDVQCGREN
 NKDYFSPPELLVLFASSLIIPAIGNIIYFARKANMKGSYSLVPEAQKSV

THIS PAGE BLANK (USPTO)

17 / 21

FIGURE 7

1 GCATGCGCCA CCATGCCAG CTAATTTGT ATTTTAACTA GAGATGGCT TTCTCCATGT TGGTCAGGCT GGCTTGAAC TCCGGGCTC AGGTGATCCG
 101 CCGCCCTCGG CCTCCCAAG TGGTGGATT ACAGGGGTGA GCCACTGTGC CTGGCTCTCT TTTATTTT TTCACTGAAC AAACCATGAA ACTTCCCGAG
 201 ATGTAATAT CTAATTCCTA TTTTCTTTT TTTAAATAA GGCATTATT TAACCATTTG AGTGTAGT ATATTTTAA GATAATATTT TAATTTAGGC
 301 ATACTGCGG TGCAAAATCT GAAGATTAT ATCTACCTG TGAGTCATTC CTCGTGAGA CAGTGCATGT TAAATATGT GAATGGCAG GTGAAAAGG
 401 AAGAAAAT GAGTAATGT TGGTATCCA CAGCTATGAA TGAGAAATG AGGTAGTAG ACTATGGATG ACAACCTAT TCTTGGTTC CTCGTGTTT
 501 TGAATTTCTA ATTACTACCA CAACCTACATG AAGACACTA AAGTTTACA ACTTTTAAA GACATAGACT TTAATGTAT ATAAATAAAA
 601 ATCATGCAT TTTGTATAT TAATAAAT GCATATACGA TATAAAGCA TGGACAAAGG TGAAGTAGCT TCAAGAGACA GAGTTTCTGA CATCATTTGA
 701 ATTTTAAGCA TCGTGGATAT TCCCGGAAA GTTTTGTAT GGCATTGGG ATTTCCCTCT TACTGGATGT GGACAAATAT CTTCTATTTAT TCACAGGAAG
 801 CAATCCCTCC TATAAAGG CCTCAGCGA AGTATGTCT AGCTGTCTT GGTGACTTC ACATCAAAAC TCTATACTG ACCTGAGACA GAGGCAGCAG
 901 TGATACCCAC CTGAGAGATC CTGCTTTGA ACAACCTCTT CCAAAACCG TAAGTGCAGA AGCTTTATA AGGGCAGCT CCGGCCATGA AACACAGATA
 1001 TGCAAAAGGC CTCTAATAA AAACCATC TGTACAAGCT CTTATTGTAT TGTAGCTAA ACCTGTCTT TCCTTTGAC CTAATATATG AAAGCTTAA
 1101 AATTGTTTA TTTATTGAT TAACTCTGA AATAAGAT ATTGCATAG TGTCTTTGC CCAAACTCT AGGATGCTG CTTAAACATC ATGGTAGAAT
 1201 AATGTAATA GCTACCCAG ATTTCTCTT TTAATTCAT TGTGTTTTA TCCTCCCGAG AAGTATTTC AAGCTTAAAC CTTTGGGTGA AAAGAATCTC
 1301 TGAAGTATG ATTCCTTAC AGTTCTCTC AGCTCTCAT TGGGTAAAT CAGTGCATGT AGACCAAGAT TCTCATICT GGCACIATAG ATATTTGAGA
 1401 CTGAAATATC CTGCTTGTG TGGGGCTGT CTGCACAGGA TATCTGGCAG CACTCTGAC CTCTACCTGC AATGTGTCT TCCCTGGCT YGGGGTCATT
 1501 TACTTTACCT CTGGGTGCT CCCTTTCCT AAGTGTAAAG TGTGGATCCG TTGACCTGCA GGTCGA

NF-kappa B
 CDNA clone 41
 Intron 1
 Intron 2
 exon 2
 translation initiation codon

THIS PAGE BLANK (USPTO)

FIGURE 8

1 AAGCTTCATT CTGCAATCAG CATTCCTCTT TATCTTTCCA GTAAAGATAG CCTTTGGAG TCGAAGATGA GGAAAAGCCT GTATTTTATA GCTTGGAAAG
 101 TGTCTTCTTT TGGCAGAGCA GAGAGAGGAG CTTGAGCAGT GAGAGCAACT GAAGGGGTTA ATAGTGGAAC TTGGCTGGCT GCTCTTTAAA CTTTTTCCCT
 201 TGGCTCTGCC CTGGCTTTGG ~~CTTGAAGGG~~ ^{NF-kappaB} ATTTCCTCC GCTCTGCCA CAAGACCTT TATAAGCAC AGACTTTCTA TTTCACTCCG CGGTATCTGC
 301 ^{CDNA clone 41} ATCTGGCTC ACTGGCTTCA ~~GAAGCTGAAT~~ ACCCTCCAG GCACACACAG GTGGGACACA AATAAGGGT TTGGAACCACT TATTTTCTCA TCAGGACAGC
 401 ~~AAGCTTAAAT GGGTGGGAA~~ ^{intron 1} TCTTGGAGC CTCAAATATA CTTTGGATAA TGTTTGGAGC TTGTAAGTTC TTTCCCTTCA TCTGTTTCAA
 501 ATGTTAGCAT TCAATTTTAG CCTCGGTTTT GGCCTCAGTC AGTTTTGCGA TAGTAGTGAA GTAAAGACAC TAGGATTTTA AACAGTAGGA AAAGTTAATT
 601 TAGCTAACT TTTAATATGC AATTGAGTTT TGCTATATAC CATTGTACTG TCATAGTTAG AGCTGAAAT TGATGTTTTT GGTATCTTTT TTTCCAAAGG
 701 CAATTCAGTA ATTTGGATTG TGTCTCTAGT CGGCTCTGCT CTTTAGTTTC CTATACTTGA CAATGAGGTC AAACCTTAGCA AATAACAAA CAGCTTTGAT
 801 AAATGACAT CAAGGTTGGA ACTGAGAAAT CTCTCTACTG AAGATGATTC CATAAACTT TTTGGCAGTG ACTTCGGTGC TTTTGGCTA CCTTGCAGTT
 901 AGTTTGAAGC AGCTTAGGAA AGAGATCAGT CTGATCATAT TTAGACATT ATACAGAGAA GAAGGAGGAG AATACTAGAC AAACCTAGTG TAAATTGCT
 1001 TCTGTCTTTT TTTGCTTTTG CAGCTCAAGC TT ^{exon 2}

THIS PAGE BLANK (USPTO)

19/21

FIGURE 9A

1	GCGGCCGCCGCTCCTCCACGCCTGCGGACGCGTGGCGAGCGGAGGCAGCG	50
51	CTGCCTGTTCGCGCCATGGGGGCACCGTGGGGCTCGCCGACGGCGGGCGGC	100
	MetGlyAlaProTrpGlySerProThrAlaAlaAl	
101	GGGCGGGCGGCGCGGGTGGCGCCGAGGCCGGGGGCTGCCATGGACCGTCT	150
	aGlyGlyArgArgGlyTrpArgArgGlyArgGlyLeuProTrpThrValC	
151	GTGTGCTGGCGGCCCGCGGCTTGACGTGTACGGCGCTGATCACCTACGCT	200
	ysValLeuAlaAlaAlaGlyLeuThrCysThrAlaLeuIleThrTyrAla	
201	TGCTGGGGGCAGCTGCCGCCGCTGCCCTGGGCGTCGCCAACCCCGTCGCG	250
	CysTrpGlyGlnLeuProProLeuProTrpAlaSerProThrProSerAr	
251	ACCGGTGGGCGTGCTGCTGTGGTGGGAGCCCTTCGGGGGGCGCGATAGCG	300
	gProValGlyValLeuLeuTrpTrpGluProPheGlyGlyArgAspSerA	
301	CCCCGAGGCCGCCCCCTGACTGCCGGCTGCGCTTCAACATCAGCGGCTGC	350
	laProArgProProProAspCysArgLeuArgPheAsnIleSerGlyCys	
351	CGCCTGCTCACCGACCGCGCTCCTACGGAGAGGCTCAGGCCGTGCTTTT	400
	ArgLeuLeuThrAspArgAlaSerTyrGlyGluAlaGlnAlaValLeuPh	
401	CCACCACCGCGACCTCGTGAAGGGGCCCCCGACTGGCCCCCGCCCTGGG	450
	eHisHisArgAspLeuValLysGlyProProAspTrpProProProTrpG	
451	GCATCCAGGCGCACACTGCCGAGGAGGTGGATCTGCGCGTGTGGACTAC	500
	lyIleGlnAlaHisThrAlaGluGluValAspLeuArgValLeuAspTyr	
501	GAGGAGGCAGCGGCGGCGGAGAGCCCTGGCGACCTCCAGCCCCAGGCC	550
	GluGluAlaAlaAlaAlaAlaGluAlaLeuAlaThrSerSerProArgPr	
551	CCCCGGCCAGCGCTGGGTTTGGATGAACTTCGAGTCGCCCTCGCACTCCC	600
	oProGlyGlnArgTrpValTrpMetAsnPheGluSerProSerHisSerP	
601	CGGGGCTGCGAAGCCTGGCAAGTAACCTCTTCAACTGGACGCTCTCCTAC	650
	roGlyLeuArgSerLeuAlaSerAsnLeuPheAsnTrpThrLeuSerTyr	
651	CGGGCGGACTCGGACGTCTTTGTGCCTTATGGCTACCTCTACCCCAGAAG	700
	ArgAlaAspSerAspValPheValProTyrGlyTyrLeuTyrProArgSe	
701	CCACCCCGGCGACCCGCCCTCAGGCCTGGCCCCGCCACTGTCCAGGAAAC	750
	rHisProGlyAspProProSerGlyLeuAlaProProLeuSerArgLysG	
751	AGGGGCTGGTGGCATGGGTGGTGAGCCACTGGGACGAGCGCCAGGCCCGG	800
	lnGlyLeuValAlaTrpValValSerHisTrpAspGluArgGlnAlaArg	

THIS PAGE BLANK (USPTO)

20/21

FIGURE 9B

801	GTCCGCTACTACCACCAACTGAGCCAACATGTGACCGTGGACGTGTTCCG	850
	ValArgTyrTyrHisGlnLeuSerGlnHisValThrValAspValPheG	
851	GCGGGGCGGGCCGGGGCAGCCGGTGCCCGAAATTGGGCTCCTGCACACAG	900
	yArgGlyGlyProGlyGlnProValProGluIleGlyLeuLeuHisThrV	
901	TGGCCCGCTACAAGTTCTACCTGGCTTTTCGAGAACTCGCAGCACCTGGAT	950
	alAlaArgTyrLysPheTyrLeuAlaPheGluAsnSerGlnHisLeuAsp	
951	TATATCACCGAGAAGCTCTGGCGCAACGCGTTGCTCGCTGGGGCGGTGCC	1000
	TyrIleThrGluLysLeuTrpArgAsnAlaLeuLeuAlaGlyAlaValPr	
1001	GGTGGTGCTGGGCCCAGACCGTGCCAACTACGAGCGCTTTGTGCCCCGCG	1050
	oValValLeuGlyProAspArgAlaAsnTyrGluArgPheValProArgG	
1051	GCGCCTTCATCCACGTGGACGACTTCCCAAGTGCCCTCCTCCCTGGCCTCG	1100
	lyAlaPheIleHisValAspAspPheProSerAlaSerSerLeuAlaSer	
1101	TACCTGCTTTTCTCGACCGCAACCCCGCGGTCTATCGCCGCTACTTCCA	1150
	TyrLeuLeuPheLeuAspArgAsnProAlaValTyrArgArgTyrPheHi	
1151	CTGGCGCCGGAGCTACGCTGTCCACATCACCTCCTTCTGGGACGAGCCTT	1200
	sTrpArgArgSerTyrAlaValHisIleThrSerPheTrpAspGluProT	
1201	GGTGCCGGGTGTGCCAGGCTGTACAGAGGGCTGGGGACCGGCCCAAGAGC	1250
	rpCysArgValCysGlnAlaValGlnArgAlaGlyAspArgProLysSer	
1251	ATACGGAACCTTGCCAGCTGGTTCGAGCGGTGAAGCCGCGCTCCCCTGGA	1300
	IleArgAsnLeuAlaSerTrpPheGluArg	
1301	AGCGACCCAGGGGAGGCCAAGTTGTCAGCTTTTGTATCCTCTACTGTGCA	1350
1351	TCTCCTTGACTGCCGCATCATGGGAGTAAGTTCTTCAAACACCCATTTTT	1400
1401	GCTCTATGGGAAAAAAACGATTTACCAATTAATATTACTCAGCACAGAGA	1450
1451	TGGGGGCCCGGTTTCCATATTTTTTGCACAGCTAGCAATTGGGCTCCCTT	1500
1501	TGCTGCTGATGGGCATCATTGTTTGGGGTGAAGGAGGGGTTCTTCCTC	1550
1551	ACCTTGTAACCAAGTGCAGAAATGAAATAGCTTAGCGGCAAGAAGCCGTTG	1600
1601	AGGCGGTTTTCTGAATTTCCCATCTGCCACAGGCCATATTTGTGGCCCCG	1650
1651	TGCAGCTTCCAAATCTCATACAACTGTTCCCGATTACGTTTTTTCTGG	1700
1701	ACCAAGGTGAAGCAAATTTGTGGTTGTAGAAGGAGCCTTGTGGTGGAGA	1750

THIS PAGE BLANK (USPTO)

21 / 21

FIGURE 9C

1751	GTGGAAGGACTGTGGCTGCAGGTGGGACTTTGTTGTTTGGATTCCCTCACA	1800
1801	GCCTTGGCTCCTGAGAAAGGTGAGGAGGGCAGTCCAAGAGGGGCCGCTGA	1850
1851	CTTCTTTCACAAGTACTATCTGTTCCCCTGTCCTGTGAATGGAAGCAAAG	1900
1901	TGCTGGATTGTCCTTGGAGGAACTTAAGATGAATACATGCGTGTACCTC	1950
1951	ACTTTACATAAGAAATGTAATCCTGAAAAGCTGCATTTAAATCAAGTCCC	2000
2001	AAATTCATTGACTTAGGGGAGTTCAGTATTTAATGAAACCCTATGGAGAA	2050
2051	TTTATCCCTTTACAATGTGAATAGTCATCTCCTAATTTGTTTCTTCTGTC	2100
2101	TTTATGTTTTTCTATAACCTGGATTTTTTAAATCATATTAAAATTACAGA	2150
2151	TGTGAAAATAAAAAAAGCGGCCGC	2175

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/02357

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5) See Attached Sheet, Part I

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

Classification System

Classification Symbols

US

See Attached Sheet Part II

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched ⁵

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category ⁶

Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷

Relevant to Claim No. ¹⁸

See Attached Sheet Part III

• Special categories of cited documents: ¹⁹

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ¹

06 August 1990

International Searching Authority ¹

ISA/US

Date of Mailing of this International Search Report ¹

26 SEP 1990

Signature of Authorized Officer

INTERNATIONAL DIVISION

For DAVID A. SAINTERS

FORM 210 (second sheet) PART I

U.S.C1.: 424/1.1, 9, 85.8, 85.91, 93;
435/7.29, 172.2, 172.3, 240.2, 240.4, 240.27, 243,
252.31, 252.33, 252.34, 255, 320, 948;
436/501, 503, 518, 536, 548; 514/2, 44;
530/300, 350, 387, 389, 391, 808, 809;
536/27

IPC(5): A61K 31/70, 37/02, 39/395, 48/00, 49/00, 49/02;
C07H 15/12; C07K 3/00, 7/00, 15/28;
C12N 15/00, 15/03-07, 15/12; C 12Q 1/02;
G01N 33/536, 33/543, 33/566, 33/577

FIELDS SEARCHED - MINIMUM... - PART II

U.S.C1.: 424/1.1, 9, 85.8 85.91, 93;
435/7.29, 172.2, 172.3, 240.2, 240.4, 240.27, 243,
252.31, 252.33, 252.34, 255, 320, 948;
436/501, 503, 518, 536, 548; 514/2, 44;
530/300, 350, 387, 389, 391, 808, 809;
536/27

A61K 31/70, 37/02, 39/395, 48/00, 49/00, 49/02;

DOCUMENTATION SEARCHED ORTHER THAN MINIMUM...

BIOSIS SEARCHES: 1) ELAM or ELAM1 or ELAMS
2) MILA or MILAS
3) VCAM# or VCAM1 or VCAM1B
4) CDX

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter¹ not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

SEE ATTACHMENT (PART IV)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. telephone practice

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to invention first mentioned in the claims; it is covered by claim numbers:

searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not payment of any additional fee.

protest

Additional search fees were accompanied by applicant's protest.

It accompanied the payment of additional search fees.

Group I, claims 176, drawn to DNA sequences, hosts, encoded ELAM 1 receptors and antibodies thereto.

Group II, claims 17-38, drawn to DNA sequences, hosts encoded CDX receptors and antibodies thereto.

Group III, claims 39-54, drawn to DNA sequences, hosts, encoded VCAM1/VCAM1b receptors and antibodies thereto.

Group IV, claims 55-75, drawn to methods of identifying adhesion inhibitors and to body treatments using these.

Group V, claims 76-81 and 119-124, drawn to labeled/toxin conjugated molecules and imaging/treatment methods using these

Group VI, claims 82-84, drawn to DNA encoding ELAM/immunoglobulin fusion proteins and the encoded proteins.

Group VII, claims 85-109, drawn to antisense or ribozyme nucleic acid compositions and treatment methods using these

Group VIII, claims 110-117, drawn to anti-idiotypic antibody preparations and methods using these

Group IX, claims 118, drawn to treatment method using antibodies to IL-1, TNF or IFN-gamma.

Group X, claims 125-128, drawn to DNA encoding VCAM/ICAM fusion protein and the encoded proteins.

Group XI, claims 129-142, drawn to tumor treatments and with transfected leukocytes.

The invention of Groups I-XI above do not meet the requirements for unity of invention for the following reasons. Groups I-III are each drawn to a distinct receptor, a method of producing the receptor (e.g., claims 10 and 47), and to a method of use of the receptor (e.g. claims 38 and 54). The treatment methods of Group V represents another different use of the receptor compositions of Groups I-III. The fusion proteins of Groups VI and X are distinct from each other and from the compositions of the other Groups and not used in the methods of the other Groups. The ribonucleic acid compositions of Group VII are distinct from the compositions of other Groups and not used in the methods of other Groups. The anti-idiotypic compositions of Group VIII are distinct from the compositions of the other groups and not used in the methods of the other groups. The antibodies used in the method of Group IX are not claimed as a composition or for use in the methods of any other Group. The leukocyte transfecting method of Group XI represents another different use of the DNA/vector compositions of Groups I-III.

PCT/US90/02357

FORM 210 - FIELDS SEARCHED -DOCUMENTATION SEARCHED ORTHER THAN
MINIMUM... - PART II (continued)

- 5) VLA4 or VLA(W)4
- 6) (TUMOR(W)INFILTRATING(W)LYMPHOCYTE#
or TIL) (15A) (TRANSPECT? or TRAN(FORM?)
- 7) (ANTIBOD? or MAB OR MCAB or MOAB)(3w)
(INTERLEVKIN or IL)(W1 or TNF or NECROSIS
or INTERFERON or INF#) and INFLAM? and
(TREAT? or THERAP?)

ATTACHMENT TO PART III (SECOND SHEET) FORM 210

- | | | |
|--------|--|--|
| X
Y | Biological Abstract, Vol. 85, No. 8 issued 15 April 1988, M.P. BEVILACQUA ET AL., "Identification of an Inducible Endothelial-leukocyte Adhesion Molecule". See page AB-506, col. 2, abstract no. 79327. Proc. Natl Acad Sci USA, 1987, 84(24), 9238-9242. | 13-16,48-50,
54,55,57,63
69 and 70
<hr/> 76,77,81 |
| P,X | Biological Abstracts Vol. 87, No. 10, issued 15 May 1989. M.P. BEVILACQUA ET AL., "Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins". See page AB-460, col. 1, abstract No. 104028. Science, 1989, 243(4895), 1160-1165. | 1-4,6,7,9 10.
13 and 14-16 |
| P,X | Biological Abstracts, Vol. 87, no. 11, issued 01 June 1989. F. E. LUSCINSKAS ET AL., "Endothelial-leukocyte Adhesion Molecule-1 Dependent and Leukocyte (CD11/CD18) Dependent Mechanisms Contribute to Polymorphonuclear Leukocyte Adhesion to Cytokine Activated Human Vascular Epithelium". See page AB-109, col. 1 abstract no. 111847. J. Immunol., 1989, 142(7), 2257-2263. | 15,16,55,57,
63,69 and 70 |
| P,X | Proc Natl Acad Sci Vol. 87, issued March 1990, C. HESSION ET AL., "Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions", pages 1673-1677. See Abstract and Fig. 1 legend. | 1-10 |
| P,X | Biological Abstracts, Vol. 89, No. 6, issued 15 March 1990, OSBORN ET AL., "Direct Expression Cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes". See page No. AB-399, Col. 2, abstract No. 58659. Cell, 1989, 59(b), 1203-1212. | 39-47 |
| T,X | Biological Abstracts, No. 89, issued 1990. M. J. ELICES ET AL., "VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4 filonectin binding site". See abstract No. 101561. Cell, 1990, 60(4), 577-584. | 56,60-63
and 72 |
| T,X | J. Clin, Invest., Vol. 85, No. 6, issued 01 June 1990, B. R. SCHWARTZ ET AL., "Identification of surface proteins mediating adherence of CD11/CD18 - deficient lymphoblastoid cells to cultured human endothelium", pages 2019-2022. See abstract and page 2020, col. 1, first full paragraph. | 51-53,55,56
60-63,72 and
75 |
| P,X | Biological Abstracts, Vol. 88, No. 7, issued 01 October 1989, G. E. GRAU ET AL., "Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor". See page AB-535, Col. 2 - page AB-536, Col. 1, abstract No. 85783. Proc Natl Acad Sci USA, 1989, 86(14), 5574. | 118 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)